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The Metabolic Syndrome 
The Metabolic Syndrome (MetS) is characterized by a clustering of several metabolic 
disturbances that are highly prevalent in industrialized countries, such as insulin 
resistance (IR), dyslipidemia, central obesity and hypertension [1]. The coexistence of 
these disorders appears to be more frequent than would be expected by chance [2]. 
Clustering of these disorders has been suggested by several scientists independently as 
early as from the 1920’s and different definitions and names have been given to them 
[2], such as syndrome X, insulin resistance syndrome, Reaven’s syndrome and 
CHAOS. 
The underlying causes of the MetS are thought to be: excess body weight (especially 
visceral / central / android obesity), physical inactivity/sedentary lifestyle, an 
atherogenic diet (high carbohydrates, low fiber, high saturated fat), high alcohol intake, 
and smoking [3]. Additionally, genetic factors can contribute to increased susceptibility 
to develop the MetS [2]. The MetS is especially related to the development of IR [4], 
which may be considered the pathogenic denominator that links all components of the 
MetS [1]. Individuals with MetS are at higher risk for developing heart disease (2- to 3-
fold), stroke (2-fold), and type 2 diabetes (5-fold). MetS is becoming more common, 
with a prevalence of 10% to 30% of the adult population in industrialized countries [5-
7] and it may therefore be considered as a major health hazard.  
Currently, there are two major definitions for MetS, provided by the revised National 
Cholesterol Education Program (NCEP) and the International Diabetes Federation 
(IDF), respectively. The Third Report of the NCEP Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment 
Panel III; ATP III), defines the MetS as the presence of three or more of the following 
risk factors: increased waist circumference, increased fasting serum glucose or 
triglyceride levels, hypertension, or low levels of high density lipoprotein (HDL) 
cholesterol [8, 9]. The current definition by the IDF however, relies on the fact that 
abdominal obesity is so highly correlated with the development of IR that additional 
measurements of IR are unnecessary. Waist circumference as a measure for abdominal 
obesity has consequently become an indispensable hallmark for the MetS, in 
combination with two of the other risk factors mentioned above [8]. 
MetS is associated with other diseases, such as non-alcoholic fatty liver disease 
(NAFLD). The liver is an important organ in whole-body lipid and glucose 
homeostasis and therefore may play an essential role in the MetS. This thesis will focus 
on diet-induced liver pathology. 
General Introduction 
 
 
- 9 - 
 
The liver in the metabolic syndrome 
Liver function and morphology 
The liver is a central organ in an organism’s metabolism. It has indispensable functions 
in lipid homeostasis, such as triglyceride (TG) and cholesterol biosynthesis and uptake, 
to maintain an equilibrium in the body during both the fed and the fasted state. It also 
produces bile to aid in the digestion and uptake of lipids from the intestine. 
Additionally, the liver has central roles in carbohydrate homeostasis via 
gluconeogenesis (de novo synthesis of glucose), glycogenesis (synthesis of glycogen 
from glucose for storage) and glycogenolysis (breakdown of glycogen to glucose). The 
liver has also important functions in protein metabolism, detoxification, the breakdown 
of several hormones and other substances, as well as synthesizing coagulation factors 
and several important proteins, such as albumin (the major transport protein in the 
circulation), and several acute phase proteins. 
Macroscopically, the liver is divided into four lobes, i.e. left lobe, right lobe, quadrate 
lobe and caudate lobe. The liver parenchyma can be divided into functional units, 
called hepatic lobules, which can be defined in different ways (Fig. 1):  
- classic lobule: hexagonal shape centred around a hepatic venule with portal 
triads (portal vein, artery, bile duct) on its edges, divided into centrilobular, 
midzonal, periportal parts. 
- acinus: diamond shape centred around a portal triad and adjacent two central 
veins at the periphery of the lobule, divided into zones based on oxygen 
supply. 
In zone 1, encircling the portal triads, hepatocytes are best oxygenized while they are 
poorest oxygenized in the proximity of the central vein (zone 3). This is caused by the 
fact that oxygen- and nutrient rich blood enters the liver via a hepatic artery and portal 
vein respectively, and flows through the sinuses to the central vein. 
Microscopically, the liver consists of several cell types, i.e. hepatocytes, which are up 
to 70% of the total mass, stellate cells, and Kupffer cells (KCs). Stellate cells or Ito 
cells are pericytes located in the perisinusoidal space (also called Disse space), which is 
the space between the sinusoids and the hepatocytes. They represent 5 to 8% of the 
total population in the liver. Stellate cells are the main cellular source of extracellular 
matrix proteins in the liver [10, 11]. 
KCs are specialized tissue macrophages in the sinusoids (adherent to endothelial cells), 
representing about 35% of non-parenchymal cells in the liver. They are resident liver 
macrophages, first described by Karl Wilhelm von Kupffer in 1876 [12] and 
correspond to approximately 10-15% of the total liver cell population [13]. These cells 
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are the first macrophage population that are encountered by several pathogens from the 
gastrointestinal tract coming into the liver via the portal vein [14] and are hence an 
important part of the innate immune system of the body. KCs originate from 
circulating monocytes that migrate into several tissues and subsequently differentiate to 
different tissue macrophages [15], although they are described to be able of limited 
self-renewal [16]. Studies on the lifespan of KCs have yielded conflicting results, 
spanning from 2 weeks to one year [15]. KCs have a major role in clearing senescent 
and malformed red blood cells from the circulation via scavenger receptors class A 
type 1 and 2 [17]. The major activating pathways of KCs act via the complement 
factors C3a and C5a, β-glucans from both bacteria and fungi, and via lipopolysacharide 
(LPS). They have been implicated to have differential roles in host defense, liver 
regeneration, and several forms of liver injury via the secretion of several mediators, 
such as cytokines [11, 15]. 
 
 
 
Figure 1. Functional units of the liver. Liver parenchyma is divided in several functional units. Either as a 
classic lobule, indicated with a bold line, or as an acinus, indicated with a dashed line and which is divided 
into three zones according to the oxygen supply (z1, z2, and z3). 
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Fatty liver as the hepatic event of the Metabolic Syndrome 
MetS was found to be a strong predictor for the development of NAFLD [18], a 
condition that represents a wide spectrum of liver disorders. It is hallmarked by hepatic 
lipid accumulation (steatosis) of more than 5% to 10% of total liver weight. All 
components of the MetS were found to correlate with NAFLD [19]. Clear correlations 
were found especially with obesity, but also with type 2 diabetes mellitus and 
hyperlipidemia [20]. It is estimated that 75% of type 2 diabetic patients have some 
form of fatty liver [21, 22]. 
The exact relation between obesity and NAFLD is still under debate. Steatosis 
prevalence increases to 57.5 % [23] and 74 % [24] in obese persons. Also in children 
there is a clear link with obesity and NAFLD, as it affects only 2.6 % of children with 
normal weight and 22.5 % [25] to 52.8 % [26] of obese children. However, several 
reports claim that steatosis can develop independently from obesity [27, 28], but rather 
is affected by fat distribution. In this regard, waist circumference correlates closely to 
steatosis development, indicating that abdominal fat is the most harmful fat depot [19]. 
These observations suggest a close relationship between steatosis and MetS. 
Accordingly, it has been postulated that steatosis may simply represent the hepatic 
manifestation of the MetS [1]. 
Non-alcoholic steatohepatitis 
NAFLD can progress to non-alcoholic steatohepatitis (NASH), which is hallmarked by 
the presence of an inflammatory response in the fatty liver. NASH has been first 
observed in 1980 by Ludwig et al. [29], describing liver biopsy specimens of 20 
patients with a thus far unnamed liver disease that histologically mimicked alcoholic 
hepatitis.  
Steatosis itself is generally considered a rather benign and reversible condition, like 
seen during prolonged fasting and re-feeding. The presence of inflammation in a fatty 
liver is the key feature of NASH and represents an irreversible step that makes 
prognosis poorer. The inflamed liver preludes further disease progression and allows 
for later stages of the disease to develop, such as IR and possibly fibrosis, cirrhosis, 
and liver cancer. Triggers that cause inflammation can activate KCs, possibly via the 
release of transforming growth factor beta (TGF-β), which activates stellate cells [30, 
31]. The activated stellate cells will synthesize and deposit collagen in between hepatic 
cells, causing hepatic fibrosis, leading to increased liver stiffness and eventually 
cirrhosis and liver failure. Moreover, chronic inflammation is known to be a risk factor 
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for the development of cancer. Indeed, patients with cirrhosis have an increased 
incidence of hepatocellular carcinoma [32, 33].  
Both inflammation and steatosis have been reported to induce IR in several ways [34], 
making NASH also an important factor contributing to the development of type 2 
diabetes. 
Clinical outline and epidemiology of NASH 
NASH closely resembles alcoholic steatohepatitis (ASH), a condition caused by 
excessive alcohol consumption. Given their histological similarity, it is believed that 
the pathogenesis of ASH and NASH have common mechanisms [29].  
The major histological hallmarks of NASH include micro- and macrovesicular 
steatosis, infiltration of inflammatory cells and hepatocyte ballooning mostly in zone 3, 
with or without the presence of deposition of collagen strands (fibrosis) [35]. 
Ballooning of hepatocytes is a form of liver cell injury that may result from 
intracellular fluid accumulation and other toxic cell damage, characterized by swelling 
of hepatocytes displaying pale to clear cytoplasm [35, 36]. Collagen deposition can 
progress from periportal expansion to septal fibrosis to complete cirrhotic remodeling 
of the liver [37]. Additionally, other abnormalities may be present, such as 
hepatocellular glycogenated nuclei (mostly in zone 1), Mallory bodies and 
megamitochondria in the hepatocytes. Glycogenated nuclei appear to be somewhat 
bigger in size and are vacuolated [36]. Mallory bodies contain Mallory hyaline, which 
are abnormal cytokeratins, usually associated with components of the proteosomal 
degradative pathway, like ubiquitin and p62. They can be identified as 
intracytoplasmatic inclusions within hepatocytes. Megamitochondria or giant 
mitochondria are thought to reflect injury or adaptive changes of the mitochondria [36]. 
NAFLD is perhaps the most common of all liver disorders [35] as it affects 10% to 24 
% of the population in various countries, while NASH is estimated to be found only in 
2% to 3% [38, 39]. Why simple steatosis progresses to NASH in some, but not most, 
individuals with NAFLD remains currently unclear.  
Diagnosis of NASH 
Most patients with the diagnosis of NAFLD are asymptomatic [38]. Of those who do 
have symptoms, fatigue, malaise and right upper quadrant discomfort are the most 
common complaints [1]. Only a few obesity-independent circulating markers for 
NAFLD and NASH are reported [40]. Elevated levels of liver enzymes may be a 
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marker of liver damage, but this may not be exclusive as a fraction of patients with 
fatty livers were found to have normal liver enzyme levels [1, 41]. 
Several non-invasive imaging techniques are frequently performed to diagnose lipid 
accumulation in the liver. Among these, ultrasound is the least costly and least invasive 
one. A more sensitive, but also more expensive way to determine steatosis is magnetic 
resonance imaging (MRI). However, both approaches have the major shortcoming that 
they cannot distinguish benign steatosis from steatohepatitis, nor can they estimate 
inflammation severity, degree of fibrosis, or stage of disease [1]. 
The golden standard for the diagnosis of NASH is a liver biopsy. A histological 
assessment is performed and the severity of the disease is classified into several classes 
and stages, thereby correlating certain histological features with long term prognosis. 
Class 1 constitutes simple steatosis, class 2 is steatosis with lobular inflammation, class 
3 requires the additional presence of ballooned hepatocytes, and class 4 requires the 
presence of either Mallory’s hyaline or fibrosis. To specifically estimate fibrosis 
severity, staging (stage 1 to 4) of liver biopsies is also performed [35]. However, taking 
liver biopsies also has several drawbacks. First, this procedure is invasive and does not 
allow for repetitive sampling. Second, the location from which the biopsy is taken 
within the liver is critical because parenchymal injury and fibrosis vary in different 
regions of the liver [36, 42], which may lead to false diagnosis. 
Additional knowledge of the development of NASH is needed to discover good 
diagnostic markers and to determine risk factors to identify patients in need of invasive 
sampling.  
Pathogenesis of NASH 
A currently popular hypothesis of NASH development was proposed by Day and 
James in 1998 [43]. They proposed that NASH develops following a sequence of 
events or ‘hits’, constituting the ‘two-hit hypothesis’ (Fig. 2). According to this 
hypothesis, NASH development requires a double hit, of which the ‘1st hit’ leads to 
steatosis [20, 43]. At this stage, liver disease is thought to be relatively benign and 
reversible. This first hit is thought to sensitize the liver, making it more prone for 
additional insults, collectively termed ‘2nd hit’. The second hit represents all factors 
that promote inflammation in the liver and subsequent fibrosis [20, 43]. In this manner, 
the normal liver can progress towards steatosis and even further to damaging NASH, 
which may lead to further liver injury, like fibrosis. 
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First hit in NASH: lipid metabolism 
The liver contributes to whole body glucose, TG, fatty acid (FA) and cholesterol 
homeostasis in concert with other organs (Fig. 3). It is the central organ in TG 
metabolism through the uptake, oxidation and synthesis of FAs, TG synthesis and their 
subsequent incorporation in very low density lipoprotein (VLDL) particles for 
secretion. Moreover, the liver is involved in cholesterol metabolism via de novo 
synthesis, uptake (in the form of VLDL and low density lipoprotein (LDL) remnants) 
and excretion (in the form of VLDL particles) of cholesterol. The liver also disposes 
cholesterol in the form of bile via the biliary system. Additionally, the liver can 
synthesize and oxidize glucose, as well as converting it into FAs for further oxidation 
or storage. In normal conditions, during the fed state, TG-rich lipoproteins 
(chylomicrons (CM) and VLDL) circulate the body and TGs are hydrolyzed by 
lipoprotein lipase (LpL) in peripheral tissues, like adipose and muscle tissue and the 
heart [44, 45]. LpL is stimulated by insulin in adipose tissue [46] and by exercise [47]. 
In this manner, peripheral tissues take up FAs which are subsequently either oxidized 
(mainly in muscle and heart tissue) or esterified to form TGs for storage (mainly in 
adipose tissue). After TG hydrolysis, lipoproteins become more dense and cholesterol-
rich, and they develop into CM-remnants and LDL, which can be taken up by the liver, 
mainly via the LDL receptor (LDLR) [48, 49]. In the fasting state, stored TGs from the 
adipose tissue are hydrolyzed by hormone sensitive lipase (HSL) [50]. HSL is inhibited 
by insulin, making its activity low in the fed state and increased in the fasting state. In 
this way, insulin thus regulates the need of storage or hydrolysis of FAs in adipose 
tissue. Most of the resulting FAs will enter the circulation and are then redistributed to 
peripheral organs, especially towards muscle and heart tissue. When the amount of 
available FAs is bigger than the demand in the peripheral tissue, e.g. in resting 
conditions, excess FAs are taken up by the liver, where they can either be oxidized or 
re-esterified to TGs [44]. 
Clearly, any disturbance in this continuous cycling of lipids throughout the body may 
lead to excessive lipid accumulation in the liver. The liver can accumulate lipids by 
both intra- and extrahepatic mechanisms (Fig. 2 and Fig. 3). Several mechanisms are 
known to induce steatosis, involving increased uptake and production of FAs, and a 
decreased utilization and efflux of FA from the liver. 
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FA uptake 
It has been reported that about 60% of TG accumulation in the liver is derived from the 
plasma albumin-bound FA pool. Increased plasma FAs are therefore thought to be the 
primary contributor to hepatic TG levels [51]. Additionally, increased uptake of CM 
remnants may also contribute to liver TG levels [52] and hyperlipidemia. More 
specifically, hypertriglyceridemia has been shown to be associated with higher 
incidence of steatosis [53]. Major causes of these disturbances are excessive uptake of 
nutrients, leading to increased depots of TGs in the adipose tissue and plasma on the 
one hand, and the lack of physical exercise, limiting utilization of FAs, on the other 
hand [51]. The uptake of lipids by the liver can be altered by for example the increased 
expression levels of  FA transporters by the liver, like CD36 [54]. Additionally, IR has 
been proposed to contribute to hepatic FA uptake as it can increase lipolysis of adipose 
tissue TGs and reduce LpL activity [46]. Increased adipose tissue lipolysis may lead to 
an amplified FA flux to the liver while the decreased LpL-mediated TG hydrolysis in 
CMs and VLDL could lead to the hepatic uptake of TG-enriched lipoproteins [55]. 
FA β-oxidation 
A reduction of hepatic FA oxidation may originate from mitochondrial dysfunction, 
causing a decreased number of FAs entering oxidation pathways or by increased levels 
of malonyl-CoA. The latter is the major inhibitor of carnitine acyl-carnitine translocase 
1 (cpt1), a key enzyme for import of FAs into the mitochondria for oxidation [56]. 
 
FA synthesis 
Increased de novo production of FAs and subsequent esterification into TGs can lead to 
increased hepatic lipid levels and may result from an increased activity of lipogenic 
enzymes in the liver. There may be an increased lipogenesis in the IR state as increased 
insulin levels can stimulate the transcription factor sterol regulatory element-binding 
protein 1c (SREBP-1c), leading to increased transcription of lipogenic genes. 
Alternatively, increased plasma glucose levels may also contribute to increased 
lipogenesis by stimulating the transcription factor Carbohydrate response element 
binding protein (ChREBP) [57], which induces lipogenic gene expression.  
 
FA efflux 
FA efflux from the liver can be decreased via impaired VLDL synthesis or transport, 
e.g. by reduced hepatic production of Apolipoprotein B, which is necessary for the 
packaging of TGs into VLDL [1, 44]. Moreover, IR can influence lipid efflux from the 
liver as insulin can target apolipoprotein B (ApoB) for translational degradation. As 
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ApoB is necessary for VLDL assembly, increased insulin levels may decrease TG 
efflux from the liver in this manner [55].  
 
 
 
Figure 3. Mechanisms contributing to hepatic accumulation. This figure summarizes hepatic lipid 
metabolism as described in the text. Dashed arrows indicate extrahepatic mechanisms that can influence 
liver lipid content and full arrows indicate intrahepatic mechanisms that may contribute to hepatic steatosis 
development. 
Mechanisms during the second hit towards hepatic 
inflammation  
Several mechanisms have been described to occur during the transition from benign 
steatosis to NASH and may therefore contribute to inflammation development. These 
include oxidative stress/lipid peroxidation, endoplasmatic reticulum (ER) stress, 
increased intrahepatic ceramide levels, membrane integrity, and extrahepatic risk 
factors such as increased plasma FA and cytokine levels (Fig. 2). These factors may all 
contribute significantly to hepatic inflammation and are responsible for the self-
sustainability of the inflammatory response. However, the actual trigger that 
determines why inflammation develops remains to be determined. 
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Oxidative stress and lipid peroxidation 
Increased lipid loads have been shown to have a critical role in causing oxidative stress 
during NASH progression [58]. Even in the basal, fat-free state, hepatocytes produce 
large amounts of reactive oxygen species (ROS). These ROS are formed at different 
sites, including mitochondrial cytochrome P450 2E1 (CYP2E1) and the mitochondrial 
respiratory chain [59]. Liver ROS formation is increased in fatty livers due to the 
increased β-oxidation rate of FAs in fatty livers [60]. ROS can directly damage 
mitochondrial DNA and proteins, leading to further mitochondrial injury which can 
lead to a further increase in ROS formation and to cell death. Moreover, ROS can 
cause nuclear factor kappa B (NF-κB) activation, which directly leads to increased 
inflammatory signaling.  
Next to their direct role in NF-κB activation, ROS can attack polyunsaturated FAs and 
thereby initiate lipid peroxidation in the cell [61], resulting in the formation of 
aldehyde by-products such as trans-4-hydroxy-2-noneal (HNE) and malondialdehyde 
(MDA). These molecules have longer half-lifes than ROS and can have deleterious 
effects on cellular function. Additionally, they can deplete the natural antioxidant 
glutathione, increase the production of the pro-inflammatory cytokine tumor necrosis 
factor (TNF), promote the influx of inflammatory cells and activate stellate cells [57]. 
All of these mechanisms can directly induce apoptosis, necrosis, inflammation and 
fibrosis: all of the histologic hallmarks of NASH. 
Endoplasmatic reticulum stress 
The ER is a network of membranes in the cell in which proteins are assembled into 
their tertiary and quaternary structures. When a protein is misfolded or remains 
unfolded, it is normally removed from the ER and targeted for degradation by the 26S 
proteasome pathway [62]. When excess unfolded proteins accumulate, the ER activates 
a complex response system which is known as the unfolded protein response (UPR). 
The UPR is mediated mainly through 3 molecules that act as ER stress sensors:  
inositol-requiring enzyme 1 (IRE-1), PKR-like endoplasmatic reticulum kinase 
(PERK) and activating transcription factor 6 (ATF6) [63, 64]. Two pro-inflammatory 
pathways are linked to IRE-1 and PERK activity during ER-stress, i.e. activating 
protein-1 (AP-1) and NF-κB. IRE-1 was shown to activate both AP-1 and NF-κB [65, 
66] and PERK activation was shown to activate the NF-κB pathway [67]. Several 
conditions linked to obesity have been postulated to trigger ER stress in the liver, 
among which lipid accumulation [68-70]. Additionally, existing inflammatory 
mediators may initiate ER stress [71] and thereby intensify an existing inflammatory 
response. Moreover, the ER is a major source of ROS in the cell [72]. Taken together, 
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ER stress may be viewed as a major contributor in the initiation of an inflammatory 
response. 
Ceramides  
Ceramide is generated as a by-product of sphingomyelin hydrolysis via the action of 
sphingomyelinase, by de novo pathways involving ceramide synthase, by the 
breakdown of complex glycosphingolipids, or by the conversion of other sphingolipid 
molecules such as sphingosine [73]. Ceramide content can be increased in the steatotic 
liver. Besides the well known ability of ceramides to induce cell death [74], these 
compounds can initiate signaling pathways that lead to the activation of both C-Jun N-
terminal kinase (JNK) and IκB kinase beta (IKKβ) [73]. 
Membrane integrity 
It has been postulated that alterations in membrane integrity can lead to hepatic 
inflammation. Phosphatidylcholine (PC) and phosphatidylethanolamine (PE) are major 
phospholipids in mammalian membranes. The PC/PE ratio has been shown to 
influence membrane integrity and reductions in PC/PE ratio increased hepatic 
inflammation in mice. Moreover, PC/PE ratio was found to be altered in many patients 
with NASH [75]. 
Extrahepatic risk factors 
In addition to increasing hepatic FA content, obesity is associated with increases of 
several cytokines, such as TNF and interleukin 6 (IL6) [76]. Therefore, in obese 
persons, the liver may be exposed to elevated levels of these cytokines, produced in 
their adipose tissue, contributing to the development of liver inflammation. Next to 
these mechanisms, obesity may induce inflammation in the liver directly via its 
increased FA release in the circulation. FAs have been found to directly activate Toll-
like receptor (Tlr) 4 signaling, consequently activating several inflammatory pathways 
[77], possibly in KCs. Additionally, there have been reports of bacterial overgrowth in 
the small intestine of NASH patients which may contribute to the development of 
NASH, perhaps by increasing intestinal permeability and promoting the absorption of 
endotoxin or other enteric bacterial products [78].  
Treatment of NASH 
Targeting the metabolic syndrome 
Given the close relationship between obesity, the MetS and NAFLD, treatment of 
suspected NASH is mainly aimed to target several parameters of the MetS, such as 
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obesity, hyperlipidemia, and IR. Treatment of NASH is an important issue because 
NASH readily progresses to cirrhosis, leaving no option but liver transplantation. 
Furthermore, NASH markedly increases the risk of developing liver cancer. 
Weight loss undoubtedly and effectively reduces steatosis [79]. However, its effect on 
the other parameters of NASH, like inflammation and fibrosis, is still unclear [40, 80]. 
Next to weight loss via a restricted diet and exercise, weight loss via bariatric surgery 
has been shown to improve NASH in a large subset of severely obese patients [81]. 
Alternatively, weight loss can be achieved through pharmacotherapy. Recent studies 
describe the effects of Orlistat (Xenical) and Sibutramine (Meridia) as potential 
weight-reducing agents. While Orlistat inhibits gastric and pancreatic lipase, thereby 
reducing fat absorption by about 30% [82], Sibutramine is a serotonergic and 
noradrenergic reuptake inhibitor that enhances satiety [83, 84]. Small scale experiments 
and pilot studies point out that these agents might be useful to treat NASH as in 
general, liver enzymes in the plasma, hepatic fat, and liver histology were improved 
[85-87]. 
To target IR, several insulin-sensitizing agents have been examined for their efficacy in 
treatment of NASH. Metformin, a insulin-sensitizing agent, was shown to improve 
both histological and biochemical features in a mouse model of NASH [88], and in 
human studies [89, 90]. Additionally, several known insulin-sensitizers are agonists for 
the nuclear receptor peroxisome proliferator activated receptor gamma (PPARγ), like 
thiazolidinediones (TZDs). TZDs bind and activate PPARγ. Despite the fact that 
PPARγ activation promotes adipogenesis and FA storage, they exert their therapeutic 
effects by reducing IR at adipose tissue, muscle and liver levels. TZDs are now widely 
used for the treatment of type 2 diabetes [91], although some side effects remain to be 
considered, such as fluid retention, edema, and increased risk of heart failure [92, 93]. 
Treatment of NASH patients with a TZD, pioglitazone, has been recently reported to 
improve steatosis [94, 95], hepatic inflammation and necrosis [94]. The use of another 
nuclear receptor as a therapeutic target, i.e. PPARα, will be discussed in more detail in 
the next section. 
PPARα  and NASH 
PPARs are transcriptional regulators involved in lipid metabolism whose natural 
ligands consist of FAs and their derivative. PPARs are therefore considered to be FA 
sensors [96]. There are three PPAR isoforms, i.e. PPARα, PPARγ (discussed above), 
and PPARβ/δ. PPARs play important roles in the control of lipid and glucose 
metabolism and have been implicated in the described metabolic diseases related to 
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obesity. PPARα is most highly expressed in the liver and is especially known for its 
central role in systemic and hepatic lipid metabolism and inflammation.  
PPARα is a ligand-activated transcription factor that can stimulate the gene 
transcription by binding to specific peroxisome proliferator response elements (PPREs) 
in the promoter regions of target genes. There are numerous target genes of PPARα, 
but most of these are involved lipid uptake and oxidative breakdown [97, 98]. 
Activation of PPARα by increased FAs thus results in their increased oxidation [99], 
thereby preventing lipid activation. Under physiological conditions, the function of 
PPARα is mainly evoked during fasting, which is associated with increased hepatic 
PPARα activation and mRNA transcription, due to increased plasma FA levels 
released from the adipose tissue, to supply substrates that can be metabolized by other 
tissue [100]. Next to the up-regulation of specific target genes, PPARα can inhibit gene 
transcription by interacting and interference with other transcription factors. In this 
manner, PPARα is known to bind and inhibit NF-κB and AP-1, thereby reducing the 
inflammatory response. Therefore, PPARα is a promising target for therapeutical 
strategies against NASH development. 
A class of synthetic PPARα agonists, fibrates, has been used for several years, mainly 
to control hyperlipidemia [101]. Fibrates were shown to decrease plasma TGs, increase 
plasma HDL levels, and decrease levels of the pro-atherogenic small dense LDL in 
human subjects [102]. The use of synthetic PPARα agonists has not yet been tested for 
the efficacy towards the development of NASH in human subjects, despite reports of 
beneficial results in mice. In mice, PPARα activation has been reported to prevent and 
even reverse NASH in a dietary mouse model [103, 104]. Additionally, steatosis can be 
ameliorated by polyunsaturated FAs, at least in part through the activation of PPARα 
[105]. 
However, mice are no men, and notable differences between these two species have to 
be appreciated. It has been shown that humans only express 5% to 10% of the amount 
of PPARα in their livers compared to mice [106], making their liver less responsive to 
PPARα ligands, but still enough to influence plasma TG levels. A possible 
contribution of PPARα to liver lipids remains to be addressed. 
Mouse models of NASH 
Due to ethical issues and practical difficulties, e.g. in diagnosis, of human subjects, 
animal models are crucial to elucidate the mechanisms causing NASH. Mostly, the 
model of choice is the mouse, as it has several advantages over other animals. These 
advantages include large litter size, easy handling and short generation span. 
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Additionally, mice are commonly used to investigate the function of specific genes in 
disease by transgenesis and gene-targeting [107]. 
Until now, the best characterized and most known models for NASH are mice deficient 
for leptin (Ob/Ob) or mice fed a diet deficient in methionine and choline (MCD) [108], 
which will be briefly discussed below. The mice used in the studies described in this 
thesis are fed a diet resembling the one that is consumed by humans in industrialized 
countries, containing increased levels of TGs, carbohydrates and cholesterol.  
Ob/Ob mice 
The Ob/Ob mouse carries a spontaneous genetic defect and was first described in 1950 
[109]. These animals carry an autosomal recessive mutation in the leptin gene and are 
hyperphagic, inactive, obese and highly insulin resistant. Leptin is normally produced 
and secreted by white adipose tissue and acts in the brain to induce satiety. Normally, it 
drives a neuroendocrine response to starvation: as adipose tissue is depleted, leptin 
levels fall, which drives a desire to seek food [110]. Additionally, leptin can influence 
several other physiological processes, among which the inflammatory response [111]. 
Leptin deficient Ob/Ob mice remain thus in a continuous state of physiological 
starvation and hypothermia, which drives these animals to overeat. 
Ob/Ob mice develop severe steatosis but fail to develop spontaneous hepatic 
inflammation. An inflammatory response can only develop by administrating these 
animals a second hit. This second hit can include a small dose of LPS that is 
insufficient to induce inflammation in wild-type animals, or via ethanol exposure or 
ischemia-reperfusion injury [112-114]. These observations are in line with the two-hit 
hypothesis and may confirm that steatosis sensitizes the liver for further injury [108]. 
This animal model has several disadvantages. First, Ob/Ob mice fail to develop hepatic 
inflammation spontaneously, unlike humans. Second, mutation of the leptin gene is not 
common in human obese NASH patients and leptin levels were shown to correlate very 
poorly with the development of NASH [115]. Third, due to the many functions known 
to be attributed to leptin, this mouse represents a complex model of obesity-related 
steatosis as both lipid and glucose metabolism, as well as immunity are disturbed in 
several manners [108]. 
Mice fed a methionine/choline deficient diet 
Both choline and methionine are essential nutrients. The MCD diet leads to an 
impaired synthesis of phosphatidylcholine, which is an essential part of the outer 
phospholipid component of lipoproteins, leading to reduced secretion of liver TGs as 
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VLDL, resulting in accumulation of liver TGs [116, 117]. Additionally, it was shown 
that MCD diet impairs mitochondrial β-oxidation [118]. Both these processes lead to 
steatosis development [118]. Moreover, choline deficiency has been shown to deplete 
hepatic anti-oxidant defences, thereby inducing hepatic inflammation via an increase in 
oxidative stress [119].  
MCD fed mice display all the hallmarks of late-stage NASH, from steatosis to 
inflammation and fibrosis development and are probably the best-established and most 
widely used mouse model to study NASH development [108]. However, MCD fed 
animals tend to lose weight (up to 50%), and display lowered plasma TG levels and 
cholesterol levels [108, 120]. In this regard, they are very dissimilar from human 
NASH patients, who are mostly obese and/or hyperlipidemic. Additionally, this mouse 
model is not overtly insulin resistant, although there are reports indicating these 
animals might develop hepatic IR only [121].  
Hyperlipidemic mice fed a high fat diet 
MetS and steatosis development are associated with high fat feeding and 
hyperlipidemia [122]. Therefore, there is a need for animal models for NASH that 
incorporate these features. Feeding hyperlipidemic mice a diet resembling the 
atherogenic diet frequently consumed in industrialized countries, enriched in 
carbohydrates, lipids and cholesterol has been shown to induce severe steatosis and 
hepatic inflammation [123, 124]. Moreover, one of these mouse models, i.e. the low 
density lipoprotein receptor deficient (ldlr-/-) mouse, has been shown to develop IR 
upon high fat feeding [125]. These mouse models are thus of particular interest to study 
NASH. 
Hyperlipidemic mouse models are constructed based on key genes involved in the 
transport and uptake of dietary lipids in the body. Because lipids are insoluble in water, 
they are packaged into lipoproteins during their transport throughout the body via the 
blood. Lipoproteins generally consist of a hydrophobic core composed of cholesterol 
esters and TGs. This hydrophobic core is surrounded by a monolayer of phospholipids, 
unesterified cholesterol, and apolipoproteins (Apo). These Apos serve to solubilise and 
stabilize the lipid content and also have specialized functions in lipoprotein 
metabolism. 
One of the mouse models used in this thesis bears a (human) mutation in the gene 
encoding ApoE. In the fed state, dietary lipid uptake results in the packaging of TGs 
and cholesterol together with ApoB48 into CM [126]. Via the lymph, CM reach the 
circulation, where they acquire ApoE from HDL particles. ApoC-II, also present in 
CM, activates LpL present on the vessel wall. LpL hydrolyzes TGs from the 
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lipoproteins to produce FAs, which can be taken up by the peripheral tissues for 
oxidation or storage (as described above). The resulting CM remnants are depleted in 
TGs and thus relatively enriched in cholesterol. They are rapidly cleared from the 
plasma by the liver by uptake via the LDL receptor (Ldlr) [127], which is specific for 
ApoB ad ApoE, and by the LDLR related protein (Lrp) [128]. Clearly, loss of function 
in ApoE will undoubtedly lead to an accumulation of these lipoproteins in the plasma, 
as will be discussed in more detail in chapter 2. 
As was mentioned before, the liver can secrete lipids into the circulation by 
synthesizing VLDL particles in an ApoB100-dependent manner for the delivery of 
lipids to peripheral tissues to sustain their energy needs. VLDL contains both TGs and 
cholesterol taken up from the plasma and from hepatic de novo synthesis. These VLDL 
particles undergo a similar hydrolysis as CM particles, yielding IDL and LDL. LDL 
particles contain mostly cholesterol and only ApoB100. Most of LDL is taken up by 
the liver through binding of ApoB tot the LDLR [129]. The internalized cholesterol is 
further processed in the liver to either cholesterol esters, bile acids, vitamins or free 
cholesterol [130]. The LDLR deficient mouse, which is also used in the experiments 
described in this thesis, is thus not capable of efficiently removing both CM and LDL 
remnants from the plasma and will also display hyperlipidemia when fed a high fat 
diet. 
Next to the delivery of TGs and cholesterol from the liver towards peripheral organs, 
cholesterol is transported back to the liver from the periphery in the form of HDL. 
HDL can take up cholesterol in an ApoA-I dependent manner via the cholesterol 
transporter ATP binding cassette (Abc) [131]. HDL particles can transfer their 
cholesterol content to TG-rich lipoproteins by cholesteryl ester transfer protein (CETP) 
[132] or it can be taken up by the liver [133]. As HDL cholesterol transport is the only 
manner in which cholesterol is removed from the body it is often referred to as ‘good’ 
cholesterol. 
The mouse models used in this thesis are genetically modified animals that are 
commonly used in atherosclerosis research and they rely on mutations in genes critical 
in whole-body lipoprotein metabolism. Each of these mouse models has specific 
characteristics as a result of the nature of the introduced mutation and are explained in 
detail in chapter 2.  
Approaches used in this thesis 
This section will briefly introduce the technique of bone marrow transplantation 
(BMT) and genomics, which are utilized in several of our studies which are described 
in this thesis. 
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Bone marrow transplantation 
Nowadays, numerous mouse models exist that bear mutations in one of their genes to 
study the role of this gene product in vivo. To study the role of macrophages (and KCs) 
specifically, we used mouse models that have mutations specifically in their immune 
cell population. Since cells from the immune system originate from the bone marrow, 
BMT was used in several of our experiments. This technique depends on the fact that 
after maturation in bone marrow and entering the circulation, these cells retain their 
capacity to repopulate the bone marrow, a process referred to as homing. 
Acceptor mice are subjected to a lethal dose of irradiation to eradicate the endogenous 
bone marrow stem cells. After irradiation, donor bone marrow from donor mice, 
carrying the desired mutation, are injected in the tail vein of acceptor mice. The donor 
cells will repopulate the bone marrow of the acceptor animals. After BMT, mice will 
be allowed to recover for several weeks as the recipient bone marrow cells are 
gradually replaced [134]. 
In this manner, murine recipients can be provided with a new and functioning 
hematopoietic system, making it feasible to study the role of specific genes in immune 
cells. It has been reported that KCs are replaced in this manner within 14 to 21 days 
[135]. An additional advantage of this approach is that there is no need to perform 
complicated and long-lasting crossings and breeding of different strains of mice, which 
can take up to several years. 
Genomics 
The development of microarrays has made it feasible to measure complete 
transcriptomes [136, 137]. Microarray technology consists of an array with spotted 
sequences to which labelled RNA samples from different cells or tissues are 
hybridized. Since the exact location of each spotted sequence is known, measuring the 
light intensities of the hybridized labels to the arrays shows how much RNA from a 
particular gene has hybridized with the complementary sequence on the array. The 
Affymetrix GeneChip® arrays used in this thesis are single color oligonucleotide 
arrays. Compared to cDNA arrays, these arrays bear oligonucleotide sequences of 25 
basepairs instead of complete cDNA sequences. These oligos are much smaller than 
complete strands of cDNA and allow for a higher density of the array. The Affymetrix 
GeneChip® arrays used in this thesis contain sets of oligos representing 29 000 
different transcripts. In single colour arrays, each expression profile is generated on a 
different chip using a single fluorescent label and scanned, after which different images 
are compared. In dual color arrays, two different RNA samples are labeled separately 
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with different fluorescent tags and then hybridized to a single array, yielding an image 
representing up- and down-regulated genes between these two samples only. In 
general, Affymetrix GeneChip® arrays use 11 to 16 probes of 25 bp to represent each 
transcript. Computer models are used to select these probes based on their specificity 
and cross-hybridization. For each probe designed, a partner probe is generated that is 
identical except for one single base mismatch, making it possible to estimate and 
subtract non-specific cross hybridization [138]. After extraction of RNA, cDNA is 
generated and transcribed in vitro to generate biotin labelled cRNA. The cRNA is then 
fragmented and subsequently hybridized to the Affymetrix GeneChip® arrays. 
Hereafter the chips are washed and stained. Scanning of the chips allows estimating the 
abundance of each represented mRNA species. 
This described technique allows for enormous amounts of knowledge to be gathered 
about the complete set of genes that are expressed at any given moment in any given 
organ, and in response to any given treatment. With several bioinformatical tools, 
biological relevant information is collected which allows increased understanding of 
how an organism responds to a particular treatment, for example (like in this thesis] a 
high fat diet. Genes that are found to be differentially expressed can be clustered 
according to biological function or according to their expression pattern. This 
clustering allows to identify the pathways responsible for a specific response or to 
identify genes that are likely to be regulated by shared regulators, due to their equal 
expression patterns. Moreover, genomics allows tissues to be classified according to 
their gene expression pattern, for example to identify the developmental stage of 
cancers. In this thesis, clustering of data was mainly done according to biological 
function and regulation. 
Thesis outline 
The experimental models that are used in this thesis are hyperlipidemic mice. In 
chapter 2, several hyperlipidemic mouse models are introduced and compared to each 
other. Since these mice are known models of atherosclerosis, their contribution to this 
field of research is also evaluated.  
The first aim of this thesis is to elucidate mechanisms during the early progression of 
NASH by using hyperlipidemic mouse models fed a high fat diet as a physiological 
model for this condition. We specifically focus on the progression from benign 
steatosis to NASH in chapter 3. This chapter describes the early development of 
NASH in the APOE2ki mouse, a humanized mouse model of hyperlipidemia, and its 
prevention by fenofibrate, a PPARα agonist.  
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To further determine which pathways are of specific importance during the early 
progression of NASH, whole-transcriptome analysis was performed in livers of 
APOE2ki mice during progression of diet-induced NASH. This is further described in 
chapter 4. 
Currently, the reason why some, but not all, people with steatosis will progress towards 
NASH remains unclear. Therefore, knowledge of the mechanisms driving 
inflammation is crucial. Chapter 5 describes dietary cholesterol to be causal in the 
early inflammation found previously in APOE2ki mice. The results were compared 
with another hyperlipidemic mouse model, i.e. ldlr-/- mice, and to the response of 
normolipidemic control mice.  
In Chapter 6, experiments are described that further elucidate the mechanisms by 
which cholesterol may act as a risk factor for developing NASH. BMT was used to 
create hyperlipidemic mice with a deficiency in the two major cholesterol scavenging 
receptors specifically in macrophages, i.e. CD36 and scavenger receptor A1 (SRA-1). 
As we found inflammation to be an early player during the progression of NASH, the 
possible contribution of the inflammatory response to development of steatosis was 
investigated in chapter 7. Here, we describe the results obtained in hyperlipidemic 
LDLR-/- mice with hyper-inflammation in their livers with respect to their liver lipid 
levels. 
Finally, chapter 8 will discuss the major findings of this thesis, place them in the 
current state of the field, and address the clinical implications of the results. 
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Abstract 
Hyperlipidemia is the most important risk factor for atherosclerosis, which is the major 
cause of cardiovascular disease. The etiology of hyperlipidemia and atherosclerosis is 
complex and governed by multiple interacting genes. However, mutations in two genes 
have been shown to be directly involved, i.e. the genes coding for the low density 
protein receptor (Ldlr) and apolipoprotein E (ApoE). Genetically modified mouse 
models have been instrumental to elucidate the underlying molecular mechanisms in 
lipid metabolism. In this review, we will focus on two of the most widely used mouse 
models, i.e. the ApoE and Ldlr deficient mice. After almost a decade of applications, it 
is clear that each model has unique strengths and drawbacks when carrying out studies 
on the role of additional genes and environmental factors such as nutrition and lipid-
lowering drugs. Importantly, we will elaborate on mice expressing mutant forms of 
ApoE, including the APOE3Leiden (APOE3L) and the APOE2 knock-in (APOE2ki) 
mouse models. These models have an outstanding potential as they are highly 
responsive to dietary factors and pharmacological interventions. 
Mouse models of atherosclerosis 
 
- 35 - 
 
Introduction 
Atherosclerosis is the major cause of cardiovascular disease (CVD) and is considered a 
complex condition caused by various genetic and environmental factors. It proved to be 
very difficult to identify the responsible hereditary factors. Susceptibility to CVD 
varies among individuals because the genetic component is the result of complex 
interactions among many genes. Only in rare cases, single gene mutations lead to 
atherosclerosis, often in genes with key roles in lipid homeostasis. The best known 
examples are the genes encoding the low density lipoprotein receptor (Ldlr) and 
apolipoprotein E (ApoE). In the early 1980s, the discovery of mutations within these 
genes initiated a major effort scrutinizing the entire set of lipid genes for mutations. A 
more recent example includes the discovery of the role of the ABCA1 gene in Tangiers 
disease, a heritable deficiency of the high-density lipoproteins (HDL).  
Despite the large number of genes linked to lipid disorders, it is still difficult to explain 
the common mild hyperlipidemias at the genetic and molecular level, and genes 
associated with atherosclerosis are even more difficult to identify via human genetic 
studies. 
At present, however, research on mouse models for atherosclerosis is providing crucial 
insights into the role of additional genes and environmental factors. Unfortunately, the 
wild-type (WT) mouse is quite resistant to CVD, due to high levels of anti-atherogenic 
HDL and low levels of pro-atherogenic lipoproteins, i.e. very low density lipoprotein 
(VLDL) and low density lipoprotein (LDL). The definite introduction of the mouse in 
the cardiovascular field, however, became only feasible when technologies, capable of 
generating transgenic and knock-out mice, became generally available. The most 
widely used mouse models were developed using the ldlr and apoe genes. By using 
these mice as sensitized background strains, it became possible to investigate the role 
of additional genes, diets and other environmental factors.  
First, we will introduce the human hyperlipidemias caused by mutations in the LDLR 
and APOE genes. Second, we will describe the models which were based on these 
mutations, and finally, we will delineate how these models are instrumental in further 
delineating  dyslipidemias and atherosclerosis. 
Lipoprotein disorders 
The most common genetic hyperlipidemic disorder is type II hyperlipoproteinemia 
(type II HLP), also referred to as familial hypercholesterolemia (FH), which is 
characterized by elevated plasma LDL levels. FH patients suffer from yellowish lipid 
deposits in the skin and subcutaneous tissue, called xanthomas. Xanthoma tuberosum 
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and tendinosum are characteristic of FH [1]. These patients are also at higher risk of 
developing atherosclerosis. One of several types of FH is a monogenic form, with a 
frequency of 1 in 500 individuals. This form is caused by defects in the gene coding for 
the Ldlr, resulting in a defective clearance of LDL from the plasma. Consequently, this 
lipoprotein, containing large amounts of cholesterol, accumulates in the circulation [2]. 
Type III hyperlipidemia (type III HLP) represents a more rare condition than FH, with 
a frequency of 1 to 4 in 10,000 individuals in the Caucasian population. The cause of 
this abnormality is either ApoE deficiency or a defective form of ApoE, which cannot 
fully bind to their receptors. This malfunctioning ApoE has also variable binding 
capacities to heparin sulfated proteoglycans (HSPG), which is needed for the uptake 
via the LDLR related protein (LRP)-mediated secretion-recapture process [3-5]. It is 
hallmarked by an accumulation of chylomicron remnants (CMR), which originate from 
intestine-derived lipoproteins, and VLDL remnants (VLDLR), originating from liver-
derived VLDL. These lipoprotein remnants are collectively called β-VLDL. The 
disorder is therefore also called familial dysbetalipoproteinemia (FD) [3, 6]. FD 
patients have elevated levels of triglycerides (TGs) and total cholesterol (TC) in the 
plasma and also suffer from xanthomas, mainly palmar crease xanthoma, which is 
indicative of this condition [1, 3]. Similar to FH, type III HLP patients have an 
increased susceptibility to atherosclerosis. 
ApoE was initially found to be a component of VLDL [7] and later of the type III 
hyperlipidemia-associated β-VLDL as well [8]. VLDL and β-VLDL were shown to 
have far higher affinity for the LDL receptor than LDL itself, which contains ApoB 
instead of ApoE [9]. ApoE thus serves for the clearance of chylomicrons and VLDL 
from the plasma. Several other functions for ApoE have also been described. It is a 
ligand for hepatic clearance via the LRP [10, 11], it modulates Lipoprotein Lipase 
(LpL) activity, presumably by masking APOCII, an activator of LpL [12, 13]. 
Furthermore, it can stimulate VLDL production in the liver [12, 14] in an isoform 
specific manner [15] and modulate cholesterol efflux from different cells and tissues 
[16, 17] (see figure 1: Major functions of APOE). Therefore it is clear that any 
malfunctioning of the APOE protein could have drastic consequences for lipoprotein 
metabolism. 
The most common cause of FD is homozygosity of the allele for the ApoE2 isoform. 
APOE2 has a gene frequency of 10% in the human population. It contains a cystein 
instead of an arginine at residue 158 [3]. Due to this mutation, ApoE has lost more than 
99% of its binding capacity to its receptor compared to ApoE3, the common isoform. 
ApoE2 is proposed to be associated with a recessive mode of inheritance. Most 
isoforms are preferentially confined to the VLDL fraction, whereas the ApoE2 isoform 
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seems to be more present in HDL. If ApoE2 and the common isoform would be present 
in the plasma at equal levels (heterozygosity), ApoE2 would preferentially associate 
with HDL, leading to VLDL containing mostly the normal ApoE3 and making them 
more suitable for clearance from the blood (reviewed by Mahley, Huang and Rall 
[18]). Nevertheless, a very small percentage (5%) of homozygote individuals will 
eventually develop FD. This probably means that, due to the low penetrance of FD, 
other genes and environmental factors have a modulatory effect on this disorder.  
 
Figure 1. Major functions of ApoE. Triglycerides (TGs), cholesterol and other lipids are packaged into 
chylomicrons (CM) after digestion and absorption in the intestine. CMs contain the apolipoprotein ApoB, 
ApoC and ApoE. The CMs enter the circulation where their TGs get hydrolyzed by LpL, which can be 
modulated by apoE. The resulting CM remnants (CMR) are rapidly taken up by the liver trough the binding 
of apoe to the LDLR and the LRP. ApoE can also stimulate VLDL production in and secretion out of the 
liver. Circulating VLDL particles, which contain ApoE and ApoB, also undergo lipolysis, turning them into 
VLDL remnants or IDL. IDLs get internalized by the liver trough binding to the LDLR and the LRP, which 
makes this process also dependent on ApoE. Further lipolysis of remaining IDLs results in LDL. These 
lipoproteins can be taken up by the LDLR trough binding with the ApoB particles present in LDLs. ApoE 
can also modulate cholesterol efflux out of the peripheral tissues to small circulating HDL. 
Other defective ApoE isoforms lead to a dominant pattern of inheritance, but are rarer. 
An example of this is the ApoE3Leiden (ApoE3L) isoform, which has an extra 7-
amino acid tandem repeat sequence at residues 121-127. This leads to a conformational 
change in the protein which prevents adequate binding to hepatic receptors [19]. 
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There are also several other lipoprotein disorders besides these two diseases, including 
type I, type IV and type V hyperlipoproteinemia. Some risk factors for these conditions 
are very well known, like LpL and ApoCII deficiency, while others remain to be found.  
The use of hyperlipidemic mouse models in 
cardiovascular research 
Using mice in atherosclerosis research has many advantages such as easy handling, 
short generation span and large litter size. On the other hand, differences between mice 
and men in terms of susceptibility for atherosclerosis, lipoprotein metabolism and 
plaque morphology have to be appreciated. 
Normally, mice are resistant to atherosclerosis, but Paigen et al. [20] demonstrated a 
huge variation in atherosclerosis formation in ten different inbred mice strains upon 
feeding a pro-atherogenic diet. Due to this diet, the mice all developed hyperlipidemia 
although the formation of atherosclerosis differed enormously between the different 
inbred strains with no correlation with plasma lipid levels. The C57Bl/6 strain appeared 
to be most susceptible for atherosclerotic lesion formation. Despite the large amount of 
cholesterol (1,25%) and the presence of (sodium) cholate (0,5%) in the atherogenic 
diet, these mice showed very simple and small lesions, mainly consisting of lipid laden 
macrophages, also called foam cells. This plaque morphology did not resemble the 
advanced human plaque, which consists of altered endothelial cells, foam cells and 
proliferating smooth muscle cells that form fibrous tissue. This fibrous tissue forms a 
fibrotic cap which overlies a core of lipid and necrotic tissue. Eventually, the fibrotic 
cap may rupture, which can cause thrombosis, thus leading to an acute coronary event 
and/or stroke [21, 22]. 
The Paigen diet [20] was determined to be unphysiological [23] and it has been 
demonstrated that the high cholesterol and the addition of cholate in the atherogenic 
diet causes an inflammatory response in the liver and other tissues, possibly arteries 
[24, 25]. Atherosclerosis is becoming increasingly known as a disease in which 
inflammation plays a major role in its development [21], so the use of the pro-
inflammatory, cholate-containing diet is controversial. Moreover, the application of the 
mouse in atherosclerosis research remained limited.  
This situation changed dramatically, when genetically modified animals where 
generated lacking certain genes important for lipid metabolism, like the apoe knock-out 
(apoe-/-) and the ldlr knock-out (ldlr-/-) mice [26, 27]. Other mice were created with 
human genes inserted into the mouse genome, e.g. the transgenic APOE3Leiden mouse 
[28]. It became also possible to specifically replace mouse genes with their human 
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counterparts like the APOE2 knock-in (APOE2ki) mouse [29]. The properties and 
application of these mouse models will be discussed below. Table 1 shows a short 
overview of the cholesterol distributions in the lipoprotein factions of these mice. 
apoe-/- mouse model 
A mouse deficient for the apoe gene was created in different laboratories [26, 27]. On a 
normal chow diet, these animals display plasma cholesterol levels of at least five times 
more than their WT counterparts. When given a high-fat diet (HFD), mildly elevated in 
cholesterol without added cholate, the mice had even a further 3-fold rise. TGs were 
lowered to half of the level that was observed in chow-fed animals [26]. A HFD 
containing higher amounts of cholesterol and cholate resulted in a very large increase 
of TC levels, while TG levels did not change [27, 30]. Cholesterol was mainly found in 
VLDL/IDL fractions in apoe-/- mice when fed chow and high-fat feeding. To a lesser 
extent it was in the LDL fraction of these animals (table 1). This lipid distribution 
resembles the lipid profiles found in type III hyperlipidemia patients although the 
composition of VLDL particles differs dramatically [4, 6]. Even heterozygous 
expression of the apoe gene caused hyperlipidemia [31]. 
Spontaneous plaque formation was found in these animals [27] but, in line with their 
enormous response to high fat feeding, it is possible to induce accelerated and more 
severe atherosclerotic plaques in many vascular areas when given a HFD [26, 28, 30]. 
Lesions consisted of foam cells and a lipid containing necrotic core. A proliferative 
cellular response was found in the vessel wall as well as a fibrous cap [26]. 
Accordingly, the lesions closely resemble advanced human plaques and therefore, the 
availability of the apoe-/- mouse can be considered an important landmark in the use of 
mouse models to study atherosclerosis.  
Due to these responses upon high fat feeding, the apoe-/- mouse has been become the 
most widely used mouse model for hyperlipidemia and atherosclerosis. This model is 
therefore particularly useful as a sensitized strain to investigate the role of additional 
genes. In particular, insights can be obtained in the role of genes that are unrelated to 
lipid metabolism. Such genes will be crucial to study in the absence of very severe 
diets, and in those cases the apoe-/- model is the preferred alternative. Using this 
strategy, various genes that are implicated in atherogenesis, ranging from genes related 
to inflammation, hyperglycemia, hypertension and coagulation, have been identified 
(for review see [32]).  
Mice carrying “candidate genes”, which are suspected to be involved in atherogenesis, 
can be crossed with apoe-/- mice. These crosses may lead to a better understanding of 
the role of that specific mutation in atherosclerosis. Unfortunately, when using such 
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crosses between transgenic mice, one remains confined to studying these candidate 
genes. It is also possible to follow an unbiased approach using mouse genetics. By 
doing a series of crosses between mice, several quantitative trait loci (QTL) can be 
found. In this manner, several loci on the mouse genome have been identified to carry 
genes likely to be involved in the pathology of atherogenesis [33, 34]. 
The clinical relevance to human atherosclerosis remained questionable since common 
clinical events such as plaque rupture and thrombosis could not be identified until, not 
so long ago, these events were found in the innominate artery by Rosenfeld et al. [35]. 
As reviewed by Cullen et al. [36] a few more mouse models of plaque rupture 
emerged, however, these models are still rather controversial. In addition, the site-
specifity of atherosclerotic plaques remains subject of debate. Probably due to 
differences in blood flow, specific parts of the vasculature are more prone to 
atherosclerosis. Therefore, it is possible that plaque formation at some sites in the 
mouse arterial tree is more relevant to human atherogenesis than others. However, up 
until recently, no more than one site was the subject of intensive research, i.e. the 
murine aortic sinus, while this site shows no atherosclerosis in humans (for review see 
[37]). This review notes that it is necessary to study more than only one site in the 
circulation. Of particular interest is the fact that even opposite results can be found at 
different sites of the artery [38]. 
As recently reviewed by Meir and Leitersdorf [39], over the past few years the apoe-/- 
mice have been extensively used to examine the effects of nutritional and 
pharmacological interventions on atherosclerosis. However, a major shortcoming of the 
apoe-/- mouse is that their lipoprotein profiles are dissimilar from human individuals, 
who have most of their cholesterol in LDL particles. Another drawback is that these 
mice do not have any ApoE, while, as stated earlier, this lipoprotein has many different 
functions in the organism. This will complicate studies and results directed to elucidate 
the mechanism of lipid metabolism, in particularly the mechanisms of drug and dietary 
action. 
A good example of this complication are statins (for review see [40]). Normally these 
drugs lower cholesterol levels drastically, by inhibiting 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, but in apoe-/- mice cholesterol levels and plaque 
area rise upon treatment with this drug [41]. Although this phenomenon may seem a 
major disadvantage, it provides a chance of studying the effects of statins on plaque 
formation despite the paradoxical hyperlipidemic effect. This was shown in an 
interesting study by Bea et al. who showed that simvastatin has a stabilizing effect on 
the atherosclerotic plaque [42]. 
Another unique feature in the apoe-/- mouse model was observed when these mice 
received fibrates. This drug normally causes an increased oxidation and a decreased 
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hepatic VLDL secretion in WT mice by serving as a ligand for the nuclear receptor 
peroxisome proliferator activated receptor alpha (PPARα), thereby lowering plasma 
lipid levels. In the apoe-/- mice, however, cipofibrate and other fibrates caused a 3- to 4-
fold increase in plasma cholesterol levels [43]. Remarkably, this study concluded that 
atherosclerotic lesions were also more advanced upon fibrate treatment (90 days) than 
in control animals. These observations are supported by a study using PPARα/apoe 
double knock-out mice, in which the PPARα deficiency resulted in less atherosclerosis 
than in the apoe-/- mice [44]. However, it was also shown that short-term treatment with 
a PPARα ligand can decrease atherosclerosis slightly [45]. The lipid-raising effect of 
fibrates could be attributed to a fibrate-induced down-regulation of the hepatic 
scavenger receptor B type I (SRBI) [46]. This receptor mediates cholesterol uptake 
from HDL particles, but also was found to bind ApoB, therefore possibly playing a role 
as backup for VLDL and LDL uptake, and to bind modified LDL [47, 48]. 
ldlr -/- mouse model 
By eliminating the functional gene for the Ldlr, Ishibashi et al. [49] created a mouse 
model that displayed mildly elevated cholesterol levels on a diet containing elevated fat 
and cholesterol levels, but no cholate. A very small part of this cholesterol was 
confined to the VLDL fraction, but the biggest rise was present in the IDL/LDL 
fraction (table 1). Compared to WT mice, HDL cholesterol was slightly augmented on 
a chow diet. In contrast to the WT lipoprotein profile, where most cholesterol is present 
in the HDL fraction, this profile is more comparable with the human plasma 
lipoprotein profile, in which cholesterol is mainly confined to the LDL fraction.  
Quantification of atherosclerosis showed mild to moderate atherosclerotic lesions in 
the aortic root and coronary arteries of mice fed a mild atherogenic diet lacking 
excessive amounts of cholesterol and cholate [20]. Despite the rise in plasma 
cholesterol in these mice, the effect was not as dramatic as expected. This is probably 
due to the fact that mice, unlike humans, produce approximately 70% of their liver 
apoB as the truncated apoB48 form [50]. ApoB48 cannot bind the LDLR, but together 
with ApoE, it does mediate clearance via the LRP [11]. Since the LDLR binds LDL via 
ApoB100, these mice have a rescue pathway through which the lipoproteins, 
containing ApoB48, can be taken up. LRP plays only a significant role in the uptake of 
ApoB48 containing lipoproteins but not of ApoB100 lipoproteins [51]. Other papers 
also have described an important role for additional receptors. The LRP pathway could 
function as a backup mechanism for the clearance of remnants when the LDLR is 
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genetically deficient [52]. Notably, in the absence of both LDLR and LRP, still 
additional routes for the uptake of lipoproteins through the liver exist [53].  
Like in the case of models involving apoe, the ldlr-/-  mice have served as a model to 
study the role of additional genes in atherosclerosis, although to a lesser extent than 
apoe-/- mice [32, 54]. 
However, the ldlr-/- mice are becoming more appreciated, serving as excellent host for 
bone marrow transplantation (BMT) experiments [55]. Using this technique, mice are 
depleted from white blood cells (WBCs) by irradiation and subsequently injected with 
WBCs isolated from mice carrying a certain (transgenic/knock-out) mutation, leading 
to an organism that contains WBCs carrying defects, which are not present in the 
remaining tissues. Since WBCs, and in particular macrophages and T-cells, have an 
established role in the pathogenesis of atherosclerosis [22], this technology is widely 
applied. The apoe-/- mouse is a less preferred host for BMT experiments, because the 
ApoE produced by the BMT cells will rescue the apoe deficiency, and the transplanted 
mice are no longer susceptible to develop atherosclerosis [56]. Therefore, apoe-/- mice 
can only be transferred with apoe-deficient bone marrow, requiring complex breeding 
schemes. A good example of the use of the ldlr-/- mice in BMT experiments includes a 
study where, unexpectedly, deletion of the nuclear factor kappa beta (NF-κB) activator 
IκB kinase beta (IKKβ) in macrophages caused a significant worsening of 
atherosclerosis in these mice [57]. This could be explained by the observed reduction 
in the anti-inflammatory cytokine interleukin 10 (IL10). These data suggest a dual role 
for NF-κB in inflammation, not only promoting the inflammatory response, but also 
controlling it. 
We have to keep in mind that in the ldlr knock-out mouse model a complete gene was 
deleted from the genome, which, as with the apoe-/- mice, may uncover the role of 
backup systems, like the LRP pathway. This route can serve as a backup mechanism 
for lipoprotein clearance in the ldlr-/- mice [58], yielding unforeseen side effects. 
APOE3Leiden mouse model 
The mouse model expressing the APOE3L gene was created by transgenesis using 
DNA from one of the APOE3L carriers to generate the gene construct [28]. The 
transgenic mouse carries a gene construct consisting of the APOE3L gene, the APOC1 
gene and a hepatic control element that was found to regulate the expression of both 
the APOE and APOC1 genes in the liver [59]. Although the APOE3L mouse still 
expresses the endogenous ApoE, it exhibits a hyperlipidemic phenotype, which is in 
line with the dominant manner of inheritance as observed in humans [28]. Mice over-
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expressing the APOC1 gene have elevated TG and TC levels (for review see [60]). 
This is mainly due to the impairment of VLDL uptake by both the LDLR and the LRP. 
Consequently, ApoC1 serves to further increase the level of plasma TGs [61]. 
When fed on chow, the APOE3L mice show a small increase in cholesterol levels and 
a doubling of plasma TGs. However, these animals seemed to be very responsive to a 
HFD containing cholate, displaying an increase in plasma cholesterol levels of about 
10-fold, mainly in the VLDL fraction. TG levels decreased to almost half of the value 
compared to the value when fed on chow [62] (table 1). After a period of only 14 days 
feeding an atherogenic diet, atherosclerotic plaques were found in these mice at the 
sinus valves, the carotid arteries and other parts of the aorta. A positive correlation was 
seen between lesion area and serum cholesterol levels, indicating the hyperlipidemia to 
be an important determinant in lesion formation [62]. However, APOE3L mice were 
found to be less susceptible to atherosclerosis than the apoe-/- mouse [63].  
  
  
mutant vs WT 
(chow)  WTD vs chow  HFC vs chow  refs 
apoe-/- VLDL  ↑↑↑  ↑↑  ↑↑↑  [27, 28, 30] 
 LDL   ↑↑  ↑  ↑↑     
ldlr-/- VLDL  ↑  ↑  ↑↑  [45, 81] 
 LDL   ↑  ↑↑  ↑↑     
APOE3L VLDL  ↑  ↑  ↑↑↑  [58] 
 LDL   ↑  ↑↑  ↑↑     
APOE2ki VLDL  ↑↑↑  ↑↑ ∗  -  [26, 70] 
 LDL  ↑↑  ↑ ∗  -   
 
Table 1. Cholesterol distribution in lipoprotein fractions of different lipoprotein fractions of the genetically 
altered mouse models. The first column (‘mutant vs WT’) indicates the levels in the mouse model when fed 
a normal chow diet compared to a wild-type (WT) mouse on a chow diet. The two other columns (‘WTD vs 
chow’ and ‘HFC vs chow’) both indicate cholesterol levels of the mouse model on a certain diet compared 
to cholesterol levels of that mouse model on a normal chow diet. Arrows indicate the amount of rising or 
lowering of the specific mouse models on specific diets: ↑: small rise;  ↑↑: considerable rise;  ↑↑↑: extreme 
rise. WTD: Western Type Diet containing moderately elevated cholesterol levels;  HFC: High fat diet 
containing cholate (pro-atherogenic diet). * Only data from male mice 
The most valuable property of this model is the excellent response to drugs and diet 
interventions. In part, this is due to the fact that the main cause of the hyperlipidemia in 
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this model is a reduction of the VLDL turnover, due to decreased LDLR binding and 
decreased lipolysis of VLDL. This modification is subtler than the complete ApoE 
deficiency in the apoe-/- model. 
Importantly, unlike the apoe-/- mouse, the APOE3L mouse shows a hypolipidemic 
response to known lipid lowering drugs as statins, like lovastatin, and to PPARα 
agonists, like gemfibrozil [64]. As mentioned before, a positive correlation was found 
between the lesion area and the serum cholesterol exposure [63], so lipid lowering 
using a statin treatment significantly retarded the progression of atherosclerotic lesions 
[65, 66]. The APOE3L model is therefore an excellent model to test the hypolipidemic 
properties of these kinds of drugs. 
The effects of dietary fish oil were tested in this hyperlipidemic mouse model [67]. In 
contrast to the apoe-/- mouse, the APOE3L mouse seemed to be highly responsive to 
this treatment. There was a strong reduction in serum VLDL, due to a decrease in 
hepatic VLDL-TG production, induced by n-3 poly unsaturated fatty acids (PUFAs). 
The APOE3L mouse is well suited to study protein function and interaction with other 
genes. Since this gene is found in humans, the nature of disease can become clearer 
using these mice. It has to be kept in mind that the mouse apoe gene is still functional. 
A major disadvantage of this mouse is that they have to be fed a cholate containing 
atherogenic diet in order to develop a large increase of plasma lipids and 
atherosclerosis. Cholate containing diets have been proven to promote inflammation, 
liver fatty acid and cholesterol changes and gall stone formation [24, 25, 68], which 
makes research of the plaque itself and its development, especially regarding to 
inflammation, very difficult. 
Common APOE alleles in mouse models 
The ApoE2 isoform causes the same phenotype in humans as ApoE3L isoform does, 
but in a recessive way, as described earlier in this review. The recessive properties of 
APOE2 also become apparent in the mouse. When fed a chow diet, the APOE2 
transgenic mouse (APOE2TG) [69] showed no higher cholesterol levels when 
compared with non-transgenic mice. Also on a HFD these mice did not develop 
hyperlipidemia. This was due to the presence of the endogenous ApoE. However, when 
expressed at very high levels (more than 50 mg/dl), cholesterol levels were 50% higher 
[70]. When mice were bred on an apoe-/- background, they became severely 
hyperlipidemic, even when given a chow diet. This is quite remarkable, because in 
humans, only a small percentage of homozygotes develops FD [3]. It was proposed that 
the reduced availability of apoB-100 could be the cause of the pronounced phenotype, 
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making the APOE2TG/apoe-/- mice much more dependent on ApoE-mediated 
lipoprotein clearance via the LDLR. 
The APOE2TG mouse was used together with the APOE3L and the apoe-/- mouse 
models to assess binding of β-VLDL to HSPG, a process necessary for the LRP-
mediated secretion-recapture process for lipoprotein uptake [11]. It showed that LpL 
enhances this process and that ApoE is no absolute requirement for binding, but results 
in an, isoform-dependent, increased binding [71]. Crossing the APOE2TG and the 
APOE3L mice on a apoe-/-ldlr-/- background showed that clearance of ApoE2 and 
ApoE3L containing lipoproteins in absence of the LDLR, thus via alternative pathways 
such as LRP, is inefficient [72]. This shows the pivotal role of the LDLR for clearance 
of VLDL remnants. 
Models containing the most common human APOE alleles, i.e. E2, E3, E4, have been 
generated in mice [29, 73, 74]. Using homologous recombination in embryonic stem 
cells, the mouse apoe gene has been replaced by the human gene. This approach has 
the advantage that the gene precisely replaces the endogenous apoe gene. Hence, the 
human ApoE isoform is expressed according to the normal physiological regulation.  
The APOE2ki mice show a phenotype very similar to human Type III HLP: a 2- to 3-
fold elevation of TC and TG plasma levels, confined to the β-VLDL fraction. These 
mice respond markedly to diets containing mildly elevated levels of fat and cholesterol. 
An advantage of this mouse model is that no cholate is needed in the diet to obtain 
severe diet-induced hyperlipidemia and atherosclerosis. Interestingly, the knock-in 
mice show the full spectrum of atherosclerotic lesions, even on a regular diet [29].  
The APOE2 knock-in mice show a complete penetrance of the type III HLP phenotype. 
To test whether the ApoB-48 hypothesis was correct, APOE2ki mice were used in a 
study where ApoB-100 instead of ApoB-48 was expressed, by deleting the gene 
responsible for ApoB-100 editing. This study showed that expression of solely ApoB-
100 was not sufficient to reverse the hyperlipidemic phenotype, probably because 
ApoB-48 and ApoB-100 influence lipoprotein metabolism differently [75]. These 
results indicate that the strong phenotype of APOE2ki mice is not entirely dependent 
on the difference in ApoB editing. Using these mice, it should be possible to determine 
which conditions predispose to the development of type III HLP in humans. A reduced 
expression of the LDLR could be one of many possible explanations. It was shown that 
plasma lipoprotein profile in mice could be ameliorated by over-expression of the 
human LDLR in APOE2ki mice [76], again suggesting an important role for this 
receptor, as also shown in the other APOE mouse models [72]. The APOE2ki mouse 
model has not yet been intensively studied, but may prove to be a good mouse model 
for hyperlipidemia and atherosclerosis. Unlike the apoe-/- mouse, this mouse model has 
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a lipoprotein profile that mimics that of Type III HLP patients. Another advantage over 
apoe-/- mice is the responsiveness to fibrates, indicating that this mouse model may also 
serve as a good model for drug-testing. Sullivan et al. [73] found large variations in the 
response on a HFD between male and female APOE2ki mice. However, it is not clear 
whether these differences are due to the difference in sex or to different administered 
diets. 
The APOE3 knock-in (APOE3ki) mouse, expressing the most common human ApoE 
isoform, and APOE4 knock-in (APOE4ki) mice show phenotypes similar to each other, 
although there are some differences in lipoprotein distribution. Both show lower 
plasma lipid levels than APOE2ki when fed on a chow diet [74]. Combining data from 
those three models led to conclude that differences in ApoE structure alone can be 
sufficient to cause differences in VLDL metabolism and atherosclerosis risk in mice 
[74]. In animals that over-express the human LDLR, a remarkable observation was 
made. It was found that APOE4ki mice with higher LDLR expression showed 
accumulation of lipoprotein remnant proteins and increased atherosclerosis, despite the 
higher affinity of this isoform for the LDLR. This could not be found in APOE3ki 
mice. The postulated explanation is that ApoE4 becomes trapped in the liver due to its 
high affinity for the LDLR. Hence newly-synthesized lipoproteins cannot acquire the 
trapped ApoE and it will become deficient in this apolipoprotein, resulting in slower 
clearance from the plasma [77, 78]. Another possible way of manipulating mice 
genetically to study ApoE function in vivo in mice is by using adenovirus-mediated 
gene transfer. This technique uses genetically modified adenoviruses to deliver 
exogenous genes to several tissues in an organism (for reviews see [78, 79]). Several 
studies have proven the use of this technique to gain more insight in lipoprotein 
metabolism [49]. This approach has been effectively used to determine which ApoE-
domains are required for cholesterol and TG homeostasis in vivo [80] as well as to 
investigate the relative importance of this apolipoprotein in remnant clearance and the 
pathology of type III HLP. 
Conclusions and future prospects   
Before setting up an animal experiment, great thought has to be put into the choice of 
the right mouse model, weighing possible advantages against the disadvantages, 
keeping the principal aim of the study in mind.  
In this review, we have demonstrated that mouse models based on two pivotal genes of 
the lipid metabolism, i.e. APOE and LDLR, have provided us with models to study the 
mechanism of lipid metabolism and atherosclerosis. For the applicability of each 
mouse model, see an overview in table 2. 
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Table 2. Application of mouse models of hyperlipidemia and atherosclerosis.  Table representing suitability 
of several discussed mouse models for the experimental use in atherosclerotic research, such as the effect of 
lipoprotein levels and types, inflammation and drug-intervention on the formation of atherogenesis as well 
as for the study of atherosclerotic plaques. Also the applicability in research of lipoprotein metabolism is 
assessed: i.e. the effect of lipid lowering drugs, nutritional intervention and gene-gene interactions.  
Applicability is shown according to following legend: +: fair mouse model, ++: good mouse model; +++: 
excellent mouse model;  -: mouse model not suitable. Remarks: 1:  ApoE-independent mechanisms: in this 
way effects of drugs can be investigated without considering their lipid-lowering effect. 2:  except for 
ApoE-dependent mechanisms as was shown that the lipid lowering effect of some nutritional interventions 
is of no effect in apoe-/- mice. 3:  All models are more or less equal, however, sometimes complementary 
studies are necessary (e.g. knock-out model together with over-expressing transgene) to study full gene 
effect. 
It appeared to be particularly useful to use genetically engineered strains as a tool to 
expose the role of additional genes in atherosclerosis. Genetic combinations can be 
easily obtained by crossing different transgenic and knock-out models. Thereby, the 
models emphasize the polygenetic nature of atherogenesis. At present, many gene-gene 
combinations have been tested. An overview of these studies has been published [39, 
81], and falls beyond the scope of this review. In the near future, the emphasis is likely 
to shift towards combining the transgenic models with mouse genetics and genome 
wide expression analysis. In each of these areas, progress has been made recently. 
Dansky et al. used two inbred strains of mice, which were both deficient for the apoe 
gene. Using these mice, that are sensitized for atherosclerosis, he was able to find 
several unique QTLs in addition to already described QTLs [82]. Taking it a step 
further, Schadt et al. combined classical genetics with expression studies [83]. They 
found so called expression QTLs (eQTL) by correlating DNA variations with gene 
  ldlr-/-  apoe-/-  APOE3L 
atherosclerosis      
lipoprotein  ++  +  ++ 
plaque formation +++  +++  +++ 
drug-intervention +  ++1  ++ 
inflammation ++  ++  - 
lipoprotein metabolism      
lipid lowering drugs +  -  +++ 
nutritional intervention +  +2  +++ 
gene-gene interaction ++3  ++3  ++3 
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expression levels, tracking down possible causes of differential expression in sequence 
variations. These studies may unravel unidentified gene-gene interactions, group 
individuals that resemble genetically and discover biochemical pathways [84]. 
A further integration of these approaches will eventually provide us with detailed 
insight in the complex genetics of CVD. 
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Abstract 
Background/aims: The molecular mechanisms leading to non-alcoholic steatohepatitis 
(NASH) are not fully understood. In mice, NASH can be inhibited by fenofibrate, a 
synthetic agonist for the nuclear receptor peroxisome proliferator activated receptor 
alpha, which regulates hepatic triglyceride metabolism. This study aimed to elucidate 
the relation between steatosis and inflammation in NASH in a human-like 
hyperlipidemic mouse model.   
Methods: Liver phenotype and gene expression were assessed in APOE2 knock-in 
mice that were fed a western-type high fat diet with or without co-administration of 
fenofibrate.  
Results: In response to a western diet, APOE2 knock-in mice developed NASH 
characterized by steatosis and inflammation. Strikingly, macrophage accumulation in 
the liver preceded the steatosis during progression of the disease. This phenotype was 
in line with gene expression patterns, which showed regulation of two major groups of 
genes, i.e. inflammatory and lipid genes. Fenofibrate treatment decreased hepatic 
macrophage accumulation and abolished steatosis. Moreover, a marked reduction in the 
expression of inflammatory genes occurred immediately after fibrate treatment.  
Conclusions: These data indicate that inflammation might play an instrumental role 
during the development of NASH in this mouse model. Inhibition of NASH by 
fenofibrate may be due, at least in part, to its inhibitory effect on pro-inflammatory 
genes. 
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Introduction 
Non-alcoholic steatohepatitis (NASH) is characterized by pathological alterations 
ranging from steatosis and inflammation to cell degeneration, fibrosis and cirrhosis [1]. 
The pathogenesis of NASH remains poorly understood. It is a component of the 
metabolic syndrome and therefore frequently associated with hyperlipidemia [2]. 
Indeed, several mouse models of hyperlipidemia, such as ldlr-/- and apoe-/- mice 
develop steatohepatitis upon high-fat feeding [3, 4].  
In order to study the development of NASH and the relationship of steatosis and 
inflammation, we used the ‘humanized’ APOE2 knock-in (APOE2ki) mouse, in which 
the human APOE2 allele replaces the murine apoe gene. These mice express human 
APOE2 under the control of the endogenous promoter sequences in a tissue specific 
manner and at physiological levels. APOE2 has a markedly reduced affinity for the low 
density lipoprotein (LDL) receptor, leading to a plasma lipoprotein profile resembling 
human type III hyperlipoproteinemia (HLP) [5].  
Similar to humans, APOE2ki mice are responsive to lipid-lowering drugs such as 
fibrates, ligands for peroxisome proliferator activated receptor (PPARα) [5]. This 
nuclear receptor enhances the expression of genes involved in fatty acid (FA) uptake, 
esterification and beta-oxidation [6] and has been shown to reverse steatohepatitis in 
mice [7]. Accordingly, fenofibrate (FF) was administrated to investigate the molecular 
mechanisms leading to the inhibition of NASH. 
In this study, APOE2ki mice were fed a high-fat diet in the absence or presence of 
fenofibrate. The changes in plasma lipids, liver phenotype and gene expression were 
followed in time to discriminate between early (primary) and late (secondary) events 
related to NASH. 
Materials and methods 
Mice and diet 
APOE2ki mice [5] were housed under standard conditions given free access to food 
and water. Experiments were performed according to Dutch laws, approved by the 
Committee for Animal Welfare of Maastricht University. 
Ninety homozygote female mice, 13 weeks old, were divided into groups of 10 mice. 
One group was kept on standard chow. Four groups were fed a western diet, containing 
17% casein, 0.3% DL-methionine, 34% sucrose, 14.5% cornstarch, 0.2% cholesterol, 
5% cellulose, 7% CM 205B, 1% vit 200, 21% butter (diet 1635, Scientific Animal 
Food and Engineering, Villemoisson-sur-orge, France) for 2, 4, 7 and 21 days. Four 
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groups were put on the western-diet completed with 0.2% fenofibrate (F6020, Sigma 
Aldrich, Zwijndrecht, the Netherlands) for 2, 4, 7 and 21 days. Blood samples were 
taken from the tail after a 4-h fast and collected in glass capillaries, coated with heparin 
and diethyl p-nitrophenyl phosphate [8] (D9286, Sigma Aldrich, Zwijndrecht, the 
Netherlands). Mice were sacrificed by cervical dislocation. Tissues were isolated, snap-
frozen in liquid nitrogen and stored at -80oC or fixed in 4% formaldehyde/PBS. 
Plasma parameters 
Plasma total cholesterol (TC) and triglyceride (TGs) were measured (1489232, 
cholesterol CHOD-PAP, Roche, Almere, the Netherlands; 337-B, TG GPO-trinder, 
Sigma Aldrich, Zwijndrecht, the Netherlands) according to manufacturer’s protocols 
on a Benchmark 550 Micro-plate Reader (170-6750XTU, Bio-Rad, Veenendaal, the 
Netherlands).  
Lipoprotein profiles were determined on pooled plasma samples from 10 mice using an 
AKTA Basic chromatography system with a Superose 6PC 3.2/30 column (Amersham 
Biosciences, Roosendaal, The Netherlands). 
RNA isolation 
Total RNA was isolated from frozen tissues homogenized in TriReagent (T9424, 
Sigma Aldrich, Zwijndrecht, the Netherlands) with the MiniBeadBeater (3110BXEUR, 
Biospec Products, Bartlesville, USA). RNA clean-up was performed using Qiagen 
RNeasy Mini Kit (74104, Qiagen, Venlo, the Netherlands). Quality and quantity were 
determined with Agilent2100 Bioanalyzer and RNA 6000 NanoLabChip (5065-4476, 
AgilentTechnologies, Amstelveen, the Netherlands). Applications were done according 
to manufacturer's instructions. 
cDNA synthesis and microarray hybridization 
Pools of 10 mice were made from equal amounts of RNA from each mouse. 6 μg of 
pooled liver RNA was used in cDNA synthesis. Samples were hybridized to 
Affymetrix Mouse Expression Array 430A (900412, Affymetrix UK Ltd, High 
Wycombe, UK) according to manufacturer's protocols. 
Microarray analysis 
Raw data from the microarrays was analyzed using GeneChip Microarray Suite 5.0 
(MAS 5.0, Affymetrix) and Data Mining Tools 3.1 (DMT 3.1, Affymetrix). To identify 
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regulated genes, ANOVA analysis was applied based on probe level information with, 
R (http://www.r-project.org) and Bioconductor (http://www.bioconductor.org) was 
used. After normalization, a model was developed, based on probe level intensity for 
each probe set. 
Genes were selected according to the p-value of the diet/treatment effect for each delay 
coefficient (4 p-values per probe set) and for the multi-testing problem Bonferroni 
correction with a threshold of 1e-6 (~ 0.05 / (22000 * 3) (Number of probe set * 
number of test by probe set) was used. Genes with a p-value lower than 10-6 were 
selected. 
Immunohistochemistry 
Four µm paraffin embedded liver sections were stained with Haematoxillin/Eosin 
(HE). Seven µm frozen-cut liver sections were fixated in acetone and stained with 
CD68 (FA11), Mac1 (M1/70) and Nimp1 antibodies (granulocytes) as described before 
[9]. 
Hepatic lipid analysis 
Approximately 50 mg of frozen liver tissue was homogenized for 30 s at 5000 rpm in a 
closed tube with 5.0 mm glass beads and 1.0ml SET buffer (Sucrose 250mM, EDTA 2 
mM and Tris 10 mM) [10]. Complete cell destruction was done by two freeze-thaw 
cycles and 3 times passing through a 27- gauge syringe needle and a final freeze-thaw 
cycle. Protein content was measured with the BCA method (23225, Pierce, Rockford, 
IL, USA). TGs were measured as described above. Protocols were done according to 
manufacturer’s instructions. 
Real-Time quantitative PCR 
Prior to Real-Time quantitative PCR (QPCR), liver RNA pools of each group were 
reverse transcribed with the iScript cDNA synthesis kit (170-8891, Bio-Rad, 
Veenendaal, the Netherlands) according to manufacturer’s instructions. cDNA 
quantification was done by QPCR on an ABI Prism 7700 (Applied Biosystems, 
Nieuwerkerk a/d IJssel, the Netherlands) with Mastermix Plus kit for Sybr Green I 
(RT-SN2X-03+*, Eurogentec, Seraing, Belgium). For each gene, a standard curve was 
generated. Normalization was done with cyclophillin A. Specific primers sets were 
developed with Primer Express 1.5 (Applied Biosystems):  
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Lipoprotein lipase (LpL) Forward (fw) 5'- GAT GCC CTA CAA AGT GTT CCA - 3' 
and reverse (rv) 5'- GCC ACT GTG CCG TAC AGA GA - 3'; Cytosolic acyl-CoA 
thioesterase 1(Cte1) fw 5'- GCA GCC ACC CCG AGG TAA A - 3' and rv 5'- GCC 
ACG GAG CCA TTG ATG - 3'; Farnesyl diphosphate farnesyl transferase 1 (fdft1) fw 
5'- CCC TGA CGT CCT CAC CTA CCT - 3' and rv 5'- GGC CAT TAC CTG TGG 
AAT AGC A - 3’; Acyl-Coenzyme A dehydrogenase very long chain (acadvl) fw 5'- 
AGA CGG AGG ACA GGA ATC GG – 3’ and rv 5'- ACC ACG GTG GCA AAT 
TGA TC – 3’;  Acyl-CoA Oxidase 1(acox1) fw 5'- CTT GAG GGG AAC ATC ATC 
ACA - 3' and rv 5'- GCC AAG GGT CAC ATC CTT AAA GT - 3'; Cyclin D1 (ccnd1) 
fw 5'- TAC CGC ACA ACG CAC TTT CTT -3' and rv 5'- CGC AGG CTT GAC TCC 
AGA AG -3'; Carnitine palmitoyltransferase 1a (cpt1a) fw 5'- TGA CCT GCT CTC 
TCT AAG GCT ACA -3' and rv 5'- GCC AGC GCC CGT CAT -3'; CD68 antigen fw 
5'- TGA CCT GCT CTC TCT AAG GCT ACA -3' and rv 5'- TCA CGG TTG CAA 
GAG AAA CAT; Nuclear factor of kappa light chain gene (nfkbia) fw 5'- TGG AAG 
TCA TTG GTC AGG TGA A -3' and rv 5'- TCA CGG TTG CAA GAG AAA CAT G 
– 3’; Cyclosporin A-binding protein fw 5'- CAA ATG CTG GAC CAA ACA CAA - 3' 
and rv 5'- GCC ATC CAG CCA TTC AGT CT – 3’. Data were analyzed with SDS 
1.9.1 (Applied Biosystems).  
Statistical analysis 
Data were analysed using Graphpad Prism 4.0. Groups were compared using Welch-
corrected 2-tailed non-paired t-tests. Data is expressed as means ± SEM and considered 
significant at p < 0.05. 
Results 
Effects of high-fat diet on lipid levels 
Western diet, containing 21% fat and 0.2% cholesterol, induced a nearly 4-fold 
increase in plasma TC levels already after 2 days (Fig. 1A), which continued to rise to 
7-fold after 21 days. Cholesterol was mainly present in very low density lipoproteins 
(VLDL) and low density lipoprotein (LDL), while on chow it was mainly present in 
high density lipoprotein (HDL) (Fig. 1C). TG levels (Fig. 1B) decreased as the high-fat 
feeding progressed, as observed previously [5]. This slight decrease was only 
significant after 3 weeks of high-fat feeding. Free fatty acid (FFA) glucose levels were 
not affected (data not shown). 
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Response to fenofibrate treatment 
The western diet-induced rise in plasma cholesterol levels was completely abolished 
upon fenofibrate treatment. Cholesterol levels decreased markedly already at 2 days 
and were kept at basal level after 4, 7 and 21 days (Fig. 1A). Similarly, fenofibrate had 
a rapid lowering effect on TGs (Fig. 1B). FF-treatment induced a substantial decrease 
in VLDL-cholesterol. These alterations in plasma lipids levels are similar to 
hyperlipidemic patients treated with fibrates [11]. 
 
Figure 1.  Lipid parameters of the APOE2ki mice upon high-fat feeding with and without fenofibrate 
addition.  At each time point (2 days (d), 4d, 7d and 21d), mice treated with a high-fat diet (black bars) and 
mice treated with a high-fat diet with fenofibrate (white bars) are shown in panels A and B. The chow group 
is added as a black bar. Significant differences are shown with *. Plasma values are shown in panels A 
(Cholesterol) and B (TGs). Panel C shows cholesterol concentration in each lipoprotein fraction. Panel D 
shows the amount of hepatic TGs at the several time points of high fat feeding (W) with and without fibrate 
(dWF and dW). A significant difference between the group and the normal chow diet is indicated by *, and 
** indicates significant difference with both the chow group and the former time point. 
Liver histology 
HE staining was performed to investigate the effect of the western diet in the liver. 
Sections showed a gradual fat accumulation in liver cells upon high-fat feeding (Fig. 
2A). After 4-7 days of high-fat feeding, lipid droplets became visible (Fig. 2A, white 
arrows). The number and size of the droplets increased with time. Consistent with the 
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morphological observations, biochemical analysis demonstrated a gradual increase in 
the hepatic content of TGs while fenofibrate treatment prevented fat accumulation (Fig. 
1D, 2A). Unexpectedly, already after 2 days of high-fat feeding, aggregates of 
inflammatory cells became visible in the HE stained-livers of the mice fed the western 
diet (Fig. 2A, black arrows). Immunohistochemical staining was performed to define 
the nature of these inflammatory cells. Compared to animals on a chow diet, already 
after 2 days of high-fat feeding an increase in CD68-positive cells was detectable (Fig. 
2B), reflecting an increased number of Kupffer cells and macrophages. Within time, 
CD68-positive cells increased even further and aggregates of inflammatory cells 
became larger. Remarkably, fibrate treatment strongly opposed this effect (Fig. 2B). 
To investigate whether the increase in CD68 marker was due to increase in the number 
of macrophages or proliferation of Kupffer cells, liver tissues were stained for Mac1 
(Fig. 3). The number of Mac1-positive cells was corrected for granulocytes (also 
positive for Mac1), using the granulocyte-specific Nimp1 antibody. The combined data 
demonstrate a significant increase in the number of liver macrophages (10.3 fold) 
already after 2 days. At 4 days the number of macrophages further increased to a 
maximal level (17.8 fold). Fibrate treatment reduced the amount of macrophages 
substantially. Altogether, these data indicate that the increase in the number of 
macrophages is an early event during development of NASH and that it is prevented 
upon PPARα-activation. 
Diet-regulated genes 
Large scale gene expression analysis showed 294 genes to be regulated; 180 (61%) 
showed up-regulation upon high-fat feeding, whereas 114 genes (39%) were down-
regulated. We focused on genes involved in inflammation and lipid metabolism, as 
these two classes of genes comprised the largest groups of regulated genes (table 1) and 
are directly linked to the pathological phenotype of these mice. The increase in 
inflammatory genes is in line with other studies in which western diet was applied to 
different types of mice such as C57Bl/6 and APOE3-Leiden [12, 13]. Strikingly, in our 
model, inflammation appeared already after 2 days. Many of these inflammatory genes 
are regulated via the transcription factor nuclear factor kappa beta (NF-κB) (i.e. 
vascular cell adhesion molecule 1, phospolipase A2, serum amyloid genes). Among the 
inflammatory genes, the acute phase response genes (i.e. serum amyloid A1, A2, A3, 
A4) were induced rapidly, followed by up-regulation of interferon-induced genes (i.e. 
interferon gamma inducible protein 30, interferon induced transmembrane protein 2, 
interferon –induced protein with tetratricopeptide) and heat shock proteins, indicative 
for the development of a stress response.   
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Figure 2.  Morphology of liver tissue.  Panel A shows HE-stained paraffin slides. White arrows indicate fat 
droplets, black arrows point at inflammatory clusters. At all time points, left pictures of mice on the high-fat 
diet (-F), right pictures of mice treated with fenofibrate (+F) are shown. Panel B. Immunostaining with 
antibodies against CD68 and counterstained with haematoxylin.  
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Among the lipid genes, mainly genes involved in FA biosynthesis such as stearoyl-
Coenzyme A desaturase 2, lipid transport (e.g. ATP binding cassette G5 and A1; 
ABCG5, ABCA1) and lipid metabolism (e.g. lipoprotein lipase [LpL] and granulin), 
were up-regulated.  
In addition, within time the expression of collagen synthesis genes like procollagen 
type 1 was also up-regulated, indicating the development of fibrosis.  
The number of inflammatory genes went up rapidly until day four, indicating a quick 
inflammatory response in the liver. After four days, the increase became less 
pronounced. In contrast, the number of lipid genes increased steadily with time (Fig. 
4). These data indicate that the early phenotypic changes in liver histology and blood 
parameters of APOE2ki mice fed a western diet are accompanied by massive 
regulation in hepatic expression of inflammatory genes followed by lipid genes.  
 
 
Figure 3.  Macrophages in the liver.  Hepatic cryoslides were stained with antibodies against Mac1 and 
counted. The counting was corrected for stained granulocytes, which also express this marker. White bars 
indicate animals on a chow diet, black bars show data from mice fed the high-fat diet and gray bars indicate 
mice fed the high-fat diet supplemented with fenofibrate. Significant differences compared to the chow 
group are indicated by *, while ** shows significance between the fibrate-treated group and the high-fat 
diet-treated group. Scale expressed as cells per mm2. 
Early NASH in APOE2ki mice 
- 63 - 
 
 
Figure 4. Amount of lipid and inflammation genes regulated in time.  This figure shows the total number of 
genes that are regulated by the diet at all time points. White bars indicate the lipid genes, while the black 
bars indicate the inflammation-related genes. Both up-and down-regulated genes are included in this figure.   
Fibrate-regulated genes 
Liver RNA from mice fed a western diet enriched with fenofibrate at two time points 
(2 days and 7 days) was collected and hybridized to Affymetrix arrays. These time 
points were chosen to identify early effects, and to avoid indirect effects. Comparison 
to the diet-regulated genes revealed relatively small overlap, suggesting a more 
important role for nuclear receptors other than PPARα in diet-induced expression 
(table 1). As expected, fibrate changed the expression of many genes, including 
previously known PPARα responsive genes. Many of these genes are involved in 
processes such as lipid metabolism and inflammation. Upon fenofibrate treatment, a 
total of 1023 genes were regulated (compared with western diet at the corresponding 
time-points). Among these genes, 830 (81%) were up-regulated and 193 (19%) were 
down-regulated. The majority of up-regulated genes included lipid metabolism genes, 
such as genes involved in FA β-oxidation and lipid transport. In contrast, down-
regulated genes belong to inflammatory pathways, mainly under control of NF-κB. 
These results are in agreement with previous studies reporting the hepatic response of 
other mice models to fibrate treatment [14]. In addition, the expression of procollagen 
synthesis genes, like procollagen type 1, was inhibited by fibrate. 
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Table 1.  Lipid- and inflammation-related genes upon feeding a high-fat diet.   
gene 2dW 4dW 7dW 21dW 2dF 7dF 
Lipid metabolism genes             
insulin induced gene 2 -1.5 ns ns ns 1.8 1.6 
RIKEN cDNA 1600020H07 gene ns ns -1.5 -1.6 ns 1.7 
farnesyl diphosphate farnesyl transferase 1 ns -2.1 -3.1 -2.4 ns 1.9 
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 ns ns -3 -4 ns 2.9 
pancreatic lipase-related protein 2 -1.2 -2.4 -7.3 -8.4 -7 -1.2 
pancreatic lipase related protein 1 1 -2.3 -11 -20 -23 -1.7 
carboxyl ester lipase ns ns -9.6 -18 -21 ns 
colipase, pancreatic ns ns -14 -39 -41 ns 
isopentenyl-diphosphate delta isomerase ns -4.2 -4.2 -5.2 -3.3 ns 
sterol-C4-methyl oxidase-like ns -3.6 -3.9 -3.6 -2.5 ns 
acetyl-CoA synthetase 2 (ADP forming) -1.8 -2.3 -3.2 -3.3 -2.7 ns 
NAD(P) dependent steroid dehydrogenase-like ns -2.1 -2.1 -2.4 -2.2 ns 
phospholipase A2, group IB, pancreas ns ns -2.9 -3 ns ns 
sterol-C5-desaturase homolog (S. cerevisae) -1.4 -1.4 -1.5 -1.5 ns ns 
sulfotransferase, hydroxysteroid preferring 2 ns ns -2.4 -2.6 ns ns 
phenylalkylamine Ca2+ antagonist binding protein ns ns -1.6 ns ns ns 
NADH dehydrogenase1,a/b 1 ns ns -1.6 ns ns ns 
fatty acid synthase ns ns ns -1.5 ns ns 
cytochrome P450, 51 ns ns ns -2.1 ns ns 
7-dehydrocholesterol reductase ns -2.1 -2.3 -2.4 ns ns 
fatty acid binding protein 5, epidermal 2.6 ns 1.7 1.5 -2.3 -2.1 
lysosomal acid lipase 1 ns 1.4 1.4 1.5 1.6 1.4 
stearoyl-Coenzyme A desaturase 1 1.2 ns ns ns ns 1.9 
fatty acid binding protein 2, intestinal 2.6 2.9 2.7 3.2 1.6 2.2 
3-ketoacyl-CoA thiolase B 1.4 1.5 ns 1.5 2.4 2.8 
lipoprotein lipase ns 2.2 2.8 4.2 2.2 3.3 
granulin ns 1.4 ns 1.6 1.5 ns 
ATP-binding cassette, sub-family G,  5 ns 1.7 1.5 2 1.7 ns 
prosaposin ns 1.8 1.8 1.9 1.6 ns 
ATP-binding cassette, sub-family A, 1 ns 1.9 1.9 2.1 ns ns 
stearoyl-Coenzyme A desaturase 2 ns 2.8 2.6 3 ns ns 
fatty acid binding protein 7, brain ns 2.8 ns ns ns ns 
phospholipid transfer protein ns ns ns 2 ns ns 
apolipoprotein B 1.3 ns ns ns ns ns 
lipopolysaccharide binding protein 1.6 1.7 1.6 1.6 ns ns 
apolipoprotein A-IV 3.9 3.9 4.2 4.1 ns ns 
Inflammatory genes       
C-type lectin, superfamily member 13 ns 1.8 1.9 1.6 ns -1.5 
interferon-induced protein with tetratricopeptide 
repeats 1 3 ns ns ns -2.5 ns 
orosomucoid 2 ns 3.4 3.9 ns ns -6.2 
serum amyloid A 1 6.1 7.3 9.8 5.8 -9.8 -26 
serum amyloid A 2 5.2 5.8 9 4.9 -7.3 -17 
serum amyloid A 3 ns 5.6 6 3.8 -2.4 -6.5 
serum amyloid A 4 2 1.9 1.7 ns -2.7 -2.7 
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Table 1 (continued) 
gene 2dW 4dW 7dW 21dW 2dF 7dF 
T-cell specific GTPase 3 ns ns ns -4.2 ns 
regenerating islet-derived 2 -4.9 -10 -11 -12 -1.2 ns 
regenerating islet-derived 1 ns -3.1 -19 -36 -2.3 ns 
phospholipase A2, group IB, pancreas ns ns -2.9 -3 -2.7 ns 
early growth response 1 -3.3 -2.1 -2.4 -2.3 2.6 ns 
heat shock protein 1, alpha ns 1.8 1.7 1.9 3.1 2.1 
heat shock protein 105 ns 1.7 ns ns 1.9 ns 
heat shock protein 1B ns ns 3.2 3.3 5 ns 
lectin, galactose binding, soluble 1 ns ns 1.7 1.7 1.6 2 
phospholipase A2, group VII  ns ns 2 2.6 ns 2.4 
S100 calcium binding protein A8 (calgranulin A) 2.1 2.9 2.3 3.3 1.5 ns 
C-type lectin-like receptor 2 ns 2.8 2.4 2.9 ns ns 
cytotoxic T lymphocyte-associated protein 2b ns 2.4 ns ns ns ns 
eosinophil-associated, ribonuclease A 2 family ns 2 2.3 2.9 ns ns 
glycoprotein (transmembrane) nmb ns ns 2.8 5.2 ns ns 
heat shock protein 8 ns ns ns 1.5 ns ns 
histocompatibility 2, class II antigen A, alpha ns ns 2.3 2.9 ns ns 
histocompatibility 2, class II antigen A, beta 1 ns ns ns 2.8 ns ns 
histocompatibility 2, class II antigen E beta ns ns 1.9 2.3 ns ns 
immunoglobulin heavy chain 6, IgM  ns 1.7 ns ns ns ns 
interferon induced transmembrane protein 2 ns 1.6 1.4 1.3 ns ns 
catenin beta ns ns ns 1.5 ns ns 
CD44 antigen ns 2.8 2.4 2.6 ns ns 
CD52 antigen ns 2.5 2.5 2.9 ns ns 
CD68 antigen ns 3.7 3.7 4 ns ns 
cDNA sequence BC032204 ns 2.3 ns 2.6 ns ns 
chemokine (C-C motif) ligand 6 ns 3.5 3.7 4.1 ns ns 
complement component 1, q alpha polypeptide ns 1.7 1.8 2 ns ns 
complement component 1, q beta polypeptide ns 2.3 2.2 2.8 ns ns 
complement component 1, q gamma polypeptide ns 2.3 2.4 2.9 ns ns 
C-type lectin, superfamily member 12 ns 3.7 4.3 5.2 ns ns 
C-type lectin, superfamily member 10 ns ns ns 2.3 ns ns 
immunoglobulin kappa chain variable 28 ns 2.8 ns 2.4 ns ns 
interferon activated gene 203 ns 2.1 2 2.3 ns ns 
interferon gamma inducible protein 30 ns 2.5 2.5 2.5 ns ns 
lymphocyte antigen 86 ns 2.1 2.1 2.2 ns ns 
macrophage receptor with collagenous structure ns 2.2 2.6 2 ns ns 
matrix metalloproteinase 12 ns ns 3 4.2 ns ns 
procollagen, type I, alpha 1 ns ns 2.4 2.5 ns ns 
procollagen, type III, alpha 1 ns 2.8 3.7 4.3 ns ns 
procollagen, type IV, alpha 1 ns 1.8 2.1 2.2 ns ns 
procollagen, type XIV, alpha 1 ns ns ns 1.6 ns ns 
protein tyrosine phosphatase,non-receptor type 
substrate 1 ns 2.6 2.7 3.2 ns ns 
transforming growth factor, beta induced ns 1.6 ns 1.8 ns ns 
vascular cell adhesion molecule 1 ns 2.6 2.3 2.3 ns ns 
pancreatitis-associated protein ns -2.9 -2.8 -3.3 ns ns 
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Table 1.  Lipid- and inflammation-related genes upon feeding a high-fat diet.  All genes in this table are 
regulated by diet only or by diet and fibrate treatment.  Fold changes of gene expression of the animals fed the 
high-fat diet are shown relative to gene expression in the chow-fed group at 2, 4, 7, and 21 days (d) on western 
diet (W), or W supplemented with fenofibrate (F). Fold changes of the gene expression of the fibrate-treated 
animals is shown relative to the high-fat treated animals at the same time point. 
Validation of the array data 
The regulation of 5 well-known PPARα responsive genes involved in lipid metabolism 
(Lpl, Cte1, Cpt1, Acadvl and Acox1) was verified by QPCR. In addition, the 
expression of two additional genes regulated on a western diet (Ccnd1 and Fdft1) and 
two inflammatory genes (CD68 antigen and NF-κBia) were also determined (table 2). 
To correlate the results obtained by QPCR and Affymetrix analysis of the 10 selected 
genes, the logarithmic values of the fold change obtained by the two techniques were 
compared (Fig. 5). These results indicate a significant correlation (Pearson correlation 
coefficient = 0.90; p<0.0001). 
Biological variation within each pool was checked by QPCR on individual mice for 
CD68 and Acox1. The degree of up- and down-regulation upon treatment with western 
diet was found to be consistent for all individual mice (data not shown). 
Collectively, the QPCR results were fully compatible with the array data and 
demonstrate the reliability of the microarray analysis.  
Discussion 
In the present study, we show that APOEki mice develop NASH in response to western 
diet, which can be inhibited by fibrate treatment.  
To our knowledge, in all other studies performed with the APOE2ki mice liver 
morphology was not subject of investigation [5, 15-17].  Interestingly, already within 4 
days of high-fat feeding these mice develop a marked liver phenotype characterised by 
steatosis, inflammation and early fibrosis. The reason for this rapid response is not yet 
clear. It has been suggested that the ApoE protein, in addition to its role in lipoprotein 
clearance, has a physiological function in the VLDL assembly-secretion cascade [18]. 
Thus, it is feasible that the balance between FA uptake and secretion is affected in the 
APOE2ki mouse due to impaired VLDL secretion. Alternatively, it is possible that the 
FFA synthesis and esterification or uptake is increased. In addition, it has been shown 
that ApoE can have a direct effect on tissue macrophage recruitment, independent of 
lipoprotein metabolism [19, 20]. Thus, the APOE2ki mice may be highly sensitive to 
develop inflammation regardless of the steatosis. Other hyperlipidemic mouse models, 
such as ldlr-/- mice and apoe-/- mice also develop a similar phenotype upon long periods 
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of high-fat feeding [3, 4]. Moreover, C57Bl/6 mice, fed an atherogenic diet for 4-5 
weeks, were also shown to induce hepatic lipid and inflammatory genes [12, 21] and to 
develop this phenotype [3].  
It has been shown that MCD (methionine and choline deficient) diet-induced fibrosing 
steatohepatitis in mice can be reversed by treatment with Wy-14,643, a PPARalpha 
agonist [7]. In our study fibrate administration prevents the accumulation of hepatic 
TGs, which is consistent with the up-regulation of a large number of genes involved in 
peroxisomal and mitochondrial β-oxidation. In addition, it prevents the infiltration of 
macrophages into the liver, consistent with the regulation of anti-inflammatory genes. 
 
Figure 5. Verification of chip data with QPCR.  Graph  showing log values of fold changes of both QPCR 
and microarray data. When plotted, a clear correlation can be seen with a Pearsson correlation coefficient of 
0.8971 and p < 0.0001.   
The high percentage of saturated FAs in the diet (21% butter) is most likely to be 
responsible for the acute inflammatory response [22-24]. Vergnes et al. [25] have 
shown that cholesterol is also contributing to the induction of genes involved in acute 
inflammation, including genes of the serum amyloid A family and various cytokine-
related genes.  
Comparison between genes regulated by diet and genes regulated by addition of 
fenofibrate to the diet revealed relatively small overlap. Some of the established 
PPARα regulated genes (e.g. Acox1, Cte1) were not regulated when mice were fed a 
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western diet. Possibly many of the diet-regulated genes were not detected due to a low 
level of difference in regulation compared with chow.  
Other transcription factors play a more prominent role in regulation of lipid genes. 
Indeed, changes in lipid genes (e.g. sterol-C4-methyl oxidase-like, sterol-C5-desaturase 
and FA synthase) are attributable to sterol response element binding factor (SREBP)-
activation [26]. Similarly, several liver X receptor (LXR)-responsive genes were 
regulated such as ATP-binding cassette, sub-family A1, stearoyl-coenzyme A 
desaturase 1 and FA binding protein. 
Among the inflammatory genes regulated upon western diet, several genes contained 
functional NF-κB binding sites in their promoter regions. NF-κB plays a crucial role in 
inflammation, by regulating the production of various cytokines that can trigger several 
inflammatory reactions [27]. Conversely, the NF-κB cascade induces alterations in FA 
metabolism [28] . 
The massive repression of inflammatory gene-expression might be related to the ability 
of PPARα to interfere with the NF-κB pathway [29, 30]. The early down-regulation in 
the expression of inflammatory genes suggests that the prevention of steatohepatitis by 
fibrates may be a direct consequence of their anti-inflammatory effect. 
Strikingly, in this mouse model the increase in macrophages in the liver preceded the 
accumulation of fat. The function of these macrophages in the pathogenesis of steatosis 
as observed in these mice is not yet clear. Similarly, the reduction in the expression of 
inflammatory genes occurred immediately after fibrate treatment, suggesting that 
inflammation may play an instrumental role during the development of NASH. These 
data are in contradiction with the current mechanistic concept of the disease in which 
an initial metabolic disturbance causes steatosis and a second pathogenic event leads to 
inflammation [31]. In support of our observation, it has been shown that inflammation, 
possibly mediated via NF-κB-regulated cytokines, can influence lipid metabolism. 
Plasma VLDL levels were found to increase due to enhanced adipose tissue lipolysis, 
increased de novo hepatic FA synthesis and suppression of FA oxidation [32, 33].  
Changes in lipid metabolism during the acute phase response have been attributed to 
decreases in the level of several nuclear hormone receptors, including PPARα. 
Pharmacological activation of PPARα in C57Bl/6 mice fed the MCD diet resulted in a 
marked attenuation of the NASH phenotype, affecting both steatosis and inflammation. 
[7, 34]. The collective findings suggest that the observed effects are not dependent on 
the specific model used.  
At present, there is no effective treatment for NASH [35] and therefore further studies 
exploring the role of macrophages in early stages of NASH, can contribute to the 
design of effective therapeutic strategies for treatment and prevention of NASH. 
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Abstract 
Background: Hyperlipidemic APOE2 knock-in (APOE2ki) mice develop non-alcoholic 
steatohepatitis (NASH) very early, which is inhibited by fenofibrate (FF), a peroxisome 
proliferator activated receptor alpha (PPARα) agonist. Previous transcriptome analysis 
of livers of these mice revealed that high fat feeding induced many inflammatory 
genes, but only few PPARα dependent genes. Current study aims to investigate the 
effects of diet-induced NASH on hepatic gene expression in detail to clarify how diet 
and FF supplementation influences gene expression. 
Methods: Microarray data from livers from APOE2ki mice fed a high fat, high 
cholesterol (HFC) diet for 2 and 7 days or HFC supplemented with FF were used for 
analysis. 
Results: Rather than PPARα-induced transcription, HFC diet induced genes under 
control of cholesterol sensors SREBP1/2 and LXR, probably due to negative feedback 
mechanisms initiated by increased levels of hepatic cholesterol and its precursor 
lathosterol. Genes regulated oppositely by FF supplementation were mainly involved in 
cholesterol metabolism and inflammation, indicating these are important pathways 
during NASH inhibition. Additionally, FF supplementation inhibited NF-κB induced 
transcription, while up-regulating AP-1 induced transcripts. 
Conclusion: Two major pathways appear important during progression and inhibition 
of NASH, i.e. cholesterol metabolism and inflammation. FF treatment inhibited 
inflammation via NF-κB rather than via AP-1. 
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is an integral part of the metabolic 
syndrome and has become an increasing health problem as obesity and insulin 
resistance are reaching epidemic proportions in Western countries. NAFLD may 
progress towards a more harmful condition, i.e. non alcoholic steatohepatitis (NASH), 
which is characterized by hepatic fat accumulation (steatosis) combined with an 
inflammatory response. Ultimately, NASH may lead to fibrosis, cirrhosis and even 
liver failure (37, 49). Treatment options for NASH remain limited as only weight loss 
has shown to be effective in rapidly reducing steatosis and hepatic inflammation (14). 
Until now, only a few controlled clinical studies have been performed for the treatment 
of NASH, which mostly focused on activators of peroxisome proliferating activated 
receptor-γ (PPARγ) as a clinical target (3, 37, 49). However, larger and longer clinical 
studies are needed to determine long-term beneficial effects. Moreover, the 
applicability of PPARγ ligands for therapeutical use is under debate (13) as they may 
increase the risk of heart failure (39, 41). Currently, some other randomized controlled 
clinical trials are being performed in human subjects, testing agents for different 
promising targets in their efficacy against steatosis and hepatic inflammation (37). One 
of these targets, PPARα, plays a central role in lipid and glucose metabolism and is a 
well known target for lipid lowering therapies. PPARα is a nuclear receptor with fatty 
acids as natural ligands (36, 44, 47). Upon ligand binding, this nuclear receptor initiates 
transcription of specific target genes that are mainly involved in lipid metabolism, such 
as mitochondrial and peroxisomal fatty acid (FA) oxidation, as well as FA uptake and 
transport (17, 40). 
APOE2 knock-in (APOE2ki) mice have the defective human APOE2 isoform instead 
of their endogenous apoe gene. They display a lipoprotein profile resembling mixed 
dyslipidemia, as frequently seen in humans (25, 61, 65). We have shown previously 
that these mice develop NASH after only a few days of high fat, high cholesterol 
(HFC) feeding, which was inhibited by co-administrating fenofibrate (FF), a synthetic 
ligand that activates PPARα. Transcriptome analysis revealed inflammation to be an 
integral part of the early response to the HFC diet. This inflammatory response was 
inhibited upon co-administration of FF (HFC+FF), possibly via the known anti-
inflammatory properties of PPARα (15, 61). Unexpectedly, little overlap of lipid genes 
was observed between HCF treatment and HFC+FF treatment. These results suggested 
very little HFC diet-induced PPARα driven gene expression during the early stages of 
NASH, despite the abundance of several natural PPARα ligands present in the HFC 
diet. Other transcription factors may thus be preferably activated by HFC during the 
progression of diet-induced NASH. 
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In the previous study, data was analyzed based on gene ontology (GO) annotation only. 
GO clustering reveals biological processes in response to the treatments. However, it 
does not provide detailed pathway information and does not incorporate gene-gene 
interactions. The current study aims to elucidate what pathways, other than PPARα 
induced transcription, were influenced by HFC feeding during the progression of diet-
induced NASH. Additionally, we determined the additional contribution of FF to 
NASH inhibition and to clarify the exact pathways involved during FF-dependent 
attenuation of inflammatory gene expression. To this end, Inginuity Pathway Analysis® 
(IPA) was used, software that performs literature-based gene clustering to reveal the 
biological significance of the regulated transcripts.  
Materials and methods 
Microarray analysis 
Data was analyzed from datasets that were described previously [13]. In short, data was 
used from hepatic mRNA hybridization to microarrays (Affymetrix® 430a) from 10 
female mice fed a HFC diet for 2 and 7 days or from mice fed the HFC diet 
supplemented with 0,2% FF. Data derived from mice receiving a standard chow diet 
only, were used as control. 
Biological pathway analysis was done with IPA® (Ingenuity Systems, Redwood City, 
USA) software, which clusters genes in pathways based on the literature. Moreover, 
IPA creates functional networks of genes of which the relations are defined according 
to their co-existence in literature. Each gene cluster and network receives a score that 
reflects cluster or network size and number of genes regulated.  
Real-time quantitative PCR 
Quantification of gene-expression was done by quantitative PCR on a Bio-Rad MyIQ® 
with the IQ5 v2 software (Bio-Rad, Hercules, CA, USA) by using IQ SYBR Green 
Supermix with fluorescein (170-5006CUST, Bio-Rad, Hercules, CA, USA) and 10 ng 
of cDNA. To standardize for the amount of cDNA, Cyclophillin A (Ppia) was used as 
reference gene. Primer sets were developed with Primer Express version 1.5 (Applied 
Biosystems) using default settings:  
5’-TGTGACCCTTGGCTCTGTTCT-3’ (Acox1 forward), 
5’-TGTAGTAAGATTCGTGGACCTCTG-3’ (Acox1 reverse), 
5’-TTCCTCCTTTCACAGAATTATTCCA-3’ (Ppia forward), 
Microarray analysis of fenofibrate-induced NASH inhibition 
 
 
- 75 - 
 
5’-CCGCCAGTGCCATTATGG-3’ (Ppia reverse). 
Data were analyzed with the IQ5 v2 software (Bio-Rad, Hercules, CA, USA) and 
Graphpad Prism 4.0. Groups were compared using 2-tailed non-paired t-tests. Data is 
expressed as means ± SEM and considered significant at p<0.05. Microarray data were 
validated by QPCR on individual samples as was shown previously [13]. 
Hepatic cholesterol analysis 
Liver specimens were dried to constant weight in a Speedvac (Savant). Sterols and 
oxysterols were extracted by chloroform/methanol (2:1) at 4°C overnight. Cholesterol 
and its precursors were determined after alkaline hydrolysis and derivatization to the 
corresponding trimethylsilyl-ethers by gas chromatography-flame ionization detection 
and gas chromatography-mass spectrometry as described before [15]. 
Results and discussion 
Gene expression induced by HFC and HFC+FF 
To investigate the contribution of PPARα to HFC-induced hepatic gene expression, 
genes were selected based on their up-regulation by HFC and HFC+FF treatments 
(table 1A). It was expected that these genes regulated in the same direction by the HFC 
diet and by FF supplementation, are induced by the HFC diet through PPARα 
activation. However, only few genes were regulated by both treatments in the same 
direction;  5 were classified into the category of “lipid metabolism”. This may indicate 
that HFC diet has only a marginal effect on PPARa activity. The genes included 
Lipoprotein Lipase (LpL), which hydrolyzes triglycerides (TG) into fatty acids that can 
consequently be taken up from the plasma; fatty acid binding protein (Fabp2), involved 
directly in FA transport; Lipase 1 (lip1), monoglyceride lipase (Mgll), which both 
hydrolyze intracellular TG and cholesteryl-esters derived from plasma lipoproteins (22, 
33), and acetyl-CoA acyltransferase 1B (Acaa1b), a peroxisomale enzyme. Together, 
these genes enable TG-derived FA to enter oxidative pathways. Mgll, LpL, Acaa1b, 
and FABP2 have been previously identified as PPARα targets (56, 62, 77) while Lip1 
may be an interesting novel PPARa target gene. Additionally,  another possible PPARα 
gene was regulated, i.e. phospholipase A2, group 7 (PLA2g7). 
Contrary to our data, it has been reported that PPARα does govern hepatic gene 
expression upon high fat feeding (51). However, in that study male instead of female 
mice were used. Female mice were recently found to have much lower PPARα activity 
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in the liver than male mice (12), which might explain the lack of response in the 
present study. Alternatively, it has been suggested that dietary fatty acids do not 
activate PPARα as effectively as de novo synthesized fat (8).  
Furthermore, due to the fact that APOE2ki mice have elevated TG levels even when 
fed a regular diet (61, 66), it is feasible that any effect on PPARα in these mice is 
masked because PPARα may already be constitutively activated even without feeding 
these animals a HFC diet. The elevated activity of PPARα may result in the 
impossibility to be activated further by this diet, thereby masking its activity. To 
exclude this possibility, the expression level of an established PPARα target gene, i.e. 
acyl CoA oxidase 1 (Acox1), on a regular chow diet in APOE2ki livers was compared 
with levels in C57BL6 wild type (WT) mice, the genetic background strain of the 
experimental APOE2ki mice (fig. 1). These results show no difference between the two 
groups, indicating that PPARα activity in APOE2ki mice is not different compared to 
WT animals. Thus, the elevated TG levels in the basal state do not seem to mask the 
effect of HFC feeding on PPARα activity in these mice. 
 
Table 1A 
ProbeSetID Gene Name Symbol 
2d 
HFC 
7d 
HFC 
2d 
HFCff 
7d 
HFCff 
1418438_at fatty acid binding protein 2 Fabp2 2.6 2.7 1.6 2.2 
1415904_at lipoprotein lipase Lpl ns 2.8 2.2 3.3 
1417500_a_at 
"transglutaminase 2, C 
polypeptide" Tgm2 1.8 2.5 1.5 ns 
1423846_x_at tubulin, alpha 2 Tuba2 1.5 1.7 1.6 ns 
1449436_s_at ubiquitin B Ubb 1.2 1.3 1.3 1.2 
1448169_at keratin complex 1, acidic, gene 18 Krt1-18 ns 1.6 2.9 1.8 
1417339_a_at dynein, cytoplasmic, light chain 1 Dnslc1 1.6 1.8 2.1 2.2 
1415849_s_at stathmin 1 Stmn1 ns 1.8 ns 1.6 
1417821_at 
DNA segment,Chr 17,human 
D6S56E 5  ns 2.6 ns 2.4 
1450872_s_at lysosomal acid lipase 1 Lip1 ns 1.4 1.6 1.4 
1419091_a_at annexin A2 Anxa2 ns 2.3 3.7 2.5 
1430700_a_at phospholipase A2, group VII Pla2g7 ns 2 1.3 2.4 
1455439_a_at lectin, galactose binding, soluble 1 Lgals1 ns 1.7 1.6 2 
1454971_x_at 
transforming growth factor beta 1 
induced transcript 4 Tgfb1i4 1.8 1.8 ns 1.7 
1426645_at heat shock protein 1, alpha Hspca ns 1.7 3.1 2.1 
1424451_at acetyl-Co A acyltransferase 1B Acaa1b 1.4 ns 2.4 2.8 
1424126_at aminolevulinic acid synthase 1 Alas1 2 ns 2.2 2.8 
1448700_at G0/G1 switch gene 2 G0s2 1.8 ns 2.9 3.5 
1450391_a_at monoglyceride lipase Mgll 1.7 ns 3.4 4.5 
1418486_at vanin 1 Vnn1 1.6 ns 4.2 4.8 
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Table 1B 
ProbeSetID Gene Name Symbol 
2d 
HFC 
7d 
HFC 
2d 
HFCff 
7d 
HFCff 
1438612_a_at --- --- ns -24,1 -55,7 -3,6 
1422479_at acetyl-Coenzyme A synthetase 2  Acas2 -1,8 -3,2 -2,7 ns 
1422682_s_at trypsin 3 Try3 -10,4 -18,4 -2,4 ns 
1417464_at troponin C2, fast Tnns2 -2,2 -7,1 -3,2 17,1 
1416139_at regenerating islet-derived 2 Reg2 -4,9 -10,6 -2,7 ns 
1424400_a_at 
formyltetrahydrofolate 
dehydrogenase Fthfd -1,6 -1,7 -2,2 -1,5 
1428102_at carboxypeptidase B1 (tissue) Cpb1 ns -12,6 -47 -4,8 
1428062_at carboxypeptidase A1 Cpa1 ns -12 -50,6 -4,6 
1433431_at pancreatic lipase Pnlip ns -11,6 -71,2 -7 
1448220_at RIKEN cDNA 2200008D09 gene   ns -9,1 -33,2 -4,2 
1448281_a_at elastase 2 Ela2 ns -12,8 -66,5 -5,9 
1416055_at amylase 2, pansreatic Amy2 ns -9,4 -140,1 -15,4 
1415954_at trypsin 4 Try4 ns -11,3 -61,7 -7,4 
1416239_at argininosuccinate synthetase 1 Ass1 -1,7 -1,5 -2,2 ns 
1451557_at tyrosine aminotransferase Tat -1,3 -1,3 -1,3 ns 
1449434_at carbonic anhydrase 3 Car3 -1,5 ns -1,6 -1,5 
1455540_at 
DNA segment, Chr 1, University 
of California at Los Angeles 3 D1Ucla3 -1,4 ns -1,4 ns 
 
Table 1. Genes regulated in the same direction by HFC and HFC+FF treatments. This table shows genes 
regulated in the same direction by both treatments, derived from the previously found HFC-induced genes 
[13]. From each gene, the probeset ID, gene title, gene symbol, fold change and p-value of fold change after 
2 and 7 days of treatment compared to chow fed animals is shown. P-values smaller than 1.10-6 were 
considered significant. A. Genes down-regulated by both treatments and B. Genes down-regulated by both 
treatments. 
Other than PPARα, there are several transcription factors that play a role in hepatic 
lipid metabolism which could have a larger effect on hepatic gene expression. 
Therefore, we performed an extensive literature search to identify other transcriptional 
regulators of genes involved in hepatic lipid metabolism, known to be of importance in 
liver function next to PPARα: liver X receptor (LXR), pregnane x receptor (PXR), 
sterol regulatory element-binding protein 1/2 (SREBP) and hepatic nuclear factor 4A 
(HNF4A). Regulation of their target genes present in our dataset was compared to 
regulation as is known in literature, determined by IPA. This software-mediated gene 
clustering allowed us to obtain information about the response of these transcription 
factors upon HFC feeding (table 2). 
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Gene 
 
Transcription Factor 
 
Regulated 
 
 
Ref 
 
 LXR PPARa PXR SREBP HNF4A 
HFC 
2d 
HFC  
7d 
HFCff  
2d 
HFCff  
7d  
ABCA1 ↑       1,9     [47] 
ABCC3 ↑  ↑   -1,7 -1,5 2,7 2,3 [48] 
ABCG5 ↑       1,5 1,7   [49] 
ACAA1  ↑    1,4  3,1 4,1 [50] 
ACAS2  ↑  ↑  -1,8 -3,2 -2,7   [51] 
acta1  ↑      -9,3   24 [52] 
AHCY   ↓     -1,5     [53] 
ApoA4   
 
 ↑ 3,9 4,2     [54] 
ApoB     ↑ 1,3      [26] 
arg  ↓    -1,5 -1,6   1,4 [53] 
asl  ↓    -1,8 -2     [55] 
CCND1   
 
 ↑   2     [56] 
crip1    ↑   2,4     [57] 
CTH   ↑   -2,1 -2,4     [53] 
ctsb     ↑   1,5     [57] 
Cyp7a1 ↑ ↓ ↑ ↓    -2.4     [58, 59] 
CYP8B1  ↑  ↑  -1,9 -2,5     [60] 
FABP2     ↑ 2,6 2,7 1,6 2,2 [61] 
fdft1 ↑   ↑    -3,1   1,9 [62, 63] 
fdps    ↑    -2,8 -2,3   [64] 
gpdh  ↑      1,8     [65] 
GSTA2   ↑   -3,6 -2,4 2,5 2,5 [60] 
Lcn2   ↑   6,2 10,1 -3,7 -6,8 [53] 
Lgals3     ↑ 2,7 5,6     [57] 
Lipa     ↑   1,4 1,6 1,4 [57] 
LpL ↑ ↑  ↑    2,8 2,2 3,3 [60] 
SAT  ↓      2     [55] 
Sc5dl    ↑    -1,4     [66] 
scd ↑   ↑  1,2    1,9 [67, 68] 
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 LXR PPARa PXR SREBP HNF4A 
HFC 
2d 
HFC  
7d 
HFCff  
2d 
HFCff  
7d  
scd2 ↑   ↑    2,6     [67] 
SREBP ↑       2,1     [69] 
Tdo2     ↑ -1,4 -1,4 1,9   [57] 
Tgm2   ↑   1,8 2,5 2,5 1,5 [53] 
 
Table 2. Activation of hepatic transcription factors. This table shows the regulation of genes according to 
IPA. Up-regulation is shown as ↑, while genes known to be down-regulated are indicated by ↓. In numbers, 
the regulation of these genes in our dataset is shown at each time point. Finally, references, as provided by 
IPA are shown. 
The analysis indicated a prominent role for HNF4a and the cholesterol sensors LXR 
and SREBP as major activated transcription factors controlling regulation of lipid 
genes upon HFC feeding. 
For HNF4a, most target genes were regulated in the same way as was found in 
literature, indicating that HNF4a may play an important role in the hepatic response to 
HFC diet. HNF4a can be activated upon binding of several fatty acid species (18, 26) 
and has been found essential in regulating key processes in the liver (24). However, 
there is evidence pointing out that the seemingly dominant character of this 
transcription factor is doubtful for two major reasons. First, table 2 shows that HNF4a 
regulates a completely specific set of genes while the other transcription factors show 
more overlap. This lack of overlap may lead to an overestimation of HNF4a activity as 
none of the other investigated transcription factors can override its effects. 
Consequently, it is difficult to estimate whether the contribution of HNF4a is in concert 
with or dominating over the other investigated transcription factors. Second, HNF4a is 
known to be active even in the absence of exogenous ligands (24, 32), suggesting that 
its activity is not necessarily  influenced by the diet. Taken together, the results 
obtained for HFN4a must be interpreted with caution. 
Table 2 shows that SREBP activity was generally inhibited, as several genes that are 
known to be regulated by this transcription factor were down-regulated. However, 
several other SREBP target genes were up-regulated, despite the presumed inhibition 
of SREBP by the elevated circulatory cholesterol levels. It is possible that for these 
genes, the activation of LXR by oxysterols overrides SREBP inhibition. 
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Figure 1. Acox1 gene expression. Relative gene expression of Acyl-CoA oxidase 1, palmitoyl (Acox1) in 
hepatic mRNA of APOE2ki female mice (black bar) and C57Bl/6 female mice (white bar) on a chow diet. * 
indicates significant differences between groups. 
The observed  regulation of these 2 regulators of cholesterol metabolism probably 
arises from an increased hepatic cholesterol load, which may serve to activate a 
feedback mechanism that inhibits cholesterol biosynthesis (23). To test this 
assumption, the cholesterol content of the livers of these mice was investigated in 
detail with gas chromatography. These data clearly show that cholesterol accumulates 
in the livers of these mice (Fig. 2A), supporting the notion that the increased 
cholesterol levels can influence the hepatic transcriptome via LXR and SREBP. 
Furthermore, in addition to cholesterol, also the cholesterol precursor lathosterol 
accumulated in the livers of these mice (Fig. 2B). Accumulation of cholesterol and its 
precursors can lead to inhibition of the cholesterol biosynthesis pathway. This is in 
excellent agreement with the observed changes in gene expression in response to HFC 
feeding, as genes of the cholesterol biosynthesis pathway were clearly inhibited, like 3-
hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (Hmgcs1) and farnesyl diphosphate 
farnesyl transferase 1 (Fdft1). 
Taken together, during the progression of diet-induced NASH, HFC feeding resulted 
mainly in the activation of cholesterol-induced transcriptional changes via LXR and 
inhibition of SREBP, rather than the activation of PPARα. These findings argue for a 
large impact of dietary cholesterol on the hepatic response during the progression of 
diet-induced NASH.  
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Figure. 2. Hepatic cholesterol and cholesterol precursor levels. Measurement of cholesterol (A) and its 
precursor lathosterol (B) in the liver of female APOE2ki mice after 2 and 7 days of HFC diet (black bars)  
and HFC+FF (grey bars) feeding compared to livers of animals fed a chow diet (white bars).  * indicates 
significant differences between groups. 
Pathways involved during the inhibition of NASH by FF 
To find pathways involved in the prevention of NASH we focused on genes of which 
the expression is increased by HFC feeding, but reversed by FF co-treatment. Since FF 
supplementation was shown to inhibit NASH development (61), the set of genes that is 
reversed by FF compared to HFC treatment likely contribute to NASH inhibition. 
Table 3 shows these genes that are regulated oppositely by HFC and HFC+FF 
treatments. Interestingly, compared to the small number of genes that were regulated 
similarly by the two interventions, a relatively large number was regulated oppositely 
by HFC diet and HFC+FF. 
Of the genes that were down-regulated by the diet and up-regulated by FF (Table 3A), 
the group of genes involved in cholesterol metabolism was over-represented (15% of 
the regulated genes in this group). These genes included: Hmgcs1 and Fdft1, both 
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involved in cholesterol biosynthesis; ATP binding casette C3 (AbcC3), involved in 
hepatic bile acid transport (4); and insulin induced gene 2 (Insig2), a regulator of 
intracellular cholesterol levels (23). This HFC-induced repression of genes involved in 
cholesterol metabolism is likely due to increased levels of liver cholesterol, which 
inhibits transcriptional activation of genes of the cholesterol biosynthesis pathway via 
SREBP (27). FF reduces hepatic levels of both cholesterol and its precursor lathosterol, 
which could indirectly increase the expression of these genes (Fig. 2A). Furthermore, 
HFC+FF treatment did not produce overt changes in the expression of additional genes 
involved in cholesterol metabolism: only a few genes classified as “cholesterol 
metabolism” or “cholesterol biosynthesis” were regulated while these genes were 
clearly overrepresented in the group of overlapping genes, suggesting that FF exerted 
its effect mainly on this pathway by normalizing cholesterol levels and had no 
additional effects. The regulated genes included HMG-CoA lyase (Hmgcl) (up-
regulated), and VLDL receptor (up-regulated).  
In the group of genes up-regulated by the diet and down-regulated by FF (Table 2B), 
most regulation was found in inflammatory and acute phase genes (42% of the 
regulated genes in this group), i.e. interferon-induced protein with tetratricopeptide 
repeats 1 (Ifit1), C-type lectin, superfamily member 13 (Clcsf13), lysozyme (Lyzs), T-
cell specific GTPase (Tgtp), serum amyloid A (SAA) 1, SAA 2 and SAA 3. Most of 
these genes were regulated ‘back’ to the same levels as was seen in chow fed mice. 
Conversely, SAA1, 2 and 4 expression was diminished to levels below the expression 
displayed by animals on chow diet. 
In conclusion, FF supplementation resulted in the reversal of the observed changes in 
cholesterol metabolism and in the inhibition of inflammation. 
FF further inhibits the inflammatory response by interfering 
with NF-κB signaling 
In general, literature-based gene clustering by IPA showed that PPARα activation 
strongly regulated genes involved in lipid breakdown, and especially β-oxidation (data 
not shown), yielding similar results as previous studies with large scale transcriptome 
analysis in mice (9, 51, 76), but also in rats (75) and primates (7). Induction of these 
genes probably contributed to the prevention of NASH development. 
HFC+FF treatment regulated many inflammatory genes in addition to the inhibition of 
HFC diet-induced genes. This group is expected to be important for the inhibition of 
NASH by FF as these genes may indicate mechanisms in addition to the reversal of 
HFC diet-induced gene expression. Many genes further regulated by HFC+FF 
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treatment were clearly involved in the inflammatory response, as was shown before 
(61).  
Most genes down-regulated by HFC+FF treatment were directly involved in the innate 
immune response. Many of the down-regulated genes are known target genes of the 
transcription factor NF-κB or are readily inducible with lipopolysaccharide (LPS) 
stimulation, which in turn activates the NF-κB pathway. This is shown in a network in 
figure 3. In addition to the reversal of several inflammatory genes to the same level as 
was observed on the control chow diet, PPARα activation thus lowers hepatic 
inflammation further than via inhibiting lipid accumulation only, as postulated earlier 
(63). 
Surprisingly, the network that included genes involved in the AP-1 pathway was 
strongly up-regulated (Fig. 4). Both the AP-1 components fos, jun, junB and junD, and 
several genes associated with AP-1 activation were up-regulated by FF treatment. This 
is in contrast with the proposed inhibitory effect of PPARα on AP-1 activity in a 
previous study (15). A possible explanation for this discrepancy may be that the 
referred study used vascular cells. Additionally, it has been postulated that PPARα 
interferes with and inhibits the AP-1 pathway via protein-protein interaction (16), but 
also in that study (human-derived) vascular cells were used. Conversely, FF has been 
shown to affect jun levels in murine liver only slightly, as it rather acts by inhibiting 
jun phosphorylation (21). Supporting our observations, it was recently shown that fos 
is a direct target gene of PPARγ (72).  
It has been suggested by several reports  that NF-κB and AP-1 activity can be 
dissociated in the liver (6, 68) and even have different activities between different cell 
types of the liver compared to hepatocytes, such as in endothelial cells (1) or in Kupffer 
cells (38). During NASH development there is an increased recruitment of 
inflammatory cells, such as macrophages, in the liver (61). The increased number of 
macrophages/Kupffer cells in this setting of NASH may thus have affected the anti-
inflammatory properties of FF in the used whole-liver samples. This interesting 
observation merits further investigation regarding the use of FF for the treatment of 
NASH in a cell-specific manner. 
In rodents, PPARα activation causes hepatic cancer. This secondary response could be 
due to the increased peroxisomal oxidation of FA, thereby generating reactive oxygen 
species (ROS), which are potent activators of AP-1 (52). Due to structural differences 
in the PPARα protein, this is not the case in human subjects, as mice expressing human 
PPARα at physiological levels had a much lower incidence of tumorigenesis than 
control mice (10, 46). Moreover, it is known that human livers express substantially 
less PPARα than murine livers (69). 
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Together, the activation of PPARα down-regulated many inflammatory genes, mostly 
by interfering with NF-κB rather than AP-1. The activation of NF-κB may counteract 
the pro-inflammatory properties of ROS via AP-1 (29, 30).  
 
 
Table 3a 
ProbeSetID Gene Name Symbol 
2d 
HFC 
7d 
HFC 
2d 
HFCff 
7d 
HFCff 
1421041_s_at glutathione S-transferase, alpha 2 Gsta2 -3,6 ns 2,5 2,5 
1417065_at early growth response 1 Egr1 -3,3 -2,4 2,6 2 
1428988_at 
ATP-binding cassette, sub-family 
C member 3 Abcc3 -1,7 -1,5 2,7 2,3 
1418918_at 
insulin-like growth factor binding 
protein 1 Igfbp1 -2,3 ns 2,5 ns 
1454159_a_at 
insulin-like growth factor binding 
protein 2 Igfbp2 -1,5 ns 1,9 2 
1448830_at dual specificity phosphatase 1 Dusp1 -2,4 -2,3 ns 2,7 
1460167_at 
aldehyde dehydrogenase family 
7,member A1 Aldh7a1 -1,5 -1,4 1,4 1,5 
1419549_at arginase 1, liver Arg1 -1,5 -1,6 ns 1,4 
1419456_at dicarbonyl L-xylulose reductase Dcxr -1,4 -1,7 ns 1,8 
1435007_s_at expressed sequence AI132487   -1,3 -1,3 ns 1,3 
1417982_at insulin induced gene 2 Insig2 -1,5 ns 1,8 1,6 
1452184_at 
NADH dehydrogenase 1 beta 
subcomplex,9 Ndufb9 -1,4 ns 1,7 1,5 
1419093_at tryptophan 2,3-dioxygenase Tdo2 -1,4 -1,4 1,8 1,9 
1416555_at etoposide induced 2.4 mRNA Ei24 -1,4 ns 1,6 1,6 
1427520_a_at 
myosin, heavy polypeptide 1, 
skeletal muscle, adult Myh1 -2,4 ns ns 16,8 
1438322_x_at 
farnesyl diphosphate farnesyl 
transferase 1 Fdft1 -1,4 ns ns 1,9 
1427735_a_at actin, alpha 1, skeletal muscle Acta1 -2,4 ns ns 24 
1416889_at troponin I, skeletal, fast 2 Tnni2 -1,7 ns ns 8,4 
1433855_at 4-aminobutyrate aminotransferase Abat -1,4 ns ns 1,9 
1449047_at RIKEN cDNA 1600020H07 gene   -1,2 ns ns 1,7 
1419312_at 
ATPase, Ca++ transporting, 
cardiac muscle, fast twitch 1 Atp2a1 -1,8 ns ns 8,9 
1429144_at RIKEN cDNA 2310032D16 gene   -1,3 ns 2,1 2,6 
1420541_at retinol dehydrogenase 6 Rdh6 -1,3 ns 1,8 4 
1451203_at myoglobin Mb -1,7 ns ns 6,5 
1455821_x_at RIKEN cDNA 2400006N03 gene   -1,1 ns 1,5 1,8 
1433444_at 
3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 1 Hmgcs1 -1,5 ns ns 2,9 
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Table 3b 
ProbeSetID Gene Name Symbol 2d HFC 7d HFC 2d HFCff 7d HFCff 
1416022_at fatty acid binding protein 5 Fabp5 2,6 1,7 -2,3 -2,1 
1417290_at leucine-rich alpha-2-glycoprotein 1 Lrg1 2 1,5 -1,4 -1,5 
1427747_a_at lipocalin 2 Lcn2 6,2 10,1 -3,7 -6,8 
1450788_at serum amyloid A 1 Saa1 6,1 9,8 -9,8 -25,8 
1450783_at interferon-induced protein with 
tetratricopeptide repeats 1 
Ifit1 3 ns -2,5 ns 
1449009_at T-cell specific GTPase Tgtp 3 ns -4,2 ns 
1434372_at expressed sequence AW112010  1,7 1,7 -2 -1,6 
1449326_x_at serum amyloid A 2 Saa2 5,2 9 -7,3 -17,3 
1424758_s_at serine (or cysteine) proteinase 
inhibitor, clade A, member 10 
Serpina10 1,5 ns -1,7 -1,5 
1455393_at ceruloplasmin Cp 1,3 1,4 -1,3 -1,3 
1419319_at serum amyloid A 4 Saa4 2 ns -2,7 -2,7 
1460197_a_at RIKEN cDNA 1110021O17 gene  2 ns -2,4 -2,9 
1420928_at beta galactoside alpha 2,6 
sialyltransferase 1 
St6gal1 1,4 ns ns -1,7 
1450826_a_at serum amyloid A 3 Saa3 3 ns ns -6,5 
1420438_at orosomucoid 2 Orm2 2,1 ns ns -6,2 
1423547_at lysozyme Lyzs 1,4 ns ns -1,7 
1449905_at C-type lectin, superfamily member 
13 
Clecsf 13 1 ns ns -1,5 
 
Table 3. Genes regulated in opposite directions by HFC and HFC+FF treatments. This table shows genes 
regulated in the differently by both treatments, derived from the previously found HFCdiet-induced genes 
[13]. From each gene, the probeset ID, gene title, gene symbol, fold change and p-value of fold change after 
2 and 7 days of treatment compared to chow fed animals is shown. P-values smaller than 1.10-6 were 
considered significant. A. Genes down-regulated by HFC and  up-regulated by HFC+FF treatment, and B. 
Genes up-regulated by HFC and down-regulated by HFC+FF treatments. 
Conclusion 
This study revealed an interesting pathway that may be of importance during early 
progression and inhibition of NASH in APOE2ki mice besides inflammation; i.e. 
cholesterol metabolism. The relation between cholesterol metabolism and 
inflammation during NASH development is gaining more attention, as several 
publications recently attributed pro-inflammatory qualities to cholesterol (31, 43, 71). 
Recently, we identified dietary cholesterol be a potent inducer of hepatic inflammation 
(73). The current results argue for a closer relationship between these two, and are of 
interest for further studies in this field. Further validation of the involvement of 
cholesterol metabolism during progression of NASH will imply that targeting this 
pathway, e.g. with statins, may be a sensible approach for treatment strategies against 
NASH. 
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Additionally, modulating inflammation may prove to be a key step in future treatments 
of NASH. Activating PPARα clearly inhibited inflammation, mainly due to the 
inhibition of NF-κB, rather than AP-1. Our results argue that these NF-κB-responsive 
genes may prove to be suitable targets for treating inflammation as a part of therapeutic 
strategies against NASH. 
 
 
 
Figure 3.  NF-κB genes regulated by FF treatment. Literature-based functional network created in 
Ingenuity Pathways® software around NF-κB. Genes in green are down-regulated in our dataset at both 
time points, while red indicates up-regulation at both time points. Grey genes are regulated at one of the 
time points only, while white genes were not found to be regulated in our dataset but are involved in the 
network according to literature-based clustering. 
Microarray analysis of fenofibrate-induced NASH inhibition 
 
 
- 87 - 
 
 
Figure 4.  AP-1 genes regulated by FF treatment. Literature-based functional network created by Ingenuity 
Pathways® software around Fos and Jun, the central components of AP-1. Genes in green are down-
regulated in our dataset at both time points, while red indicates up-regulation at both time points. Grey 
genes are regulated at one of the time points only, while white genes were not found to be regulated in our 
dataset but are involved in the network according to literature-based clustering. 
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 Chow  2d HFC  2d HFCFF  7d HFC  7d HFCFF 
Present 9473 41,7%  9496 41,9%  11193 49,3%  9478 41,8%  11507 50,7% 
Absent 12749 56,2%  12713 56,0%  11106 48,9%  12720 56,1%  10777 47,5% 
Marginal 468 2,1%  481 2,1%  391 1,7%  492 2,2%  406 1,8% 
Regulated   79  986  196  987 
SF 2,461  2,571  1,515  2,904  1,701 
 
Supplementary Table 1. This table shows technical aspects of the arrays that were used in this study. At 
each time point, the total number of probe sets on the array is shown together with the number found to be 
present, absent or marginally present after hybridization. Furthermore, the genes that were found to be 
statistically regulated at each time point are depicted together with the correction scaling factor (SF) for 
each array.  
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Abstract 
Introduction:  Non-alcoholic steatohepatitis (NASH) involves liver lipid accumulation 
(steatosis) combined with hepatic inflammation. The transition towards hepatic 
inflammation represents a key step in the pathogenesis, as it will set the stage for 
further liver damage, culminating in hepatic fibrosis, cirrhosis and liver cancer. The 
actual risk factors that drive hepatic inflammation during the progression to NASH 
remain largely unknown.  
Aim: Investigate the role of steatosis and dietary cholesterol in the etiology of diet-
induced NASH was investigated by using hyperlipidemic mouse models fed a western 
diet.  
Materials and methods: Livers of male and female hyperlipidemic (low density 
lipoprotein deficient [ldlr-/-] and apolipoprotein E2 knock-in [APOE2ki]) mouse 
models were compared with livers of normolipidemic wild-type (WT) C57Bl/6 mice 
after short term feeding with a high fat diet with high cholesterol (HFC) and without 
cholesterol (HFnC).  
Results:  Whereas WT mice displayed only steatosis after a short term on HFC diet, 
female ldlr-/- and APOE2ki mice showed steatosis with severe inflammation 
characterized by infiltration of macrophages and increased nuclear factor kappa beta  
(NF-κB) signaling. Remarkably, male ldlr-/- and APOE2ki mice developed severe 
hepatic inflammation in the absence of steatosis after 7 days on HFC diet compared to 
WT animals. HFC diet induced bloated ‘foamy’ Kupffer cells in male and female ldlr-/- 
as well as in APOE2ki mice. Hepatic inflammation was found to be linked to increased 
plasma very low density lipoprotein (VLDL) cholesterol levels. Omitting cholesterol 
from the HFC diet lowered plasma VLDL cholesterol and prevented the development 
of inflammation and hepatic foam cells. 
Conclusion: These findings indicate that dietary cholesterol, possibly in the form of 
modified plasma lipoproteins, is an important risk factor for the progression to hepatic 
inflammation in diet-induced NASH.  
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a condition ranging from benign lipid 
accumulation in the liver (steatosis) to steatosis combined with inflammation. The 
latter is referred to as non-alcoholic steatohepatitis (NASH). NAFLD may be 
considered the hepatic event in the metabolic syndrome and is, therefore, linked with 
all common metabolic syndrome risk factors like obesity, insulin resistance, 
hypertension and dyslipidemia [1]. The prevalence of NAFLD in the general 
population is increasing, but only a small proportion will develop NASH. Estimates in 
USA are that only 2-3% of all adults have NASH, compared to an estimation of 20% of 
Americans with NALFD [2].  
Steatosis alone is considered a relatively benign and reversible condition. The 
transition towards NASH represents a key step in pathogenesis, as it will set the stage 
for further damage to the liver, including fibrosis, cirrhosis and liver cancer. The actual 
risk factors that drive hepatic inflammation during the progression to NASH remain 
largely unknown. Therefore, knowledge about events that induce hepatic inflammation 
is of great importance for the diagnosis and treatment of NASH. 
Currently, NASH is thought to develop via the “two-hit model” [3]. According to this 
hypothesis, hepatic steatosis is the critical first hit and prerequisite for further liver 
injury to develop. A second hit can be represented by oxidative stress [4]. However, 
recent reports doubt steatosis being a prerequisite for development of inflammation 
during NASH progression [5-7]. In line with these observations, we have previously 
shown that in APOE2 knock-in (APOE2ki) mice, a mouse model with a human-like 
lipoprotein profile, hepatic steatosis and inflammation (i.e. steatohepatitis) develop 
very rapidly when fed a western type diet with moderate amounts of fats. Already after 
2 days of feeding a western diet enriched with triglycerides (TGs) and cholesterol, 
female APOE2ki mice show a marked liver inflammation [8]. Inflammation thus 
developed alongside rather than subsequent to steatosis.  
The APOE2ki mouse carries the defective human APOE2 isoform that replaces the 
endogenous mouse apoe gene. ApoE is highly expressed in macrophages and has been 
shown to influence several inflammatory processes [9]. Therefore, to exclude defects in 
ApoE as the cause of such early inflammation in the liver, we first investigated diet-
induced NASH development in another hyperlipidemic mouse model that does not 
have a defect in ApoE, i.e. the ldlr-/- mouse [10]. C57Bl/6 wild-type (WT) mice, with 
the genetic background of both mouse models, were used as control. Second, pilot 
experiments revealed a difference between female and male ldlr-/- and APOE2ki mice 
as the male mice did not develop steatosis after short term high fat feeding. 
Consequently, we investigated male hyperlipidemic APOE2ki and ldlr-/- mice to 
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unravel whether steatosis is necessary for hepatic inflammation to develop. Third, 
based on the results from these diet intervention studies, a correlation was found 
between plasma total cholesterol (TC) and hepatic inflammation. Therefore, the role of 
plasma TC was further investigated. 
Materials and methods 
Mice and diet 
Mice were housed under standard conditions given free access to food and water. 
Experiments were performed according to Dutch laws, approved by the Committee for 
Animal Welfare of Maastricht University. Several experiments were performed. In the 
first experiment, 12-week old female C57Bl/6 and ldlr-/- mice were fed a high fat diet 
containing 21% milk butter and 0.2% cholesterol (HFC), for 2, 4, 7 and 21 days. A 
single group was kept on a standard chow diet until the age of 12 weeks and served as 
control group. In the second experiment, male C57Bl/6, ldlr-/-, and APOE2ki mice were 
put either on HFC for 7 days or were kept on chow diet. In the third experiment, male 
and female C57Bl/6, ldlr-/-, and APOE2ki mice were fed HFC or the high fat diet 
without the added cholesterol (HFnC) for 7 days. The HFnC diet contained only the 
residual cholesterol derived from the butter component, i.e. 0.05%. Collection of blood, 
sacrificing of the mice, and tissue isolation was done as described previously [8].  
Lipid analysis 
Approximately 50 mg of frozen liver tissue was homogenized as described previously 
[8]. Both plasma and liver lipid levels were measured with enzymatic color tests 
(1489232, cholesterol CHOD-PAP, Roche, Basel, Switzerland; TR0100, TG GPO-
trinder, Sigma Aldrich, St. Louis, MO, USA; 999-75406, NEFAC, ACS-ACOD, Wako 
Chemicals, Neuss, Germany) as described before [8]. 
RNA isolation and first strand cDNA synthesis 
Total RNA was isolated from approximately 25 mg of mouse liver tissues as described 
previously [8]. All applications were done according to manufacturer’s protocols. Total 
RNA (500 ng) from each individual mouse was converted into first strand cDNA with 
iScript cDNA synthesis kit (170-8891, Bio-Rad, Hercules, CA, USA) according to the 
manufacturer’s instructions.  
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Quantitative PCR 
The changes in gene expression of inflammatory markers were determined by 
quantitative PCR on a Bio-Rad MyIQ with the IQ5 v2 software (Bio-Rad, Hercules, 
CA, USA) by using IQ SYBR Green Supermix with fluorescein (170-5006CUST, Bio-
Rad, Hercules, CA, USA) and 10 ng of cDNA. For each gene a standard curve was 
generated with a serial dilution of a liver cDNA pool. To standardize for the amount of 
cDNA, Cyclophillin A (Ppia) was used as the reference gene. Primer sets for the 
selected genes were developed with Primer Express version 1.5 (Applied Biosystems, 
Foster City, CA, USA) using default settings. Primer sequences: 
MCP1-forward, 5’-GCTGGAGAGCTACAAGAGGATCA-3’; 
MCP1-reverse, 5’-ACAGACCTCTCTCTTGAGCTTGGT-3’; 
CD68-forward, 5’-TGACCTGCTCTCTCTAAGGCTACA-3’; 
CD68-reverse, 5-TCACGGTTGCAAGAGAAACATG -3’; 
TNFa-forward, 5’-CATCTTCTCAAAATTCGAGTGACAA-3’; 
TNFa-reverse, 5’-TGGGAGTAGACAAGGTACAACCC-3’; 
Ppia-forward, 5’-TTCCTCCTTTCACAGAATTATTCCA-3’; 
Ppia-reverse, 5’-CCGCCAGTGCCATTATGG-3’. 
Data from qPCR were analyzed according to the relative standard curve method. 
Taqman® Low Density Arrays  
To perform gene-expression analysis on a medium scale, Taqman® Low Density Arrays 
(TLDA) 96a (PN 4342259) were used. Each TLDA plate contained 4 x 96 annotated 
and validated individual TaqMan® Gene Expression Assays (forward primer, reversed 
primer and Taqman® Probe) (supplementary table 1). Per individual assay 2 ng cDNA 
of a single liver was loaded together with the TaqMan® Universal PCR Master Mix 
(PN 4324018). Of each group, mRNA from 5 individual mice was used. TLDA plates 
were run on an ABI Prism 7900HT Sequence Detection System with a TaqMan® Low 
Density Array Upgrade. Data were analyzed by using RQ Manager 1.2 software. 
Technically failed assays were omitted from analysis. Materials, equipment and 
software necessary to perform TLDA gene expression studies were obtained from 
Applied Biosystems, Foster City, CA, USA. All data were normalized to Ppia 
expression. Significant differences were determined with student t-tests; p-values < 
0.05 were considered significant.  
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Liver histology 
Four µm paraffin embedded liver sections were stained with Haematoxillin/Eosin (HE) 
and Periodic acid Schiff (PAS)-diastase. Frozen liver sections (7 µm) were fixed in 
acetone and stained with CD68 (FA11) or Mac1 (M1/70). Pictures were taken with a 
Nikon® digital camera DMX1200 and ACT-1 v2.63 software (Nikon® Corporation, 
Tokyo, Japan).  
Electron microscopy. 
Livers were freshly isolated from the mice, perfused and fixed overnight with 2.5% 
glutaraldehyde (Ted Pella, Redding, CA, USA). Tissue fragments were washed and 
post-fixed in 1% osmium tetroxide. Tissues were subsequently dehydrated trough 
100% ethanol, cleared with propylene oxide, and embedded in epoxy resin. Sections of 
1 μm were stained with toluidine blue to identify the presence of foamy Kupffer cells. 
Next, sections of 70-90 nm were cut on an ultra-microtome, mounted on Formvar-
coated (1595E, Merck) 75 mesh copper grids and counterstained with uranyl acetate 
and lead citrate before analysis on a Philips CM100 transmission electron microscope. 
Statistical analysis 
Data were analyzed using Graphpad Prism 4.0. Groups were compared using 2-tailed 
non-paired t-tests or ANOVA with a Dunnet post test, based on the statistical 
relevance. Data are expressed as means ± SEM and considered significant at p < 0.05. 
Results 
Plasma lipid levels in female hyperlipidemic mouse models 
Female ldlr-/-, APOE2ki and WT mice were fed an HFC diet for up to 3 weeks and 
changes in plasma lipids were monitored (experiment 1). Results on female APOE2ki 
mice were published earlier [8] and are included in figure 1 (black bars) for clarity. WT 
mice only displayed minor changes in their lipid profile. Compared to control chow 
levels, female ldlr-/- mice showed increased plasma TGs (Fig. 1A) and free fatty acids 
(FFA) (Fig. 1B) levels and diet-induced hypercholesterolemia (Fig. 1C) upon HFC 
feeding. Historical data of female APOE2ki mice (black bars) shows that these animals 
have elevated basal plasma TG levels that tended to decrease within time (Fig. 1A), 
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while FFA remained at basal levels (Fig. 1B) and TC levels increased markedly 
throughout the dietary period (Fig. 1C) [8].  
 
 
 
 
Figure. 1 Plasma lipid levels in female mice. Figure shows plasma lipids of three mouse models at several 
time points after HFC treatment: 2, 4, 7 and 21 days (d) compared to chow-fed control mice. A. plasma 
triglycerides (TGs). B. plasma free fatty acids (FFA) and C. plasma total cholesterol (TC). Bars represent 
time points (2, 4, 7 and 21 days) and are grouped per genotype:  WT mice (grey bars), ldlr-/- mice (white 
bars) and APOE2ki mice (black bars). Statistical analysis was done with one way ANOVA with Dunnet’s 
post test; * indicates significant difference from levels on chow diet. 
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Only female ldlr-/- and APOE2ki mice develop liver 
inflammation  
APOE2ki and ldlr-/- mice showed equal accumulation of lipid droplets in their livers 
after 7 days of HFC which was comparable with livers of control WT animals (Fig. 
2A). Fig. 2B shows that all mouse models had similar increases of liver TGs after short 
periods of HFC feeding. Liver TC showed a similar response (Fig. 2C). HFC feeding 
thus induced a degree of hepatic steatosis in ldlr-/- and APOE2ki mice similar to what 
was observed in WT animals. These observations were confirmed by Oil red O (ORO) 
staining (data not shown). 
As HE staining revealed inflammatory clusters in the livers (Fig. 2A), antibodies 
against the macrophage marker Mac1 were used to identify inflammatory cells. The 
number of Mac1 positive cells was counted to determine the level of liver 
inflammation. Interestingly, WT livers were completely free of inflammation upon 
HFC feeding, while ldlr-/- mice displayed inflammatory cell clusters similar to those 
observed previously in APOE2ki mice [8] (Fig. 2D), albeit that inflammation was less 
severe in ldlr-/- mice. 
Gene expression analysis of several inflammatory genes was performed in livers of the 
mouse models outlined at 2, 4, 7 and 21 days after HFC feeding. These genes were 
monocyte chemoattractant protein 1 (Mcp1) (Fig. 2E), CD68 (Fig. 2F), a macrophage 
marker, and tumor necrosis factor (TNF) (Fig. 2G), a cytokine. Expression of these 
genes in ldlr-/- and APOE2ki mice was strongly up-regulated after HFC feeding. In 
contrast, control WT mice showed only a moderate increase in liver gene expression, 
apparently insufficient to drive an overt inflammatory response as determined by liver 
histology. 
Hence, in HFC-induced fatty liver, female APOE2ki and ldlr-/-, but not WT mice, are 
sensitive to developing inflammation, indicating that diet-induced steatosis does not 
necessarily lead to the immediate development of an inflammatory response in the 
liver. 
Liver gene expression profiling reveals an inflammatory 
profile in ldlr-/- but not in WT female mice 
To investigate the hepatic response to HFC feeding in more detail, custom TLDA 
assays were designed to compare the expression of 96 genes involved either in lipid 
transport and metabolism, or in inflammation. The expression of Mcp1, CD68 and 
TNF, determined by QPCR, was similar between ldlr-/- and APOE2ki mice (Fig. 2 E-  
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Figure. 2 NASH parameters in female mice. A. Representative pictures (200x) of HE stained liver sections 
were taken of female mice after 7 days high fat, high cholesterol (HFC) diet. Black arrows indicate 
inflammatory cell clusters. Liver triglycerides (TGs) (B) and total cholesterol (TC) (C) levels were 
quantified biochemically. D. Liver sections were stained for Mac1 (CD11b) and counted. Gene expression 
analysis with quantitative RT-PCR for three known inflammatory marker genes: MCP1 (E), CD68 (F) and 
TNF (G). Data was set relative to wild-type (WT) animals on chow diet. Bars represent time points (2, 4, 7 
and 21 days) and are grouped per genotype:  WT mice (grey bars), ldlr-/- mice (white bars) and APOE2ki 
mice (black bars). Statistical analysis was done with one way ANOVA with Dunnet’s post test; * indicates 
significant difference from levels on chow diet. 
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G). Additionally, previous microarray analysis has already shown a profound 
inflammatory response after feeding female APOE2ki mice HFC diet [8]. The response 
of ldlr-/- mice to 7 days of HFC feeding was compared to WT mice. Table 1 shows 
changes in expression levels for these genes and indicates the pathway to which each 
gene belongs to. Genes involved in lipid metabolism showed only few changes after 7 
days of HFC diet in either mouse model (table 1A). Inflammatory gene expression, 
including several known targets of NF-κB, was markedly up-regulated in female ldlr-/- 
mice, but not in female WT mice (table 1B). The inflammatory response consisted 
mainly of the increased expression of macrophage specific genes (table 1B), like 
CD68, Fc Gamma receptor 1 and Mac1, but not other immune cell specific genes, like 
CD19 (B-cells), CD4 (Th-cells), CD8a (Tc-cells), and myeloperoxidase (MPO) 
(neutrophils). These data suggest that inflammation is mainly related to macrophage 
accumulation and activation. Also Icam1 and Vcam1, involved in inflammatory cell 
migration and invasion, were up-regulated. Additionally, genes involved in chemotaxis 
(table 1B), such as ccl2 (mcp1), ccl3 and ptgs2 were strongly regulated, indicating an 
important role of these gene products in the development of hepatic inflammation.  
Steatosis is not necessary for the development of HFC diet-
induced hepatic inflammation 
Male ldlr-/- and APOE2ki mice were put either on chow diet or HFC diet for 7 days 
(experiment 2). Male WT animals were used as control. Both male ldlr-/- and APOE2ki 
mice showed increased diet-induced plasma TGs (Fig. 3A) and TC (Fig. 3B) compared 
to control mice, although APOE2ki mice were less responsive than ldlr-/- mice. The 
changes in TGs were similar to those observed in female mice for the ldlr-/- animals, 
while APOE2ki mice differed in their TG response as female APOE2ki mice had 
elevated starting levels of TGs that did not change after dietary intervention (Fig. 1A). 
While in the female animals the APOE2ki mice were more responsive with respect to 
plasma TC (Fig. 1C), male APOE2ki mice had a smaller increase than ldlr-/- mice. 
Biochemical assessment of liver lipids showed no increase in liver TG levels in male 
hyperlipidemic mice. Male WT mice did show an increase in hepatic TGs, however, 
the levels after 7 days of HFC did not exceed the ones displayed in the ldlr-/- and 
APOE2ki males (Fig. 3C). On the other hand, liver TC levels did rise significantly after 
HFC in all models (Fig. 3D). Likewise, ORO staining did not reveal overt steatosis 
(data not shown). 
 
 
 
Cholesterol induces hepatic inflammation 
- 103 - 
 
Table 1. Liver Gene expression 
A 
gene group 
WT LDLR-/- 
HFC vs chow HFC vs chow 
Cd36 Lipid  Uptake 1.4 1 
Fabp1 Lipid  Uptake 1.2 0.9 
Lipc Lipid  Uptake 1.1 0.9 
Lpl Lipid  Uptake 1.3 3.7 
Lrp1 Lipid  Uptake 1.5 1.1 
Slc27a1 Lipid  Uptake 1.1 0.9 
Acaa1a lipid Oxidation and efflux 1.3 1 
Acox1 lipid Oxidation and efflux 1.2 0.8 
Cpt1a lipid Oxidation and efflux 1.5 0.8 
Crot lipid Oxidation and efflux 1.5 0.9 
Ech1 lipid Oxidation and efflux 0.9 0.8 
Hadha lipid Oxidation and efflux 1.1 1 
Mttp lipid Oxidation and efflux 1 0.8 
Ppara lipid Oxidation and efflux 1.4 0.9 
Ppard lipid Oxidation and efflux 1.2 1.2 
Pparg lipid Oxidation and efflux 1.1 1.1 
Fasn Lipid Met. Synthesis 0.5 0.4 
LXRa Lipid Met. Synthesis 1.6 1.1 
FXR Lipid Met. Synthesis 1.1 0.7 
Scd1 Lipid Met. Synthesis 1.2 0.6 
Srebf1 Lipid Met. Synthesis 1.2 1.3 
Abca1 Cholesterol efflux 1.5 1.7 
Cyp7a1 Cholesterol efflux 2 1.6 
Scarb1 Cholesterol efflux 1.8 1.4 
Adfp Intracellular lipid distribution 1.3 0.8 
Cav1 Intracellular lipid distribution 1.2 0.9 
Cav2 Intracellular lipid distribution 1.2 0.9 
M6prbp1 Intracellular lipid distribution 1.4 1 
Npc1 Intracellular lipid distribution 1 0.6 
Idi1 Cholesterol metabolism 0.2 0.1 
Insig2 Cholesterol metabolism 1.5 0.7 
Cyp8b1 Other 1.3 0.3 
Cd19 Cell Markers 0.8 1.4 
Cd4 Cell Markers 2 1.3 
Cd68 Cell Markers 1.7 3.1 (a) 
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Table 1 (continued)  B. 
gene group 
WT LDLR-/- 
HFC vs chow HFC vs chow 
Cd8a Cell Markers 1.4 2 
Fcgr1 Cell Markers 2.2 2.4 (a) 
Itgam/Mac1 Cell Markers 1.5 5.7 (a) 
Mpo Cell Markers 3 7.9 
Icam1 Cell Markers 1.9 3 
Vcam1 Cell Markers 1 3 
Vegfa Cell Markers 1.1 1 
Ccl2/mcp1 Chemotaxis 3 9.5 (b) 
Ccl3/mip1 Chemotaxis 3.4 11.2 (b) 
Ccr2 Chemotaxis 1.8 1.9 (b) 
Ptgs2/Cox2 Chemotaxis 1.2 25.4 (b) 
Cat Oxidative stress 1.1 0.8 
Gsta2 Oxidative stress 0.5 0.2 
Hmox1 Oxidative stress 1.8 2.8 
Ikbkb Oxidative stress 1 1.3 
Por Oxidative stress 1.3 0.8 
Bcl2 Apoptosis 1.2 2 
Fasl Apoptosis 2 2.2 
Il10 Anti-inflammatory 2.5 1.7 
Il10ra Anti-inflammatory 1.5 2.9 
Socs1 Anti-inflammatory 2.6 2.3 
Socs3 Anti-inflammatory 1.3 1.9 
Cd14 General Inflammation 1.8 4.5 
Cd40 General Inflammation 2.1 2.7 
Cd80 General Inflammation 2.7 2.7 
Cd86 General Inflammation 2.2 3 
CsfF General Inflamm. 0.6 0.9 
Cxcl10 General Inflammation 3 3.5 
Ifng General Inflammation 1.1 1.7 
Il18 General Inflammation 1 0.9 
Il18r1 General Inflammation 1.9 4 
Il1b General Inflammation 1.4 6.3 
Il1r1 General Inflammation 0.8 2 
Il1r2 General Inflammation 1.1 5.4 
Il6 General Inflammation 1.6 6 
Il6ra General Inflammation 0.6 0.7 
Nfkbia General Inflammation 1.2 1.4 
Saa1 General Inflammation 2.3 19.9 
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Table 1 (continued) 
gene group 
WT LDLR-/- 
HFC vs chow HFC vs chow 
Stat1 General Inflammation 1.8 1.8 
Stat3 General Inflammation 1.2 1.4 
Tlr2 General Inflammation 2.3 4.9 
Tlr4 General Inflammation 1.5 2.4 
Tnf General Inflammation 3 10 
Tnfrsf1a General Inflammation 1.3 1 
Tnfrsf1b General Inflammation 1.3 1.4 
 
Table 1. Liver gene expression. Table shows gene abbreviation and classification according to function. 
Expression is shown as fold change compared to levels of animals on standard chow diet for WT and ldlr-/- 
female mice after 7d of HFC. Significant changes (student t-tests), compared to chow are shown bold and 
underlined. A. Genes involved in lipid metabolism and B. Genes involved in inflammation. Regulated 
genes used as cell markers are marked by (a); regulated genes involved in chemotaxis are marked by (b). 
Lipid accumulation is generally considered an initial and causal factor in the 
progression from steatosis to NASH [11]. Surprisingly, despite the lack of steatosis in 
male mice, there was a severe inflammatory response, reflected by a 3- to 5-fold 
increase in Mac1 positive cells (Fig. 3E) and increased gene expression of Mcp1 (Fig. 
3F), CD68 (Fig. 3G) and TNF (Fig. 3H) compared to controls. These responses were 
more pronounced in APOE2ki than in ldlr-/- male mice. Overall, this indicates that liver 
lipid accumulation is not a prerequisite for hepatic inflammation to develop in these 
mouse models.  
Foam cells and modified lipoproteins in hyperlipidemic mice 
Previously, we found that female APOE2ki mice displayed an increase in the size of 
CD68 positive cells after dietary intervention [8]. Immunostaining against CD68 now 
indicated a comparable increase in size rather than number of CD68 positive cells, i.e. 
Kupffer cells and macrophages, in livers of male and female ldlr-/- and APOE2ki mice, 
but not of WT mice (Fig. 4A) (experiments 1 and 2). Additionally, toluidine blue 
staining clearly illustrated that these cells with foamy appearance are located in the 
sinusoidal space of the liver, suggesting that these cells are KCs (Fig. 4B). Further 
detail was provided with electron microscopy (Fig. 4C). EM pictures showed clear 
differences between livers of the animals. KCs appeared to have more cytoplasm and 
filled a larger fraction of the sinus, indicating that these cells are swollen compared to  
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Figure 3. Plasma and liver lipid levels in male mice. Plasma TGs (A) and TC (B) were determined of male 
mice. Data from animals fed chow diet or 7 days of HFC. Liver triglyceride (C) and cholesterol (D) levels 
were quantified biochemically. E. Liver sections were stained with antibodies against Mac1 (CD11b) and 
counted. Gene expression analysis with quantitative RT-PCR for three known inflammatory genes: MCP1 
(F), CD68 (G) and TNF (H). Data was set relative to WT animals on chow diet. Bars are grouped per 
genotype: WT mice (grey bars), ldlr-/- mice (white bars) and APOE2ki mice (black bars). Statistical analysis 
was done with student t-tests; * indicates significant difference from levels on chow diet. 
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chow fed animals. In HFC fed animals, cytoplasm of KCs contained lipid droplets and 
filled lysosomes. Moreover, these cells contained cholesterol crystals, which is 
indicative for the uptake of cholesterol by these cells. 
Omitting dietary cholesterol reduces plasma VLDL TC and 
protects against developing hepatic inflammation 
A consistent finding was that plasma TC was increased in the mouse models that 
developed hepatic inflammation. Accordingly, we hypothesized that plasma TC is an 
important determinant of hepatic inflammation. To test this hypothesis, mice (both 
male and female) were put on the high fat diet with or without added cholesterol (HCF 
and HFnC; high fat no cholesterol) (experiment 3). Omitting dietary cholesterol 
induced lower levels of VLDL-TC than HFC diet in both sexes of the hyperlipidemic 
mice (Fig. 5) and lowered total plasma TC by approximately 50% in APOE2ki and   
ldlr-/- animals (data not shown). Female WT mice also displayed lowering of TC levels, 
while this was not observed in male WT mice (data not shown).  
Omission of dietary cholesterol did result in lower TGs and TC levels in WT controls, 
while it did not diminish liver TG content in APOE2ki and ldlr-/- mice (Fig. 6 A, B). In 
male mice, omitting cholesterol even tended to enhance TG content in the livers (Fig. 
6C). The level of liver TC remained low in female APOE2ki mice and in male ldlr-/- 
mice (Fig. 6 B, D).  
Strikingly, Mac1 staining of liver sections showed that macrophage infiltration was 
limited when ldlr-/- and APOE2ki mice of both sexes were put on the HFnC diet (Fig. 6 
E, F). Control mice did not show hepatic inflammation in any of the conditions. HE 
staining revealed that upon feeding HFnC diet, in male and female ldlr-/- and APOE2Ki 
mice no swollen, foamy KCs were detected (Fig. 7). Additional evidence was found 
with PAS-diastase staining. Figure 8 shows the lack of swollen KCs upon feeding the 
mice HFnC compared to mice fed HFC diet. 
Accordingly, expression levels of Mcp1, CD68 and TNF were down-regulated in 
female mice fed HFnC compared to HFC and similar trends were observed in male 
mice (Fig. 9). Thus, lower levels of diet-induced VLDL-TC are associated with less 
hepatic inflammation in ldlr-/- and APOE2ki mice. 
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Figure 4. Hepatic foam cells. A. Representative pictures (400x) of female APOE2ki liver sections stained 
against CD68 on control chow diet and after 7 days of HFC. B. Representative pictures (400x) of toluidine-
stained liver sections from APOE2ki female mice on a chow diet and after 7 days of HFC. Black arrows 
indicate foamy Kupffer cells. C. Representative electron microscopy pictures (1550-fold magnification) of 
female APOE2ki mice fed either chow or HFC diet. Cholesterol crystals are indicated with black arrows. 
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Figure 5. Treatment with HFnC diet lowers VLDL cholesterol levels. Figure shows lipoprotein fractions 
after 7 days HFC and 7 days HFnC in female ldlr-/-  (A), female APOE2ki (B), male ldlr-/-  (C) and male 
APOE2ki (D) mice. 
Discussion 
This study clearly dissociates steatosis and inflammation in the livers of hyperlipidemic 
mice. HFC feeding induced a very early inflammatory response in the livers of ldlr-/- 
and APOE2ki female mice. Contrary, female WT mice developed comparable steatosis 
but no inflammation. Additionally, we found that in male mice, inflammation increased 
rapidly in the absence of steatosis. Together, these results suggest that liver 
inflammation can arise independently of steatosis upon high fat feeding. Subsequent 
experiments showed that omitting cholesterol from the HFC diet prevented VLDL-TC 
accumulation and hepatic inflammation, while parameters of steatosis remained largely 
unaffected. The presence of bloated foamy KCs only in HFC fed hyperlipidemic mice 
suggests that scavenging of modified lipoproteins by KCs may initiate this early 
inflammation. 
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Figure 6. Omitting cholesterol from the high fat diet prevents inflammation development without affecting 
steatosis. Biochemical measurements of liver lipids are shown for TGs in female (A) and male (C) mice 
and for TC content in female (B) and male (D) mice after 7 days of treatment with HFC or HFnC. Counting 
of Mac1 positive cells is shown in liver sections of female (E) and male (F) mice. Data are shown from WT 
(grey bars), ldlr-/- mice (white bars) and APOE2ki mice (black bars). Statistical analysis was done with 
student t-tests;  * indicates significant difference from levels on HFC diet. 
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Hyperlipidemic mice are sensitive to develop early diet-
induced NASH  
Until now, the best characterized and most known models for NASH are mice deficient 
for leptin (Ob/Ob) or mice fed a diet deficient in methionine and choline (MCD) [11]. 
However, Ob/Ob mice do not spontaneously develop liver inflammation but require a 
second hit, like the administration of lipopolysaccharide (LPS) to activate 
inflammatory signaling. Furthermore, mutation of the leptin gene is not common in 
human obese NAFLD patients. MCD fed mice display all hallmarks of NASH, from 
steatosis to inflammation and fibrosis development. However, MCD fed animals tend 
to lose weight and display lowered plasma TG levels [11] and are therefore very 
different from human NASH patients, who are mostly obese and/or hyperlipidemic.  
Dyslipidemia is commonly associated with NAFLD. It was postulated that 
abnormalities in lipid metabolism such as the increase of serum TGs, TC and LDL-TC 
levels and decrease of HDL-TC may be contributing factors of NASH development 
[12]. Consequently, hyperlipidemic mice have been shown previously to develop diet-
induced NASH, not only in APOE2ki mice [8], but also in ldlr-/- and ApoE deficient 
(apoe-/-) mice [13]. Unlike human subjects, WT mice carry most of their lipids in high-
density lipoproteins. In contrast, ldlr-/- mice and mice with various defects in the ApoE 
protein have a human-like lipoprotein profile and may serve as physiological mouse 
models to study the early progression of NASH. 
Medium-scale gene expression analysis showed that, despite the presence of steatosis, 
not many lipid genes were regulated in either ldlr-/- or in WT control mice. This is 
probably due to the early time point of 7 days of high fat feeding, which might be too 
early to evoke a large transcriptional response of these genes. In line with this, we have 
found that HFC-induced expression of genes involved in lipid metabolism increases 
gradually with time [8]. Alternatively, the physiological response on lipids may also be 
due to secondary feedback mechanisms regulated on the protein level rather than the 
gene level, resulting in the lack of transcriptional regulation.  
In contrast to the lipid genes, a large set of inflammatory genes was regulated in the 
HFC fed ldlr-/- mouse, but not in WT mice, confirming our histological data. The data 
show that the inflammatory response consisted mainly of genes involved in chemotaxis 
and infiltration of macrophages. Furthermore, many genes that were up-regulated are 
known targets of the transcription factor NF-κB, suggesting an important role for this 
transcription factor in response to HFC feeding and NASH development, as was 
previously postulated in HFC fed APOE2ki mice [8] and in MCD fed mice with 
C57Bl/6 background [14]. Moreover, in NASH patients, NF-κB expression was found 
to be up-regulated and correlated with hepatic inflammation and fibrosis [15]. The 
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other regulated genes are involved in several inflammatory signaling pathways, such as 
IL18, IL1, IL6, TNF and toll-like receptor signaling.  
Steatosis is dissociated from the development of hepatic 
inflammation 
In contrast to the two-hit model, where hepatic steatosis is generally considered as the 
first hit in the transition towards inflammation [1], male mice had an inflamed liver 
even without steatosis. The lack of steatosis development in male mice compared to 
female mice was somewhat surprising, as estrogen is normally known to be protective 
against NASH. It has been shown that estrogen replacement in deficient mice lowers 
steatosis development [16]. We postulate that the lack of steatosis in male mice may be 
explained by the fact that in the livers of male mice, PPAR isoforms are up to 100-fold 
more active than in livers of female mice [17]. Therefore, it is conceivable that in male 
mice, activation of PPAR can compensate for the increased lipid load. In support of 
this, we showed previously that feeding female APOE2ki mice HFC for short periods 
did not activate PPARα significantly [8]. 
Another gender-specific difference was found in APOE2ki mice, as female APOE2ki 
mice displayed no change in plasma TG levels, while male APOE2ki mice did show 
increases upon HFC feeding. A possible explanation for this observation may be that 
estrogens can increase activities of hepatic lipase and lipoprotein lipase [18], which 
could consequently lead to increased hydrolysis of TGs in the plasma.  
Clearly, steatosis is not mandatory for progression towards hepatic inflammation in the 
mouse models used. In fact, others have postulated TG accumulation in the liver may 
even serve as a protective mechanism against inflammation development, by acting as 
a reservoir for harmful FFA’s [6].  
Plasma cholesterol may mediate hepatic inflammation 
We found a correlation between plasma TC and the development of hepatic 
inflammation, rather than with steatosis. This observation led us to hypothesize plasma 
TC as an important cause for the development of inflammation in these animals. 
Feeding the animals HFnC diet kept plasma VLDL-TC low and prevented the 
development of inflammation in all hyperlipidemic mouse models, without diminishing 
liver TGs. Liver TGs even increased in male APOE2ki mice without any apparent 
explanation, an observation that further strengthens the dissociation of steatosis from 
hepatic inflammation. Recent publications also point to the importance of dietary 
cholesterol in liver inflammation and NASH in both rodents [5, 19] and rabbits [20]. 
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Figure 7.  HFnC diet does not induce hepatic foam cells. Representative pictures (400x) of HE-stained liver 
sections from ldlr-/- and APOE2ki male and female mice after 7 days HFC and HFnC. Black arrows indicate 
foamy Kupffer cells. Inserts show foamy Kupffer cells when present on higher magnification. 
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Moreover, in human subjects, it was found that high cholesterol feeding increased C-
reactive protein and Serum Amyloid A levels [21].  
 
 
 Figure 8. PAS-diastase staining. Representative pictures of liver sections stained with PAS-diastase. The 
displayed pictures are from male APOE2ki mice that received either HFC diet or HFnC diet. Black arrows 
indicate Kupffer cells. 
Recently, Mari et al. reported that high cholesterol feeding may serve as the first hit 
that sensitizes rat livers to develop hepatic inflammation after exposure to a second hit, 
like TNF or fatty acid synthase (FAS) [5]. In contrast, in the current study, we 
observed that high cholesterol feeding alone is sufficient to cause a very early 
inflammatory response. Several differences between the studies could explain this 
dissimilarity. First, Mari et al. used rats, which are known to be more resistant to 
developing hyperlipidemia than mice [22]. Our current study utilizes mouse models 
with genetic modifications specifically involved in plasma lipoprotein clearance and 
lipid metabolism. Consequently, it is possible that other mechanisms may be of greater 
importance in the rat model that was used in their study. Second, the manner of 
inducing steatosis was different. In our study, a mild high fat diet was used while Mari 
et al. used choline deficiency to evoke steatosis in the rats. Moreover, the diet of Mari 
et al. contained high levels of cholesterol (2%) supplemented with sodium cholate but 
no elevated TG content. In these concentrations, both cholesterol and cholate have been 
shown to induce an inflammatory response in livers of C57Bl/6 mice [23]. The diet 
used in our study contained elevated TG levels to evoke steatosis and had cholesterol 
levels of only 0.2%, which is much closer to the average daily cholesterol intake in 
humans. Therefore, the diet used in our study appears to be more relevant in terms of 
induction of NASH in human patients. 
Cholesterol induces hepatic inflammation 
- 115 - 
 
Interestingly, in line with the present observations, male apoe-/- mice were shown to 
develop liver inflammation when fed cholesterol levels of 0.25% and higher [24]. This 
again points to an important role for dietary cholesterol in hepatic inflammation. 
However, this inflammatory response was investigated after several weeks of high fat 
diet and in the presence of steatosis. Our data suggests a very early impact of dietary 
cholesterol, possibly in the form of plasma VLDL-TC, on hepatic inflammation 
regardless of steatosis development. 
 
Kupffer cells may initiate the early hepatic inflammation by 
scavenging modified lipoproteins 
The mice used in our study are commonly used in atherosclerosis research as they have 
atherogenic lipoprotein profiles, because of increased modified remnant lipoproteins 
(oxLDL) [25]. OxLDL binds to the scavenger receptors CD36 and SRA, which are also 
present on KCs, and can trigger an inflammatory response [26, 27]. In livers of the 
mice with hepatic inflammation, we found bloated, foamy cells, which resemble lipid-
laden KCs, as has been described previously [13, 28]. 
Injection of modified LDL has been shown to result in an immediate uptake 
preferentially by non-parenchymal cells, such as KCs [29, 30]. Moreover, it has been 
shown that modified LDL injection in mice activates the hepatic NF-κB pathway and 
subsequent inflammation [31]. Therefore, it is possible that in our hyperlipidemic 
mouse models, circulating levels of modified lipoproteins are scavenged by hepatic 
KCs, thereby triggering an inflammatory response. In WT mice on the other hand, 
cholesterol-rich lipoproteins are rapidly cleared from the blood by hepatocytes via the 
LDLR, before they can be modified and taken up by KCs.  
Taken together, it is feasible that oxLDL may be a causal factor for the development of 
diet-induced hepatic inflammation. Recent papers have shown a correlation between 
postprandial LDL conjugated dienes and hepatic necroinflammation and fibrosis 
development in human subjects [32]. LDL levels, possibly in modified form, were also 
found to be increased in NASH patients [12], confirming the clinical relevance of our 
findings. 
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Figure 9. Gene expression in mice fed HFnC diet. Gene expression analysis in female and male mice with 
quantitative RT-PCR for two known inflammatory genes: MCP1 (A), CD68 (B), and TNF (C). Bars are 
grouped per genotype:  WT mice (grey bars), ldlr-/- mice (white bars) and APOE2ki mice (black bars). Data 
was set relative to WT animals on HFC diet). Statistical analysis was done with student t-tests;  * indicates 
significant difference from levels on chow diet. 
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Conclusions 
This study demonstrates that dietary cholesterol, possibly in the form of modified 
plasma lipoproteins, rather than liver steatosis, may be a risk factor for progression of 
NASH development. Currently, most therapies for NASH patients involve weight loss 
and most diagnostic tests of NASH severity depend solely on the degree of steatosis. 
Further studies may unravel the exact contribution of cholesterol to the risk of 
developing NASH and may provide evidence for alternative strategies for new 
therapies and markers for diagnostic tests. 
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Abstract 
Introduction and aim: Non-alcoholic steatohepatitis (NASH) is a disorder which is 
characterized by steatosis and hepatic inflammation. Currently, it is unknown why 
some, but not all, people with steatosis will progress towards NASH. We have recently 
identified dietary cholesterol as a factor that directly leads to hepatic inflammation in 
hyperlipidemic mouse models. In these animals, Kupffer cells (KCs) were found to be 
swollen and rich in cholesterol upon high fat feeding, resembling foam cells. We 
proposed a mechanism where KCs take up modified cholesterol-rich lipoproteins via 
scavenger receptors (SRs). KCs thereby accumulate cholesterol, may get activated and 
subsequently trigger an inflammatory response. Scavenging of modified lipoproteins 
has been shown to depend predominantly on two receptors: SRA and CD36. Therefore, 
we evaluated the role of these SRs in the development of diet-induced NASH in 
hyperlipidemic ldlr-/- mice. 
Materials and methods: ldlr-/- mice were depleted from their hematopoietic system by 
lethal irradiation and transplanted with bone marrow (BM) from animals lacking SRA 
and CD36 (double knock-out/dKO). Control mice were injected with wild-type bone 
marrow.  
Results: High fat feeding resulted in equal steatosis levels in mice transplanted with 
dKO BM compared to mice that received control BM as both hepatic triglyceride and 
cholesterol levels were comparable. Counting of Mac1 positive cells showed that 
hepatic inflammation was significantly decreased compared to control mice. This 
response was confirmed by measuring expression levels of known inflammatory 
mediators, such as tumor necrosis factor. Surprisingly, no difference in hepatic foam 
cell formation could be found. 
Conclusion: Uptake of modified lipoproteins via SRA and/or CD36 is partially 
responsible for diet induced hepatic inflammation, even without affecting hepatic foam 
cell formation.  
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Introduction 
Non-alcoholic steatohepatitis (NASH) is a disorder characterized by hepatic lipid 
accumulation (steatosis) and inflammation. It is currently thought to develop via a 
series of events or “hits” in the liver [1]. The first hit leads to the accumulation of lipids 
and sensitizes the liver to a second hit, which subsequently causes inflammation. While 
steatosis itself is generally considered benign and reversible, the presence of 
inflammation may lead to further progression of NASH, possibly resulting in liver 
fibrosis, cirrhosis, and even liver failure and hepatocellular carcinoma [2]. Thus, the 
progression towards hepatic inflammation represents a key step in NASH development. 
Currently, it is unknown why some, but not all, people with steatosis will develop 
NASH. Although several processes have been identified to participate during hepatic 
inflammation, like increased oxidative stress [3], lipid peroxidation [4], endoplasmatic 
reticulum stress [5], and ceramide accumulation [6, 7], the actual trigger causing an 
inflammatory response is still unclear. 
We and others have recently identified cholesterol as a factor that can directly lead to 
inflammation in the liver (chapter 5) [8, 9]. We have shown that hyperlipidemic mice, 
but not normolipidemic wild-type (WT) animals, developed hepatic inflammation as 
early as after 4 days of high fat feeding (chapter 5) [10]. The fact that hepatic 
inflammation is induced at this early stage, argues that cholesterol is a very powerful 
trigger for an inflammatory reaction to develop. In the livers of these animals, bloated 
Kupffer cells (KCs) were found, resembling foam cells. These foam cells were also 
identified previously in other studies in the sinusoidal space of the liver [11, 12]. 
Omitting cholesterol from the diet resulted in complete inhibition of hepatic 
inflammation and foam cell formation. An attractive hypothesis is that due to the 
decreased lipoprotein uptake by hepatocytes in these mice, lipoproteins have a longer 
residence time in the plasma and are therefore prone to be modified and subsequently 
scavenged by KCs. This process can result in KC activation, which may be responsible 
for triggering the hepatic inflammation and foam cell formation (chapter 5). 
It has been shown that KCs express scavenger receptors (SRs) as typical macrophages 
[13], making them capable of taking up modified lipoproteins. Moreover, the liver is 
the major site for taking up acetylated low density lipoproteins (acLDL) [14]. 
Additionally, injection of oxidized LDL (oxLDL) into the circulation of mice has been 
shown to cause hepatic inflammation, leading to a similar gene expression pattern that 
was observed mice fed a high fat diet [15]. 
Foam cell formation has been shown to majorly depend on two different SRs, i.e. SRA 
and CD36 [16]. SRA was found to account for the majority (80%) of macrophage 
uptake of acLDL, but to have lower affinity for oxLDL [16, 17]. CD36 was shown not 
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to bind acLDL but rather binds moderately oxidized LDL [18], and was found 
necessary for oxLDL-induced C-Jun N-terminal kinase (JNK) activation [19]. These 
observations suggest a role for these SRs in hepatic foam cell formation and 
subsequent activation. To test the possible role of oxLDL and these SRs during NASH 
development, we performed bone marrow transplantation (BMT) of donor bone 
marrow from mice lacking SRA, and CD36 (double knock-out/dKO) to ldlr deficient 
(ldlr-/-) recipient mice. This generated animal model lacks these SRs in hematopoietic 
cells, like KCs and macrophages, but not in other cell types. We predicted that they 
would fail to generate hepatic foam cells, thereby leading to decreased inflammation in 
their livers. 
Materials and methods 
Mice, diet and bone marrow transplantation 
Mice were housed under standard conditions given free access to food and water. 
Experiments were performed according to Dutch laws, approved by the Committee for 
Animal Welfare of Maastricht University. Ten week old female ldlr-/- mice were put in 
filter-top cages. The mice received acidified water supplemented with neomycin (100 
mg/l) and polymyxin B sulphate (60,000 U/l) during one week before transplantation. 
One day before transplantation, the mice were irradiated with a lethal dose of 10 Gray 
röntgen. The bone marrow of five female wild-type mice and five female dKO 
littermates was collected and pooled. Bone marrow cells were derived by flushing the 
femur and tibia of the mice. For transplantation, 7 mice received wild-type bone 
marrow and 8 mice received transgenic bone marrow. Bone marrow cells (107) were 
injected in the tail vein of each animal. After a recovery period of 9 weeks, mice were 
given high fat, high cholesterol (HFC) diet, containing 21% butter and 0,2% 
cholesterol, for 12 weeks. Blood was collected before the dietary period, after 7 weeks 
of HFC feeding and at the day of sacrifice (12 weeks). Collection of blood, sacrificing 
of the mice, and tissue isolation was done as described previously [10]. 
Lipid analysis 
Approximately 50 mg of frozen liver tissue was homogenized as described previously 
[10]. Both plasma and liver lipid levels were measured with enzymatic colour tests 
(1489232, cholesterol CHOD-PAP, Roche, Basel, Switzerland; TR0100, TG GPO-
trinder, Sigma Aldrich, Sigma Aldrich, St. Louis, MO, USA; 999-75406, NEFAC, 
ACS-ACOD, Wako Chemicals, Neuss, Germany) as described before [10]. 
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RNA isolation and quantitative PCR 
Total RNA was isolated from approximately 25 mg of mouse liver tissue as described 
previously [10]. All applications were done according to manufacturer’s protocols. 
Total RNA (500 ng) from each individual mouse was converted into first strand cDNA 
with the iScript cDNA synthesis kit (170-8891, Bio-Rad, Hercules, CA, USA) 
according to the manufacturer’s instructions. 
The changes in gene expression of inflammatory markers were determined by 
quantitative PCR (QPCR) on a Bio-Rad MyIQ with the IQ5 v2 software (Bio-Rad, 
Hercules, CA, USA) by using IQ SYBR Green Supermix with fluorescein (170-
5006CUST, Bio-Rad, Hercules, CA, USA) and 10 ng of cDNA. For each gene a 
standard curve was generated with a serial dilution of a liver cDNA pool. To 
standardize for the amount of cDNA, Cyclophillin A (Ppia) was used as the reference 
gene. Primer for the selected genes were developed with Primer Express version 1.5 
(Applied Biosystems, Foster City, CA, USA) using default settings. Primer sequences: 
MCP1-forward, 5’-GCTGGAGAGCTACAAGAGGATCA-3’; 
MCP1-reverse, 5’-ACAGACCTCTCTCTTGAGCTTGGT-3’; 
CD68-forward, 5’-TGACCTGCTCTCTCTAAGGCTACA-3’; 
CD68-reverse, 5-TCACGGTTGCAAGAGAAACATG -3’; 
TNFa-forward, 5’-CATCTTCTCAAAATTCGAGTGACAA-3’; 
TNFa-reverse, 5’-TGGGAGTAGACAAGGTACAACCC-3’; 
Mac1-forward, 5’-ACTTTCAGAAGATGAAGGAGTTTGTCT-3’; 
Mac1-reverse, 5’-TGTGATCTTGGGCTAGGGTTTC-3’; 
ICAM1-forward, 5’-CTACCATCACCGTGTATTCGTTTC-3’; 
ICAM1-reverse, 5’-CGGTGCTCCACCATCCA-3’; 
IL6-forward, 5’-GCTACCAAACTGGATATAATCAGGAAA-3’; 
IL6-reverse, 5’-CTTGTTATCTTTTAAGTTGTTCTTCATGTACTC-3’; 
Ppia-forward, 5’-TTCCTCCTTTCACAGAATTATTCCA-3’; 
Ppia-reverse, 5’-CCGCCAGTGCCATTATGG-3’. 
Data from QPCR were analyzed according to the relative standard curve method. 
Liver histology 
Four µm paraffin embedded liver sections were stained with Haematoxillin/ Eosin 
(HE). Frozen liver sections (7 µm) were fixated in acetone and stained against Mac1 
(M1/70). Pictures were taken with a Nikon® digital camera DMX1200 and ACT-1 
v2.63 software from Nikon® Corporation. 
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Statistical analysis 
Data were analyzed using Graphpad Prism 4.0. Groups were compared using 2-tailed 
non-paired t-tests or ANOVA. Data are expressed as means ± SEM and considered 
significant at p < 0.05. 
Results and discussion 
We investigated the involvement of SRA and CD36 in triggering hepatic inflammation 
during the progression of NASH. In order to generate animals that lack these SRs in 
inflammatory cells only, we performed BMT of donor bone marrow from mice lacking 
these two SRs (double knock-out/dKO) to ldlr-/- recipient mice.  
HFC increased plasma triglycerides (TGs) and total cholesterol (TC) levels in both 
groups (Fig. 1A, B). However, dKO animals displayed lower TG levels than animals 
that received WT bone marrow (Fig. 1A). Free fatty acid (FFA) levels decreased in 
response to HFC feeding in the control group while this could not be observed in the 
experimental animals. However, there was a trend towards decreased FFA levels after 
12 weeks of HFC in these mice. Between the two groups, t-tests failed to show 
significant differences in FFA levels (Fig. 1C). Interestingly, plasma TC levels 
increased in both groups after high fat feeding, but no difference was observed between 
the two groups (Fig. 1B).  
Previous publications with animals systemically lacking either CD36 or SRA show 
mixed results concerning plasma lipids. In a female apoe deficient (apoe-/-) 
background, deficiency of these scavenger receptors has been reported to increase 
plasma TGs and FFA, but not TC, a finding that contradicts our data [20]. Both CD36 
and SRA were found to influence these parameters separately. In line with our data, it 
has also been reported that systemic disruption of CD36 resulted in a decrease in 
plasma TGs but not plasma TC on an apoe-/- background [21]. It is important to note 
that both these experimental models were created by cross-breeding of mice. This 
difference in experimental setting may explain differences with our results. Moreover, 
there may have been differences in the purity of the background strain, depending on 
the amount of backcrossing that was performed prior to the experiments. Genetic 
background has been suggested before to influence experimental outcome and may 
explain the contradicting results [22]. In similar experimental settings as described in 
this paper, ldlr-/- mice transplanted with SRA-deficient bone marrow were shown not to 
display altered plasma lipids upon high fat feeding [23]. This result suggests that not  
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Figure 1. Plasma lipds. White bars represent animals transplanted with wild-type (WT) bone marrow, while 
black bars represent animals that received double knock-out (dKO) bone marrow, all at time points 0, 7, and 
12 weekd of high fat feeding. A. plasma triglycerides (TGs); B. plasma total cholesterol (TC); C. plasma 
free fatty acids (FFA). * indicates significant differences with the same groups on t=0. Differences between 
the groups are indicated above the graphs with * + line. 
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SRA, but rather CD36, is mainly responsible for the observed differences in plasma 
TGs. Confirming this point of view, apoe-/- female mice transplanted with CD36 
deficient bone marrow were shown to display decreases in plasma TGs, but not in other 
plasma parameters [24]. This effect was attributed to the absence of CD36 in its 
capacity as a fatty acid transporter, and was previously noted in CD36 null mice [25]. 
Since the KCs should theoretically fail to incorporate modified cholesterol-rich 
lipoproteins in the used experimental model, lower liver TC levels were expected in the 
animals that received dKO bone marrow. However, no such difference was observed 
(fig. 2B), which could be due to the fact that KCs make up only a relatively small 
fraction of total liver mass, making any difference too subtle to detect. 
High fat feeding during 12 weeks resulted in the development of equal levels of 
steatosis in both groups. Neither hepatic TG levels, nor hepatic TC differed between 
the two groups (Fig. 2A, B). This observation was confirmed by HE-stained liver 
sections, which were scored blindly by a pathologist (data not shown). The observed 
liver lipid levels are indicative for the presence of steatosis as was described previously 
(chapter 5). Thus, differences in hepatic steatosis cannot affect the development of 
inflammation in this model. 
Liver sections were stained with antibodies against Mac1 to determine the degree of 
hepatic inflammation in these animals. Counting of Mac1-positive cells showed that 
hepatic inflammation was decreased in the animals that received dKO bone marrow 
compared to control. The animals that received WT bone marrow displayed more mac-
1 positive cells in their livers compared to the animals that received dKO bone marrow 
(Fig. 3A). Counting these cells indicated a decrease from 235 ± 86 to 171 ± 34 cells 
(Fig. 3B). This indicates that hepatic inflammation is attenuated in the dKO group. 
To further define the differences between the two groups, gene expression analysis of 
several genes known to be involved in inflammation was performed: monocyte 
chemoattractant protein 1 (MCP1), a chemokine (Fig. 4A); CD68, a macrophage and 
Kupffer cell marker (Fig. 4); Mac1, a macrophage marker (Fig. 4C); tumour necrosis 
factor (TNF) and interleukin 6 (IL6), both pro-inflammatory cytokines (Fig. 4D, E); 
and intracellular adhesion molecule 1 (Icam1), a cellular adhesion molecule (Fig. 4F). 
Expression levels of TNF were significantly lower in the dKO mice, clearly confirming 
the observed decrease in inflammation. All the other tested genes failed to reach 
statistical significance, but they all displayed trends towards lower expression levels, 
adding to the observed effect on hepatic inflammation.  
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Figure 2. Liver lipds. White bars represent animals transplanted with WT bone marrow, while black bars 
represent animals that received dKO bone marrow A. liver triglycerides (TGs); B. liver total cholesterol 
(TC);  * indicates significant differences.  
Surprisingly, despite an effect on inflammation, scoring HE-stained sections did not 
reveal differences between the two groups in the presence or size of foamy KCs (Fig. 
3C), which may indicate that SRA and CD36 are not the major SRs responsible for 
uptake of modified lipoproteins in KCs. These observations can explain why plasma 
and liver TC failed to display the expected trends. Even though SRA and CD36 have 
been proposed to be the most important SRs in foam cell formation [16-18], it has to be 
appreciated that modified lipoproteins can also be taken up by alternative SRs [18]. 
Additionally, there are other routes of modified lipoprotein uptake possible which do 
not involve SRs and do not require lipoproteins to be modified, like pinocytosis [18]. 
The role of SRs in the uptake of modified lipoproteins is extensively studied in the 
field of atherosclerosis. While clear effects of SRA and CD36 in cholesterol uptake and 
foam cell formation could be found in vitro, without any compensation by other SRs 
[16], in vivo results showed less clear results [18], ranging from less foam cell 
formation and atherosclerosis to no effect or even more foam cell formation and 
atherosclerosis in different mouse models lacking one or more of these SRs [18, 26]. 
These discrepancies have also been found in studies in the liver. Uptake of acLDL by 
SRA accounted for 50% in vitro, this was not reflected in vivo, as SRA deficient mice 
were shown to have of only 17% decrease in uptake [27]. 
Taken together, the in vivo mechanisms of modified lipoprotein uptake appear to be 
complicated and difficult to address. Despite the fact that there was no effect on foam 
cell formation, there was a significant effect on hepatic inflammation in the animals 
that received dKO bone marrow. 
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Figure 3. Liver inflammation. A. Representative pictures of Mac1-stained liver sections of animals that 
received WT (left panel) or dKO (right panel) bone marrow; B. Quantification of Mac1 positive cells; C. 
Scoring of hepatic foams cells on HE-stained liver sections. White bars represent animals transplanted with 
WT bone marrow, while black bars represent animals that received dKO bone marrow. * indicates 
significant differences with the same groups.  
These observations indicate that lacking these SRs have effects other than on foam cell 
formation. It has been shown that CD36 deficiency does not influence macrophage 
motility [28]. Thus, lacking CD36 is unlikely to affect migration of macrophages 
into the liver directly. Alternatively, several roles have been attributed to CD36 which 
may influence inflammatory status. Binding of apoptotic cells to CD36 has been shown 
to result in an anti-inflammatory phenotype [29]. Contrary, CD36 has been proposed to 
play a role in the innate immune response as it was shown to be essential to some toll-
like receptor 2/6 responses which induce NF-κB activation [30]. Additionally, oxLDL  
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Figure 4. Liver inflammatory gene expression. Gene expression of inflammatory genes in the liver, relative 
to control animals that received WT bone marrow.  A. MCP1, B. CD68, C. Mac1, D. TNF, E. IL6, and F. 
Icam1. White bars represent animals transplanted with WT bone marrow, while black bars represent 
animals that received dKO bone marrow. * indicates significant differences with the same groups. 
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has been shown to activate CD36-dependent signaling resulting in JNK activation, 
which can consequently lead to inflammation [19]. Therefore, lacking this SR may lead 
to attenuated inflammatory responses due to its known role in innate immunity, SR 
activity, NF-κB activation, and consequent cytokine production [31]. Additionally, it 
has been shown that SRA deficient macrophages display slower adherence rates than 
WT macrophages [17]. Together, these processes may contribute to the effect seen on 
inflammation and indicate that further research is needed to elucidate the role of SRs in 
the development of NASH.  
Conclusions 
SRA and/or CD36 are partially responsible for diet-induced hepatic inflammation, even 
without a marked effect on foam cell formation. Investigating the individual 
contribution of SRA and CD36 to hepatic inflammation should resolve the contribution 
to hepatic inflammation and what pathways, other than foam cell formation, are 
involved. 
These results can be of major importance, as the involvement of mechanisms similar to 
atherosclerosis may lead to the use of known drugs, targeting foam cell formation in 
the treatment of NASH. These options should be subject of further research. 
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Abstract 
Non-alcoholic steatohepatitis (NASH) is characterized by pathological alterations 
ranging from steatosis and inflammation to cell degeneration, fibrosis and cirrhosis. 
The current concept for the pathogenesis of NASH is a two-hit model where steatosis 
precedes inflammation. In contrast, we previously showed that upon a high-fat, high 
cholesterol diet (HFC), hyperlipidemic ldlr knock-out (ldlr-/-) mice develop NASH 
characterized by very early inflammation. These observations indicate that 
inflammation may play an early role in the etiology of NASH. Therefore, we 
investigated the role of inflammation on steatosis during the development of NASH. 
First, we investigated whether a correlation existed between the development of hepatic 
inflammation and steatosis by comparing ldlr-/- mice with C57Bl/6 wild-type (WT) 
mice after long term high fat diet feeding. Ldlr-/- mice, displaying increased hepatic 
inflammation, developed 25% less accumulation of liver lipids than WT animals that 
did not develop inflammation in their livers. Next, in order to determine whether 
hepatic inflammation was causal for the decrease in steatosis, we aimed to generate 
ldlr-/- mice with increased hepatic inflammation. These mice were created by 
transplantation of bone marrow from TNF receptor non-sheddable mice, displaying 
increased TNF signaling, to lethally irradiated ldlr-/- mice. These animals displayed a 
doubling of hepatic inflammation and a subsequent reduction in liver lipids of 25%. 
Finally, we have preliminary data which indicates that inhibiting the anti-inflammatory 
interleukin 10 (IL10) pathway in high fat diet fed ldlr-/- mice with neutralizing 
antibodies resulted in a decrease in liver triglycerides. However, at present we have not 
yet detected an effect of IL10 removal on hepatic inflammation. 
Conclusion:  Hyper-activation of inflammatory signaling, either by increasing TNFR 
signaling, or by inhibiting IL10 signaling, inhibited liver lipid accumulation in a 
hyperlipidemic mouse model of NASH. 
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Introduction 
Non-alcoholic steatohepatitis (NASH) is characterized by pathological alterations 
ranging from steatosis and inflammation to cell degeneration, fibrosis and cirrhosis, 
which develop in the absence of excessive alcohol intake [1]. It is considered the 
hepatic event in the metabolic syndrome and is therefore strongly associated with 
obesity, hyperlipidemia, artherosclerosis and insulin resistance. Currently, 2-3% of 
adults are estimated to meet the diagnostic criteria for NASH [2]. As the prevalence of 
obesity and diabetes continues to increase rapidly, an equivalent increase is expected in 
the prevalence of NASH and its associated morbidity. 
NASH is currently believed to develop via the “two-hit model” [3]. According to this 
hypothesis, hepatic steatosis is the critical first hit and prerequisite for additional insults 
(second hits), such as oxidative stress, resulting in development of an inflammatory 
response [4]. We have previously shown that when fed a high-fat diet, hyperlipidemic 
APOE2 knock-in (APOE2ki) and ldlr deficient (ldlr-/-) mice develop hepatic 
inflammation very early next to steatosis [5] (chapter 5). Consequently, the presence of 
an inflammatory response this early during NASH development suggested that 
inflammation could play a modulating role during the early stages of this condition. 
There are indeed several lines of evidence for a direct role of inflammation in lipid 
metabolism, including observations that some cytokines acutely induce higher serum 
triglyceride (TG) levels and can increase de novo fatty acid (FA) and TG production [6, 
7]. More specifically, experimental evidence suggests that steatosis and tumor necrosis 
factor (TNF) production are tightly related [8, 9]. TNF is one of the major activators of 
nuclear factor kappa beta (NF-κB), a transcription factor that plays a crucial role in 
inflammation and regulates the production of TNF and multiple other cytokines [10]. 
In addition to activation of the inflammatory response, TNF promotes insulin 
resistance [11]. However, actual data regarding the role of inflammatory signaling on 
hepatic steatosis remain contradictive [12].  
In the current paper we aim to determine the effect of inflammatory signaling on 
steatosis during NASH progression. Ldlr-/- mice have been shown to develop liver 
inflammation very early upon feeding them a high fat, high cholesterol diet (HFC), 
while wild-type (WT) animals fail to develop hepatic inflammation on this diet 
(chapter 5). We exploited this difference in search of a correlation between hepatic 
inflammation and lipid accumulation. Hereto, ldlr-/- mice were compared to C57Bl/6 
(WT) animals after long term high fat feeding to assess whether the development of 
hepatic inflammation can influence steatosis levels. Interestingly, WT animals 
developed higher levels of steatosis than the inflammatory ldlr-/- mice. These data 
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indicated that an inverse correlation between hepatic inflammation and liver steatosis 
exists. 
Consequently, we investigated whether increased inflammation was causal for the 
lower levels of steatosis by enhancing TNF signaling selectively in hematopoietic cells. 
This was done by performing a bone marrow transplantation (BMT) to lethally 
irradiated hyperlipidemic ldlr-/- mice, using a graft from a novel mouse line, i.e. p55-
TNFR non-sheddable (TNFRns) mice in which impaired shedding of the TNFR leads 
to enhanced inflammatory signaling. These mice have been shown to be hyper-
inflammatory and to spontaneously develop hepatic inflammation [13].  
Additionally, we injected HFC fed ldlr-/- mice with IL10 neutralizing antibodies. IL10 
is a potent anti-inflammatory cytokine that normally inhibits the action of TNF and 
other pro-inflammatory cytokines. Therefore, acutely neutralizing this anti-
inflammatory cytokine is expected to result in increased inflammatory signaling. These 
complementary mouse models of increased hepatic inflammation were used to 
determine the contribution of inflammation to steatosis development. 
Materials and methods 
Mice and diet 
Female ldlr-/- mice were housed under standard conditions given free access to food 
and water. Experiments were performed according to Dutch laws, approved by the 
Committee for Animal Welfare of Maastricht University. Up until the age of 12 weeks, 
animals were kept on regular chow diet (ssniff Spezialdiäten GmbH, Soest, Germany). 
In the first experiment, ldlr-/- and WT mice were give high fat, high cholesterol (HFC) 
diet, containing 21% butter and 0,2% cholesterol (diet 1635, Scientific Animal Food 
and Engineering, Villemoisson-sur-orge, France) for 13 weeks. Blood was collected 
before the dietary period, after 8 weeks of HFC feeding and at the day of sacrifice. A  
second experiment was done with mice that were transplanted with either TNFRns 
bone marrow (TNFRnsBMT mice) or WT bone marrow (WTBMT mice). Mice were 
put on HFC diet for 11 weeks and blood was collected before, after 4 and 8 weeks of 
HFC feeding, and at the end of the experimental period. Neutralizing IL10 was done by 
injection of IL10 neutralizing antibodies in PBS or injection of vehicle the day before 
the start of the dietary period. Mice were re-injected after 3 days of HFC and sacrificed 
after 7 days of HFC feeding. Blood was collected before and after the dietary period. 
Collection of blood, sacrificing of the mice, and tissue isolation was performed as 
described previously [5]. 
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Bone marrow transplantation 
Ten week old female ldlr-/- mice were put in filter-top cages. The mice received 
acidified water supplemented with neomycin (100 mg/l) and polymyxin B sulphate 
(60,000 U/l) during one week before transplantation. One day before the actual 
transplantation, the mice were irradiated with a lethal dose of 10 Gray röntgen. The 
bone marrow of five female wild-type mice and five female TNFRns littermates was 
collected and pooled. Bone marrow cells were derived by flushing the femur and tibia 
of the mice with PBS. For transplantation, 20 mice received wild-type bone marrow 
and 20 mice received transgenic bone marrow. The cells (107) were injected in the tail 
vein of each mouse. 
Lipid analysis 
Approximately 50 mg of frozen liver tissue was homogenized as described previously 
[5]. Both plasma and liver lipid levels were measured with enzymatic color tests 
(1489232, cholesterol CHOD-PAP, Roche, Basel, Switzerland; TR0100, TG GPO-
trinder, Sigma Aldrich, Sigma Aldrich, St. Louis, MO, USA; 999-75406, NEFAC, 
ACS-ACOD, Wako Chemicals, Neuss, Germany) as described before [5]. 
RNA isolation and quantitative PCR 
Total RNA was isolated from approximately 25 mg of mouse liver tissues as described 
previously [5]. All applications were done according to manufacturer’s protocols. Total 
RNA (500 ng) from each individual mouse was converted into first strand cDNA with 
the iScript cDNA synthesis kit (170-8891, Bio-Rad, Hercules, CA, USA) according to 
the manufacturer’s instructions. 
The changes in gene expression of inflammatory markers were determined by 
quantitative PCR on a Bio-Rad MyIQ with the IQ5 v2 software (Bio-Rad, Hercules, 
CA, USA) by using IQ SYBR Green Supermix with fluorescein (170-5006CUST, Bio-
Rad, Hercules, CA, USA) and 10 ng of cDNA. For each gene a standard curve was 
generated with a serial dilution of a liver cDNA pool. To standardize for the amount of 
cDNA, Cyclophillin A (Ppia) was used as the reference gene. Primer sets for the 
selected genes were developed with Primer Express version 1.5 (Applied Biosystems, 
Foster City, CA, USA) using default settings. Primer sequences: 
MCP1-forward, 5’-GCTGGAGAGCTACAAGAGGATCA-3’; 
MCP1-reverse, 5’-ACAGACCTCTCTCTTGAGCTTGGT-3’; 
CD68-forward, 5’-TGACCTGCTCTCTCTAAGGCTACA-3’; 
CD68-reverse, 5-TCACGGTTGCAAGAGAAACATG -3’; 
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TNFa-forward, 5’-CATCTTCTCAAAATTCGAGTGACAA-3’; 
TNFa-reverse, 5’-TGGGAGTAGACAAGGTACAACCC-3’; 
Ppia-forward, 5’-TTCCTCCTTTCACAGAATTATTCCA-3’; 
Ppia-reverse, 5’-CCGCCAGTGCCATTATGG-3’. 
Data from qPCR was analyzed according to the relative standard curve method. 
Taqman® Low Density Arrays  
To perform gene expression analysis on a medium scale, Taqman® Low Density Arrays 
(TLDA) 96a (PN 4342259) were used. Each TLDA plate contained 4 x 96 annotated 
and validated individual TaqMan® Gene Expression Assays (forward primer, reversed 
primer and Taqman® Probe) (supplementary table 1). Per individual assay 2 ng cDNA 
of a single liver was loaded together with the TaqMan® Universal PCR Master Mix 
(PN 4324018). Of each group, mRNA from 5 individual mice was used. TLDA plates 
were run on an ABI Prism 7900HT Sequence Detection System with a TaqMan® Low 
Density Array Upgrade. Data was analyzed by using RQ Manager 1.2 software. 
Technically failed assays were omitted from analysis. Materials, equipment and 
software necessary to perform TLDA gene expression studies were obtained from 
Applied Biosystems, Foster City, CA, USA. All data were normalized to Ppia 
expression. Significant differences were determined with student t-tests; p-values < 
0.05 were considered significant.  
Liver histology 
Four µm paraffin embedded liver sections were stained with Haematoxillin/Eosin 
(HE). Frozen liver sections (7 µm) were fixated in acetone and stained with CD68 
(FA11) or Mac1 (M1/70). Pictures were taken with a Nikon® digital camera DMX1200 
and ACT-1 v2.63 software from Nikon® Corporation. 
Statistical analysis 
Data were analyzed using Graphpad Prism 4.0. Groups were compared using 2-tailed 
non-paired t-tests or ANOVA. Data is expressed as means ± SEM and considered 
significant at p < 0.05. 
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Results 
Liver inflammation is inversely correlated with liver TGs 
Plasma parameters of female WT C57Bl/6 and ldlr-/- mice before and after 7 and 13 
weeks of HFC are displayed in figure 1. As expected, ldlr-/- mice appeared to be more 
responsive to HFC feeding than WT animals. These WT mice displayed a very small 
increase in total cholesterol (TC) (Fig. 1A), which only reached statistical significance 
after 13 weeks. Plasma TG levels were decreased at both time points in WT mice (Fig 
1B). Conversely, both TC (Fig. 1A) and TGs (Fig. 1B) levels in plasma of ldlr-/- mice 
were dramatically increased after 7 weeks and 13 weeks of high fat feeding. 
The amount of Mac1 positive cells was counted as a measure of inflammation (Fig 
1C). WT animals did not develop hepatic inflammation while ldlr-/- mice displayed a 
clear inflammatory response in their livers. Gene expression analysis for three 
inflammatory markers, i.e. TNF (Fig. 1E), MCP1 (Fig. 1F) and CD68 (Fig. 1G) also 
showed much higher expression levels in livers of ldlr-/-  mice than in  livers of WT 
mice, confirming the Mac1 staining. 
Both mouse models developed steatosis as can be concluded from TG levels in their 
livers (Fig. 1C). The observed levels are much higher than the levels that are usually 
detected when these animals are fed a standard chow diet (chapter 5). Remarkably, 
liver TG measurements showed that ldlr-/- mice accumulated less TGs (25% reduction) 
in their livers compared to WT mice. Scoring HE-stained liver sections confirmed all 
of these observations (data not shown). 
Liver hyper-inflammation results in inhibition of steatosis in 
ldlr-/- mice 
To investigate whether the increased inflammation was causal for the lower TG levels 
in the liver, a model of increased hepatic inflammation was created without directly 
altering hepatocyte function. Hereto, bone marrow transplantation was performed with 
ldlr-/- recipient mice, using donor bone marrow of TNFRns animals.  
Plasma parameters showed that these mice responded well to HFC diet with significant 
increases in plasma TC (Fig. 2A) and TG levels (Fig. 2B). Interestingly, mice that 
received the mutant bone marrow displayed lower plasma TC (Fig. 2A) and TG levels 
(fig. 2B) than controls, while these parameters were equal before the start of the diet. 
Recipient ldlr-/- mice with TNFRns bone marrow (TNFRnsBMT mice) displayed a two-
fold increase in Mac-1 positive cells (Fig. 2C), indicative of a good experimental 
model for hyper-inflammation in the liver. Table 1 shows regulation of genes involved 
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in inflammation in the livers of TNFRnsBMT mice. As expected, most inflammation 
genes tested showed trends towards up-regulation in TNFRnsBMT mice compared to 
control mice that received bone marrow from WT animals (WTBMT mice). 
 
Figure 1. Liver inflammation and steatosis show an inverse correlation. White bars represent WT C57Bl/6 
mice and black bars represent ldlr-/- mice. A. plasma total cholesterol (TC) and B. plasma triglycerides 
(TGs) of mice fed HFC on t=0, t=7 weeks (w), and t= 13w. C. Quantification of Mac1 positive cells after 13 
weeks HFC feeding. Liver TG levels after 13 weeks HFC. Relative gene expression in livers of mice fed 
HFC during 13 weeks of mcp1 (E), CD68 (F), and TNF (G). * indicates significant differences between the 
mouse models. 
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However, only a part of these genes could reach statistical significant changes in their 
expression levels, partially due to high variation within the groups. Among these genes, 
there were pro-inflammatory proteins and cytokines, like Icam1, CD40, IL6, SAA1 and 
TNF. Interestingly, there were also anti-inflammatory genes regulated; i.e. IL10 and 
Stat3, suggesting increased IL10 signaling in livers of these mice. 
TNRFnsBMT mice clearly showed less steatosis development as is clear from 
biochemical assessment of liver TGs (Fig. 3D). Comparable with the correlation that 
was found between inflammation and steatosis in WT and ldlr-/- mice fed the HFC, this 
reduction in steatosis was approximately 25%. Genes involved in lipid metabolism 
were also investigated (table 2) to unravel the pathways responsible for the altered 
steatosis levels. However, except for one of the tested genes, i.e. lipin C (LipC), we 
found none of them to be regulated. 
Blocking the anti-inflammatory cytokine IL10 inhibits 
steatosis in ldlr-/- mice 
Additionally to the described experiments, a pilot study was performed to systemically 
inhibit IL10 function. Hereto, ldlr-/- mice were injected with IL10 neutralizing 
antibodies before and during feeding HFC diet for 7 days. Control animals received 
PBS vehicle. 
Interestingly, while the control animals remained at the same weight, anti IL10 treated 
animals showed a significant lowering of body weight (data not shown). Plasma TC 
did not differ between treated and untreated animals, but did increase in both groups 
after dietary intervention (Fig. 3A). The experimental group treated with anti IL10 had 
significantly higher plasma TG levels compared to control mice (Fig. 3B).  
Surprisingly, no difference in Mac1 positive cells was found between treated and 
untreated animals (Fig. 3C). Indeed, analysis of the inflammatory gene expression of 
anti IL10 treated animals vs control revealed regulation of only a very few 
inflammatory genes (table 1): Vcam1 (up), Cxcl10 (down), IL1b (down), IL6Ra (up). 
Contrary, the anti-inflammatory suppressors of cytokine signaling (SOCS) 1 and 3 
were both down-regulated compared to control mice. Also plasma levels of the 
inflammatory marker amyloid P component (SAP) were measured and showed no 
difference between the two groups. SAP levels were moderately higher than levels 
before dietary intervention in both groups (data not shown). 
Despite the absence of an effect on hepatic inflammation levels, there was a clear 
inhibition of steatosis development (Fig. 3D). Hepatic TG levels showed to be 
comparable to levels seen in normal livers (chapter 5). Gene expression analysis 
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revealed none of the tested genes involved in lipid metabolism to be regulated upon 
IL10 treatment (table 2).  
 
 
Figure 2. TNFRns BMT mice display increased liver inflammation and lower steatosis levels. White bars 
represent WT C57Bl/6 mice and black bars represent ldlr-/- mice. A. plasma total cholesterol (TC) and B. 
plasma triglycerides (TGs) of mice fed HFC on t = 0, t = 4 weeks (w ), t = 8 w  and t = 11w. C. 
Quantification of Mac1 positive cells after 11 weeks HFC feeding. Liver TG levels after 11 weeks HFC.     
* indicates significant differences between the mouse models. 
Discussion 
In this paper, we show that mice displaying hepatic inflammation have less steatosis 
compared to animals that do not develop inflammation in their livers. These results 
argue for an inverse correlation between inflammation and lipid accumulation in the 
liver. To investigate whether a causal link exists, we performed two complementary 
experiments. First, we used a model of TNF hyper-signaling in hematopoietic cells, 
thereby creating a mouse model with increased hepatic inflammation. Indeed, these 
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mice displayed reduced liver lipids upon high fat feeding. Second, in a pilot study, we 
injected neutralizing antibodies against IL10, a well known anti-inflammatory 
cytokine. In these animals, steatosis development was inhibited. Together, these results 
suggest that increased inflammation leads to a decrease of diet-induced steatosis. 
 
 
Figure 3. Inhibiting IL10 does not influence inflammation but inhibits steatosis development. White bars 
represent control ldlr-/- mice and black bars represent ldlr-/- mice injected with anti-IL10 antibodies. A. 
plasma total cholesterol (TC) and B. plasma triglycerides (TGs) of mice before (t=0) and after lice were fed 
HFC for 7 days (t = 7d). C. Quantification of Mac1 positive cells after 7 days HFC feeding. Liver TG levels 
after 7 days HFC.  * indicates significant differences between the mouse models. 
Liver inflammation is inversely correlated with liver TGs 
In this study, we show an inverse correlation between hepatic inflammation and 
steatosis development, which is to our knowledge unreported until now. We have 
previously shown that WT mice do not develop hepatic inflammation upon short term 
high fat feeding while ldlr-/- mice show an inflammatory response already after a few 
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days (chapter 5). The current observation shows that this phenotype is retained even 
after longer periods of dietary stress. 
Ldlr-/- mice, showing an increase of Mac1 positive cells in their livers, had 25% less 
liver TGs compared to WT animals without hepatic inflammation. A possible 
explanation for this observation is that less lipid-containing lipoproteins are taken up 
due to the loss of the ldlr in these mice. However, the LDL particles that remain in the 
circulation in this way contain mostly cholesterol and not TGs. The latter are mainly 
hydrolyzed in the peripheral tissues, making it improbable that less TGs enters the liver 
via this mechanism. Moreover, we have previously shown that short term high fat 
feeding resulted in equal steatosis levels in both ldlr-/- and WT mice (chapter 5), 
indicating that the loss of the ldlr does not affect hepatic steatosis directly. 
Consequently, it is feasible that the effect on liver lipids is due to the chronic presence 
of an inflammatory response in the liver. 
The presence of inflammatory cells results in augmented levels of inflammatory 
mediators in the micro-environment of hepatocytes, as analysis of gene expression 
revealed an increase in several inflammatory markers after 13 weeks of high fat 
feeding, like TNF, MCP1, and CD68. These inflammatory mediators probably can 
influence hepatocyte function. It has been repeatedly shown that TNF can directly 
influence lipid metabolism [11, 14, 15] although the exact contribution of TNF remains 
somewhat controversial. Consequently, in a follow-up experiment, we focused on TNF 
signaling to delineate the exact contribution of pro-inflammatory signaling to lipid 
deposition in the liver.  
Liver hyper-inflammation inhibits steatosis in ldlr-/- mice 
With BMT, we created a mouse model with increased inflammation in their livers 
without directly influencing hepatocyte TNF signaling. It has been postulated that 
Kupffer cells (KCs) are the major source of hepatic TNF [16]. Therefore, the exact 
contribution of infiltrating inflammatory cells and of activated KCs can be identified in 
this manner. Murine KCs were shown to have a life span of approximately 21 days 
[17] which is also the replacement time of KCs in mice after BMT [18]. 
Our results show that increased inflammation due to macrophage-specific hyper-
activation of TNF signaling leads to decreased steatosis development. 
It should be noted that plasma lipid levels of the hyper-inflammatory mice was slightly 
lower than what was found in control mice. Although decreased food intake of hyper-
inflammatory mice cannot be excluded, other mechanisms are more likely to play a 
role. It has been well documented that inflammation and whole body lipid and 
lipoprotein metabolism can influence each other in several ways [14]. We propose that 
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due to a decrease in liver TG levels, VLDL production is hampered, thereby decreasing 
both plasma TGs and TC. Additional experiments, using metabolic cages and 
measuring VLDL production will address this issue. The role of TNF in steatosis is 
controversial as several lines of evidence show different results. It has been well 
established that TNF may be detrimental for the liver and that it can induce liver 
inflammation and fibrosis [9, 16]. Additionally, contrary to our results, deletion or 
inhibition of TNF has been repeatedly shown to be protective against liver lipid 
accumulation both via neutralizing antibodies [9, 19], and by using genetically 
modified animal models [20]. The detrimental effect of TNF has been proposed to 
happen due to its known effect of promoting insulin resistance (IR) [21, 22], which can 
indirectly lead to steatosis, as described in chapter 1. Alternatively, TNF can have 
direct effects on lipogenic gene expression, including effects on genes as stearoyl CoA 
desaturase 1 (SCD1) [9] and fatty acid synthase (FAS) [23], possibly via the induction 
of Sterol Regulatory Element Binding Protein 1c (SREBP1c) [24, 25]. Not only TNF, 
but several other pro-inflammatory cytokines and signaling pathways have been shown 
to promote lipogenesis, e.g. via the regulation of mitochondrial TG transfer protein 
(MTP) expression by IL1 and LPS [26], increased lipoprotein uptake induced by 
macrophage-derived factors [27] or toll-like receptor (Tlr) induced down-regulation of 
PPARα [28]. A major difference with these studies, however, is that in our 
experiments a model is used that specifically targets inflammatory cells rather than the 
whole organism. 
Contrary to these publications and in line with our data, several studies question this 
proposed contribution of TNF to steatosis development. Memon et al. indicated that 
TNF is not the cause of a fatty liver in obese diabetic mice [29], showing similar liver 
lipid content between Ob/Ob and Ob/Ob-p55/p75-null animals, lacking both receptors 
for TNF. Moreover, an inverse relationship has been found between TNF and steatosis 
in mice lacking TNF upon high cholesterol feeding [30]. Interestingly, rather than TNF 
itself, hepatic NF-κB signaling has been implied to induce hepatic inflammation in 
NASH [31]. In addition, Cai et al. found that in mice with hepatocyte-specific 
constitutive up-regulation of NF-κB activity, liver lipids were shown to be decreased 
by about 30% and that hepatocyte-specific activation of NF-κB signaling promoted 
whole-body IR in a mechanism relying on IL6 [21]. Next to an induction of TNF 
expression, our results show up-regulation of the pro-inflammatory cytokine IL6 in the 
livers of TNFRnsBMT mice compared to WTBMT mice. IL6 is a target gene of TNF 
and was shown to reduce liver lipid levels, partially by inducing increased FA 
oxidation in a PPARα dependent manner, in addition to increased excretion of TGs and 
TC from hepatocytes [32, 33]. 
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Table 1: Inflammatory genes. 
gene group 
TNFRns anti-IL10 
vs C56BL/6 vs control 
Cd19 Cell Markers 1,9 0,7 
Cd4 Cell Markers 3,8 0,6 
Cd68 Cell Markers 1,2 1,1 
Cd8a Cell Markers 1,8 1,5 
Fcgr1 Cell Markers 1,3 0,9 
Itgam/Mac1 Cell Markers 1,7 1,0 
Mpo Cell Markers 1,6 4,7 
Icam1 Cell Markers 1,7 0,8 
Vcam1 Cell Markers 1,6 1,6 
Vegfa Cell Markers 1,0 1,3 
Ccl2/mcp1 Chemotaxis 1,2 0,8 
Ccl3/mip1 Chemotaxis 1,2 1,1 
Ccr2 Chemotaxis 2,1 1,1 
Ptgs2/Cox2 Chemotaxis 1,8 0,5 
Cat Oxidative stress 0,9 1,0 
Gsta2 Oxidative stress 1,4 0,7 
Hmox1 Oxidative stress 1,9 1,1 
Ikbkb Oxidative stress 1,3 0,9 
Por Oxidative stress 1,3 1,1 
Bcl2 Apoptosis 1,2 0,9 
Fasl Apoptosis 2,9 1,0 
Il10 Anti-inflammatory 2,5 0,8 
Il10ra Anti-inflammatory 1,6 0,9 
Socs1 Anti-inflammatory 2,2 0,7 
Socs3 Anti-inflammatory 2,9 0,7 
Cd14 General Inflammation 1,6 1,1 
Cd40 General Inflammation 3,1 1,0 
Cd80 General Inflammation 1,3 1,1 
Cd86 General Inflammation 1,2 0,9 
CsfF General Inflamm. 1,1 1,2 
Cxcl10 General Inflammation 2,0 0,6 
Ifng General Inflammation 3,3 0,8 
Il18 General Inflammation 1,1 1,0 
Il18r1 General Inflammation 1,1 0,7 
Il1b General Inflammation 1,6 0,5 
Il1r1 General Inflammation 1,8 1,3 
Il1r2 General Inflammation 1,9 2,0 
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Table 1 (continued) 
gene group 
TNFRns anti-IL10 
vs C56BL/6 vs control 
Il6 General Inflammation 2,8 0,3 
Il6ra General Inflammation 1,5 1,8 
Nfkbia General Inflammation 1,2 1,0 
Saa1 General Inflammation 3,7 1,2 
Stat1 General Inflammation 1,7 0,9 
Stat3 General Inflammation 1,6 0,9 
Tlr2 General Inflammation 1,6 0,8 
Tlr4 General Inflammation 1,2 1,2 
Tnf General Inflammation 2,7 0,7 
Tnfrsf1a General Inflammation 1,2 1,0 
Tnfrsf1b General Inflammation 1,2 1,4 
 
Table 1. Liver inflammatory gene expression. Table shows gene abbreviation and classification according to 
function. Expression is shown as fold change compared to levels of control animals. Significant changes 
(student t-tests), compared to control are shown bold and underlined. 
Indeed, IL6 is known to induce hyperlipidemia [34]. However, our data do show that 
plasma TG and TC levels were lower in TNFRnsBMT mice then in WTBMT mice, 
arguing against increased excretion of lipids by the liver. 
Moreover, we could not find any clear change in gene expression involved in liver lipid 
homeostasis. Therefore, any change in hepatocyte lipid metabolism that could lead to 
the decreased level of steatosis, may be present on the protein level. Additionally, the 
observed reduction in steatosis may originate from the high energy demand of the 
increased inflammation [35], leading to increased FA-usage for mitochondrial 
oxidation in the high number of inflammatory cells. 
Further studies investigating the oxidation and the secretion of hepatic lipids may 
reveal what mechanisms are responsible for the effects observed in the performed 
experiments. 
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Table 2: Lipid genes 
gene group 
TNFRns anti-IL10 
vs C56BL/6 vs control 
Cd36 Lipid  Uptake 0,9 1,0 
Fabp1 Lipid  Uptake 0,6 0,9 
Lipc Lipid  Uptake 0,7 1,0 
Lpl Lipid  Uptake 1,1 0,9 
Lrp1 Lipid  Uptake 1,2 0,8 
Slc27a1 Lipid  Uptake 1,1 0,9 
Acaa1a lipid Oxidation and efflux 1,0 0,9 
Acox1 lipid Oxidation and efflux 1,0 0,9 
Cpt1a lipid Oxidation and efflux 1,2 0,9 
Crot lipid Oxidation and efflux 0,9 1,0 
Ech1 lipid Oxidation and efflux 0,9 1,0 
Hadha lipid Oxidation and efflux 1,0 1,0 
Mttp lipid Oxidation and efflux 1,1 1,1 
Ppara lipid Oxidation and efflux 1,0 1,0 
Ppard lipid Oxidation and efflux 1,2 1,0 
Pparg lipid Oxidation and efflux 1,0 1,0 
Fasn Lipid Met. Synthesis 0,5 1,0 
LXRa Lipid Met. Synthesis 1,1 1,1 
FXR Lipid Met. Synthesis 1,1 1,0 
Scd1 Lipid Met. Synthesis 0,9 1,3 
Srebf1 Lipid Met. Synthesis 1,0 0,9 
Abca1 Cholesterol efflux 1,1 1,0 
Cyp7a1 Cholesterol efflux 1,1 1,2 
Scarb1 Cholesterol efflux 1,0 0,9 
Adfp Intracellular lipid distribution 1,0 0,8 
Cav1 Intracellular lipid distribution 0,9 0,9 
Cav2 Intracellular lipid distribution 0,9 0,9 
M6prbp1 Intracellular lipid distribution 1,1 0,9 
Npc1 Intracellular lipid distribution 1,2 0,9 
Idi1 Cholesterol metabolism 1,1 1,1 
Insig2 Cholesterol metabolism 1,0 1,3 
Cyp8b1 Other 1,2 1,2 
 
Table 2. Liver lipid gene expression. Table shows gene abbreviation and classification according to 
function. Expression is shown as fold change compared to levels of control animals. Significant changes 
(student t-tests), compared to control are shown bold and underlined. 
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Blocking the anti-inflammatory cytokine IL10 may inhibit 
steatosis in ldlr-/- mice 
Gene expression data from TNFRnsBMT mice suggested increased IL10 signaling in 
their livers due to regulation of IL10 and Stat3.  
Therefore, we performed a pilot experiment to increase hepatic inflammation by 
blocking the anti-inflammatory cytokine IL10. Hereto, ldlr-/- mice were injected with 
antibodies that neutralize IL10. Control mice were injected with PBS (vehicle). As 
expected, anti-inflammatory gene expression was down-regulated, as can be seen by 
the inhibition of two known target genes of IL10 signaling, i.e. SOCS1 and SOCS3 
[36, 37]. However, injection of IL10 neutralizing antibodies failed to increase the 
amount of Mac1 positive cells and pro-inflammatory gene expression, despite the well 
described effect of this antibody [38, 39]. A possible explanation for the lack of effect 
on hepatic inflammation may be that HFC induces only mild inflammation, which does 
not result in overt IL10 expression. In line with this possibility, we found only 
moderate increases of plasma SAP levels after 1 week of HFC, and no differences were 
observed between the groups at any time point. Therefore, any effect of neutralizing 
this small amount of IL10 in HFC fed ldlr-/- mice may be too subtle to have effect on 
hepatic inflammation.  
As was seen in TNFRnsBMT mice, anti-IL10 treatment inhibited steatosis 
development. It is known that SOCS-3 can up-regulate the expression of the lipogenic 
enzymes acyl-CoA carboxylase (ACC) and FAS via inhibition of STAT3 
phosphorylation and a subsequent increase in SREBP1c expression [40]. Therefore, 
inhibition of this pathway via neutralizing IL10 could lower liver lipid synthesis. 
Unfortunately, we were unable to find transcriptional evidence for this mechanism. As 
the other tested lipid genes were not significantly affected by anti-IL10 treatment, the 
observed effect in lipid metabolism may be present on protein rather than on 
transcriptional level. A possible mechanism may be an increase in VLDL production 
and secretion from the liver, resulting in decreased liver TGs. In line with this, we 
found a doubling of plasma TG levels in the mice treated with antibodies against IL10. 
It has been previously found by Caligiuri et al. that systemic IL10 deficiency could 
have an effect on lipoprotein metabolism [41]. However, in that study, no differences 
were observed in plasma total plasma TG levels. Future experiments to measure VLDL 
secretion should be performed to confirm this mechanism. Moreover, although the 
equal plasma cholesterol levels in the groups suggest equal ingestion of the diet, we 
found that body weight of treated animals dropped significantly. Therefore, it remains 
unsure whether experimental animals consumed equal amounts of food as control 
animals. Pair-wise feeding of the groups may resolve this issue. Additionally, 
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differences in energy utilization and activity should also be investigated in metabolic 
cages.  
Interestingly, den Boer et al. found endogenous IL10 to be protective against diet-
induced hepatic steatosis [42] without altering whole-body insulin sensitivity, a finding 
contradicting our data. Moreover, no effect on body weight was observed. A possible 
explanation for these differences is the fact that den Boer et al. used whole body IL10 
deficient mice, which chronically lack IL10 from birth. Our experiments neutralize 
IL10 in an acute manner. Therefore, it is possible that there are compensating 
mechanisms that impact results in the IL10 deficient animals, which were not 
established yet in our experimental model due to the short time span.  
It should be noted that there are some major differences between the experiments we 
performed (TNFRnsBMT vs anti-IL10). Differences in terms of Mac1 positive cells, 
steatosis level, and plasma lipids between the experiments suggest that the mechanisms 
lowering liver TG levels in these experimental models are different. While 
TNFRnsBMT animals may display a reduction in hepatic lipids due to the presence of 
actual inflammation, animals treated with IL10 neutralizing antibodies may be effected 
more by direct effects in the IL10 signaling pathway of hepatocytes rather than 
inflammation itself.  
A final major issue remains to be addressed. A proper control was lacking for the 
experiment using Abs neutralizing IL10. The control group was injected with vehicle 
instead of an isotype control Ab. Therefore, it cannot be excluded that the lack of an 
effect on hepatic inflammation and the observed effects on liver lipids are due to an 
unexpected artifact created by the Ab itself rather than by neutralizing IL10. This could 
also serve as an explanation for the marked differences with the TNFRnsBMT mice in 
terms of liver and plasma lipids. Consequently, repeating the current experiment with a 
proper Ab control will be crucial to ensure that the effect we have observed on liver 
lipids is not due to the Ab itself instead of a biological consequence of neutralizing 
IL10. Additionally, repeating this experiment in the previously used APOE2ki mice 
will also strengthen our conclusions. The data currently described should therefore be 
viewed as preliminary evidence that remains to be confirmed.  
Conclusions 
Our current study suggests that hepatic inflammation may inhibit hepatic lipid 
accumulation. The current results raise some questions about the role of hepatic 
inflammation. Initially, any inflammatory response is initiated in an attempt to exert 
beneficial effects. Therefore, it is feasible that early inflammation in response to acute 
hepatic lipid influx assists the liver in coping with the increased metabolic stress. 
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However, when this response fails to repair injury due to persistent hepatic lipid 
overload, this inflammatory reaction may become chronic and gradually exerts the 
negative effects that are known in NASH and IR. This may explain why several studies 
find contradicting results in terms of the relation between inflammation and steatosis, 
depending on which inflammatory “window” the experiments are performed. The 
clinical relevance of these studies remains uncertain until this issue is resolved. The 
final question remains whether lipid accumulation per se is detrimental, or whether 
steatosis becomes only a problem when chronic inflammation establishes itself. 
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General Discussion 
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In the prize-winning documentary “Supersize me”, Morgan Spurlock describes a “one 
man experiment” of a human subject (himself) eating a high fat regime for a period of 
30 days. During this period, he was not allowed to eat anything that wasn’t sold at 
McDonalds. Additionally, he decreased his physical activity to simulate a sedentary 
lifestyle. Spurlock starts the experiment in excellent physical condition. Before the 
experiment, most doctors predict no drastic outcome, as the human body is thought of 
as extremely adaptable. However, besides gaining weight, about 11 kg in 30 days, only 
20 days of high fat feeding resulted in plasma values that are indicative of hepatic 
steatosis and damage, next to increased plasma lipid levels.  
 
The documentary described above illustrates that in a relatively short time span, high 
fat feeding can result in dramatic changes in the body, especially in terms of body 
weight, plasma lipids and the liver. Although actual liver inflammation was not 
assessed, it shows that a severe liver phenotype may develop as early as after 20 days 
of high fat feeding, which is in line with the findings described in this thesis. Clearly, 
ethical issues hamper similar large scale studies in human subjects. Therefore, the use 
of mouse models is imperative for the investigation of the hepatic effects of such diets.  
This thesis describes the early development of non-alcoholic steatohepatitis (NASH) in 
a mouse model which is relatively new in this field of research, i.e. hyperlipidemic 
mice fed a diet enriched in triglycerides and cholesterol (HFC diet). This experimental 
model was the first to incorporate very early time points to study pathways involved 
during the early stages of NASH. Additionally, while studying the important transition 
to harmful steatohepatitis, dietary cholesterol was identified as a strong risk factor for 
the development of hepatic inflammation. Finally, the impact of early inflammation on 
steatosis development was investigated. 
In this chapter the major findings of this thesis will be discussed in the light of the 
current state of the field and its clinical implications. Finally, some future perspectives, 
in relation to the obtained results, will be addressed. 
From steatosis to inflammation to steatosis 
From steatosis to inflammation 
NASH has been proposed to develop via a series of hits [1]. The first of which leads to 
increased liver steatosis, thereby sensitizing the liver for further insults, collectively 
called, second hit. In this view, steatosis development is generally thought of as a 
prerequisite for further propagation of the disease and liver damage. In this thesis 
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however, we describe how hyperlipidemic mouse models develop NASH almost 
immediately when fed a high fat diet. Rather than hepatic lipid accumulation, plasma 
cholesterol was found to directly lead to hepatic inflammation regardless of steatosis 
development. Collectively, our data argue against the need of a “second hit” in NASH 
development. Contrary, we found that cholesterol was responsible for an immediate 
“strike out” of the liver. Although the two-hit hypothesis is generally accepted within 
the field of research, the current results shed some new insights on the pathogenesis of 
NASH. 
More specifically, in chapter 3 of this thesis, we found that high fat feeding resulted in 
NASH development very rapidly. Inflammation developed alongside with, rather than 
subsequent to, steatosis in female APOE2 knock-in (ki) mice, an unexpected finding in 
view of the two-hit hypothesis. These results were confirmed in chapter 5, where 
another female hyperlipidemic mouse model (ldlr deficient/ldlr-/- mice) displayed a 
similar response. Furthermore, we showed that male hyperlipidemic mice failed to 
develop steatosis after 7 days of high fat feeding, while they did develop an 
inflammatory response in the liver, thereby completely disconnecting hepatic 
inflammation development from steatosis. To our knowledge, up until now, hepatic 
inflammation has always been associated with increased liver lipids [2-5]. Other 
evidence also exists that argues against hepatic triglycerides (TGs) predisposing to 
liver inflammation: hepatic TGs have for example been found protective rather than 
harmful for the liver. TGs were thought to form an inert pool that may protect the liver 
from lipotoxicity by free fatty acids (FFAs) [6].  
Chapter 5 showed that normolipidemic animals failed to develop hepatic inflammation 
although they developed equal levels of steatosis. When combined, these findings 
clearly illustrate that steatosis does not necessarily lead to the development of hepatic 
inflammation; moreover, it was found not to be required for the propagation of hepatic 
inflammation. These findings created an interesting window in which we could explore 
why some animals develop full NASH, while other mice develop steatosis only. This is 
of clinical relevance because an important hallmark of NASH is the transition from 
benign steatosis towards an inflamed liver. It is believed that the presence of 
inflammation is required for liver disease to progress towards fibrosis, cirrhosis, and 
subsequent liver failure and/or liver cancer [5]. However, the actual trigger that 
determines why some, but not most, patients with steatosis will develop NASH 
remains unknown. 
We could thus not establish a correlation between steatosis and the development of 
hepatic inflammation. Alternatively, we did find a correlation between hepatic 
inflammation and plasma total cholesterol levels. Additional hints in the direction of 
cholesterol as an important risk factor for NASH were found in chapter 4. Microarray 
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analysis showed the “cholesterol metabolism” pathway to be overrepresented among 
regulated liver gene transcripts during the early progression of NASH in APOE2ki 
mice. 
Together, these findings led us to the hypothesis that, at least in our experimental 
mouse models, plasma cholesterol, and not steatosis, determines whether an 
inflammatory reaction establishes itself in the liver. This hypothesis was tested by an 
experiment where cholesterol was omitted from the HFC diet. Indeed, animals 
receiving this diet showed a similar response in terms of steatosis, but hepatic 
inflammation was completely inhibited. In this manner, the involvement of dietary 
cholesterol was proven. Omitting cholesterol from the diet resulted in a clear reduction 
of cholesterol-rich lipoproteins in the plasma, suggesting that this form of plasma 
cholesterol plays a major role. 
The importance of alternative mechanisms rather than liver lipid accumulation per se, 
is gaining more interest. This is illustrated by the fact that the potential role of 
cholesterol in NASH development is more and more appreciated [7, 8]. Collectively, 
our results suggest that hyperlipidemia, and cholesterol in particular, may be an 
important diagnostic marker to explain why some patients develop hepatic 
inflammation and others do not. 
Unfortunately, clinical data on the sequence of events during NASH progression and 
the involvement of plasma and/or dietary cholesterol are scarce. Only a few studies 
have shown a correlation between low density lipoprotein (LDL) conjugated dienes (as 
a marker for oxidized LDL) and hepatic inflammation and fibrosis development in 
human subjects [9]. LDL levels, possibly in modified form, were also found to be 
increased in NASH patients [10], confirming the clinical relevance of our findings. In 
addition, a recent report has shown a progressive increase of free cholesterol levels in 
patients with non-alcoholic fatty liver disease (NAFLD) to NASH compared to 
controls [11]. 
In search of a molecular mechanism by which plasma cholesterol induces hepatic 
inflammation, we observed Kupffer cells (KCs) to be increased in size, rather than in 
number, after high fat feeding of hyperlipidemic mouse models (chapters 3 and 5). It 
has been shown that depletion of KCs blunted histological evidence of steatohepatitis 
[12], indicating that KCs are of major importance for NASH development. The 
working hypothesis that emerged was the following: due to the increased residence 
time of lipoproteins in the plasma of the hyperlipidemic animals, these lipoproteins are 
modified (e.g. oxidized, acetylated) and subsequently scavenged by KCs in the liver. 
To test this hypothesis, we performed a bone marrow transplantation (BMT) 
experiment where irradiated ldlr-/- animals were injected with bone marrow lacking 
SRA and CD36, the scavenger receptors (SR) that are known to be mostly responsible 
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for modified lipoprotein uptake and foam cell formation. As hypothesized, these 
animals displayed less hepatic inflammation when fed the HFC diet. However, no 
effect on actual foam cell formation could be found (chapter 6), arguing for alternative 
mechanisms via which binding of modified lipoproteins to SRs could affect 
inflammation in the liver, which is discussed in more detail in chapter 6. These results 
are interesting, as they put forward the involvement of KCs in triggering inflammation 
by scavenging modified lipoproteins, a hypothesis that is new in the field and 
definitively deserves more attention as it can open the door to new insights and 
therapeutic options.  
From inflammation to steatosis 
Inflammation and lipid metabolism have been described to influence each other 
considerably. Not only in the sense as described in the previous section, that lipids, and 
cholesterol in particular, can induce an inflammatory status, but also inflammation 
itself has been described to induce marked changes in lipid metabolism [13, 14]. As we 
found inflammation to be a very early player in the development of NASH in our 
experimental models, it was conceivable that inflammatory cells release mediators such 
as chemokines and cytokines in the micro-environment of the liver. Accordingly, these 
could have their effect on hepatic lipid metabolism and consequently on steatosis. 
In general, inflammation is thought to aggravate fatty liver as several inflammatory 
mediators are known to increase de novo lipid synthesis and insulin resistance (IR), 
both of which may therefore lead to increased hepatic lipid levels [15-20]. 
Surprisingly, as described in chapter 7, we found an inverse correlation between 
hepatic inflammation and steatosis levels. To investigate whether a causal relationship 
existed between increased inflammation and a decrease in steatosis, we generated 
mouse models with increased inflammation in their livers, by using two 
complementary approaches. This was either done by BMT of bone marrow cells of 
mice with increased tumor necrosis factor (TNF) signaling to ldlr-/- recipient mice, or 
by inhibiting the anti-inflammatory cytokine interleukin 10 (IL10) with neutralizing 
antibodies. Interestingly, we found that these models had reduced levels of liver TGs, 
indicating that increased inflammation may lead to decreased steatosis. The two 
models used in this study suggest roles for both TNF and IL10 signaling pathways in 
this process. 
Besides being described to worsen steatosis and NASH, TNF has been identified to be 
identical to cachectin [21]. Cachectin was known to decrease body weight and increase 
plasma lipids [22], by decreasing lipoprotein lipase (LpL) activity and expression, and 
by increasing hormone sensitive lipase (HSL) activity and VLDL production and 
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secretion [23]. Despite this catabolic function attributed to TNF, in 1993, TNF was 
proposed to play an important role in obesity and IR by Hotamisligil et al. [24]. These 
findings are now well accepted and thus attribute both anabolic and catabolic roles to 
TNF. The actual role that TNF plays in the development of steatosis may depend on 
the relative amounts of TNF that are expressed and the presence of other cytokines and 
hormones in the micro-environment, as proposed before [23]. 
Collectively, our results raise an important question. Our previous data suggested that 
inflammation is a very early event in the development of NASH. Therefore, it could be 
sensible to target inflammation in therapeutical strategies against NASH. However, the 
results in chapter 7 suggest inflammation to “protect” against steatosis development. 
On the one hand, this could lead to a protective view on inflammation in terms of lipid 
levels. On the other hand, it has to be kept in mind that inflammation can set the stage 
for fibrosis and further damage to the liver, which will lead to severe liver disease [1, 
25]. Therefore, these results indicate that caution has to be applied when targeting 
inflammation only in treatment of NASH. In this regard, several issues remain to be 
resolved. 
First, the central issue is whether increased steatosis per se is such a detrimental 
outcome when inhibiting inflammation. As a normal physiogical response to fasting, 
the liver is known to be able to accumulate TGs, following the increased flux of FFA 
derived from increased lipolysis in the adipose tissue. This response is needed for the 
energy demands of the body, which are regulated via the liver [26, 27]. Thus, steatosis 
may not be that harmful, but can be viewed as a normal physiological process. 
Therefore, rather than targeting steatosis only, lowering liver inflammation may be a 
first concern in the treatment of NASH, despite a possible increase in hepatic lipid 
levels. 
Second, there is substantial evidence that key metabolic and immune functions have 
evolved from common ancestral structures, which implies that there are continuous and 
direct interactions between these two. The inflammatory response has evolved 
throughout the years as a protective mechanism against pathogens invading the body, 
which has led to a system equipped with a powerful, yet sometimes oversensitive 
immune response [28]. Given this possible evolutionary relationship between lipid 
metabolism and the immune system, it is conceivable that the immune system also 
reacts to metabolic insults. A well known example of this is the involvement of toll-
like receptors (Tlrs) in FFA-induced inflammation. FAs have been found to directly 
activate Tlr4 signaling, consequently activating several inflammatory pathways of the 
innate immune system [29], possibly also in KCs [12]. Interestingly, also CD36 has 
been proposed to play a role in the innate immune response. This SR was shown to be 
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essential to some toll-like receptor 2/6 responses which induce nuclear factor kappa 
beta (NF-κB) activation [30]. 
As we have shown in this thesis, the immune response to lipids can be very fast and 
robust. The presence of inflammation in the liver relatively early after a metabolic 
challenge could therefore serve as a mechanism which helps the liver coping with the 
lipid overload. As we have shown in chapter 7, the presence of inflammation may 
indeed attenuate steatosis, thereby assisting the liver during the disposal of excess 
lipids. However, due to a persistent overload, the once protective inflammation 
response may become chronic and exert its detrimental effects. Therefore, the problem 
may not be the response itself, but rather the persistence of the stimulus [14]. 
How, when, where? 
The relation between lipid accumulation and hepatic inflammation in the light of the 
findings of this thesis is represented in figure 1 as a circle. Collectively, our data show 
that the current view on the sequence of events (Fig. 3 of chapter 1) may be bypassed 
by cholesterol (Fig. 1, from left to right), thereby leading to hepatic inflammation 
directly, even without being preceded by the accumulation of hepatic TGs. 
It is known that inflammation can influence hepatic lipid accumulation (represented in 
Fig. 1 from right to left). However, the exact contribution of inflammatory mediators 
remains elusive, as several reports display conflicting results. While our data attribute 
an inhibitory role to inflammation in terms of steatosis development, several other 
studies have shown the opposite. It is possible that the outcome of such experiments 
relies heavily on the timing and the type of immune response that is affected. This 
possibility is nicely illustrated in an elegant experimental model where macrophages 
can be selectively depleted at any given moment. Depending on the timing of 
macrophage depletion, a mouse model of hepatic fibrosis displayed either amelioration 
or worsening of fibrotic lesions. Hereby, it was shown that macrophages could play 
distinctive roles in tissue injury and repair, even over a period as short as two days [31, 
32]. In conclusion, whether going from lipid accumulation towards inflammation and 
subsequent NASH development, or from inflammation to lipid accumulation, the 
outcome may determined by how, where, and when the circle is entered. 
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Animal models of NASH 
Due to ethical issues and practical difficulties in the diagnosis of human subjects, 
animal models are of crucial importance to investigate the molecular pathogenesis of 
NASH. Animal models, and specifically mouse models, have several advantages as 
was extensively portrayed in chapter 2. Until now, the most frequently used animal 
models of NASH are the Ob/Ob mouse and mice fed methionine and choline deficient 
(MCD) diet. Although these animal models are very well described and widely used, 
they have several drawbacks, as was put forward in the introduction section. 
In this thesis, we used hyperlipidemic mouse models which are fed a diet enriched in 
TGs, sucrose, and cholesterol. In chapter 3, we have shown that feeding APOE2ki mice 
a high fat diet induces both steatosis and inflammation in their livers fast. Additionally, 
we found another genetically modified mouse model to develop a similar phenotype, 
i.e. the ldlr-/- mouse (chapter 5). The hyperlipidemic mouse models used in this thesis 
develop NASH when fed a diet only moderately enriched in TGs and cholesterol, 
resembling the diet consumed in industrialized countries. Hyperlipidemic mouse 
models thus elegantly incorporate elements that also occur during the natural course of 
NASH in human patients, like the consumption of a high caloric diet rich in fat and the 
subsequent consequences, like hyperlipidemia. 
In chapter 3, we show that APOE2ki mice displayed increased levels of collagen A1 
gene expression, which may indicate that there is activation of stellate cells [33], 
although fibrosis development itself has not yet been identified in these animals. The 
lack of fibrosis in this animal model is not necessarily a disadvantage, as in human 
subjects there is also no fibrosis development during the early stages of NASH. MCD 
diet induces fibrosis relatively rapid in mice [34]. Therefore, hyperlipidemic mouse 
models may have an extra advantage particularly in the study of the early stages of 
NASH. 
Interestingly, we found in chapter 5 that inflammation was present in the liver even 
before there was detectable steatosis. These mice may thus be of particular interest to 
further study the contribution of early inflammation to NASH development as 
inflammation actually precedes steatosis. Additionally, it has been shown that male 
mice develop obesity and IR more easily than female mice [35, 36], and that APOE2ki 
mice do not develop obesity and IR, thereby uncoupling NASH development from 
these conditions in this model [37]. Contrary, ldlr-/- mice do develop glucose 
intolerance on a diet similar to the one used in our study [8]. These differences between 
gender and strain open interesting opportunities to delineate additional risk factors for 
the development of NASH and IR.  
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Clinical implications of the results 
Atherosclerosis 
The liver is a known source of plasma inflammatory markers in response to the diet. In 
line with our results, it has been shown that liver-derived inflammatory markers, such 
as c reactive protein 1 (CRP1) and serum amyloid A (SAA), are augmented in the 
plasma after only a few days of high fat feeding [38]. These inflammatory proteins may 
contribute to an increased inflammatory status. Inflammation is known to be of major 
importance for the development of atherosclerosis.  
As was reviewed in chapter 2, the hyperlipidemic models used in this thesis are known 
for their contribution to the research field of atherosclerosis. Hypercholesterolemia 
itself may predispose to foam cell formation in the vessel wall on the one hand, but 
also may lead to a very early pro-inflammatory status in the body, originating from the 
NASH development, on the other hand. In line with this, an increased incidence of 
cardiovascular disease (CVD) was found in patients with type 2 diabetes and NASH 
[39]. The presence of NASH early during the pathogenesis of CVD may thus be more 
important than currently envisioned. Supporting this view, it has been shown that 
circulating CRP levels are able to accelerate atherosclerosis development [40].  
Moreover, it has been recently shown that hepatic IR, which may originate from 
NASH, is sufficient to produce an atherogenic lipoprotein profile and increased 
susceptibility to atherosclerosis [41]. 
Diagnosis of NASH 
As was described in the introduction, NAFLD patients usually remain asymptomatic, 
unless cirrhosis is present [42]. Therefore, evaluation of patients with possible NAFLD 
or NASH mainly includes assessment of features of the metabolic syndrome (MetS), 
which are all associated with these liver disorders [43]. Additional criteria are mostly 
based on the levels of liver enzymes in the plasma. However, these tests have been 
shown not to be very specific. The gold standard for the diagnosis of NASH is taking a 
liver biopsy, as it is the only reliable method for diagnosing, staging and grading of 
NASH. However, it is an invasive procedure which is not pleasant for the patient, not 
suitable for routine use, and is not completely without risk [43]. Non-invasive 
procedures, like magnetic resonance imaging (MRI), are non-quantitative and fail to 
detect the presence of inflammation consistently in steatohepatitis [5]. 
The identification of cholesterol as a potent risk factor for the development of hepatic 
inflammation may contribute to the regular criteria of MetS to identify patients at risk 
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that are in need of a liver biopsy, in combination with the current features of MetS. 
Additional to some existing clinical studies that report correlations between cholesterol 
and hepatic inflammation and/or fibrosis [9, 10, 44], the value of plasma cholesterol as 
a diagnostic predictor of hepatic inflammation needs to be investigated in greater detail 
and in human subjects. 
Treatment of NASH 
Until now, features of NASH can not be targeted directly, making treatment options 
limited. Therefore, treatment of NASH depends largely on reducing body weight and 
other components of MetS [5, 45], like hypertriglyceridemia, IR and type 2 diabetes. 
Thiazolidinediones (TZDs) have been widely used to treat type 2 diabetes and some 
reports about their efficiency for NASH treatment have been published [46, 47]. 
However, the efficacy of TZDs against NASH remains unclear. Despite some 
promising results, a recent report showed a 10-fold increase in hepatic TG content 
upon treatment of Ob/Ob mice with rosiglitazone [48]. Moreover, it has been shown 
that any beneficial effect was not sustained in human subjects after discontinuation of 
the treatment with TZDs [49]. Additionally, contributing to the debate on the use of 
TZDs, it was recently claimed that patients receiving TZDs to treat type 2 diabetes are 
at increased risk of developing congestive heart failure and subsequent cardiovascular 
death [50-52], which has started an intense debate on TZD safety [53]. Collectively, 
there is a clear deficiency in large-scale, well-controlled double blind clinical studies 
that show clear effects in ameliorating NASH. Moreover, there are many contradictive 
reports, which argue against large-scale use of TZDs to treat NASH, indicating the 
need for alternative strategies. Additionally, NASH itself, i.e. hepatic lipid 
accumulation, inflammation, and fibrosis, is impossible to target locally. Treatment 
mainly focuses on systemic abnormalities, linked to MetS. 
Agonists of peroxisome proliferator activated receptor alpha (PPARα) have been used 
for several years for the treatment of dyslipidemia, especially hypertriglyceridemia and 
in combination with statins [54]. Several reports, including in this thesis, have shown 
that fenofibrate, a potent activator of PPARα inhibits NASH development (chapter 3 
and chapter 4). Additionally, PPARα agonists have been shown to reverse the 
development of NASH in mice [34]. The applicability of these agonists in the 
treatment of NASH in human subjects has not been intensively studied, although it has 
been suggested that they might be useful [54]. Notably, in chapter 4 we found that 
PPARα activation inhibited the inflammatory response via inhibition of NF-κB, rather 
than activating protein 1 (AP-1). In contrast, we found that AP-1 target genes, mostly 
known tumour promoter genes, were induced. However, this response is not present in 
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humans, where PPARα activation also leads to down-regulation of AP-1 target genes 
[55]. On a further note, no increased risk of liver cancer has been reported in mice with 
human PPARα [56, 57]. This effect is partially due to the fact that humans only 
express 5% to 10% of the amount of PPARα in their livers compared to mice [58] and 
due to structural differences between human and murine PPARα [56, 57]. 
From human studies, fibrates appeared to be relatively safe, with some minor side 
effects including muscle toxicity, increased plasma creatine levels, and increased 
plasma homocysteine levels [59]. From the tested fibrates, fenofibrate appears to elicit 
the fewest side effects in combination with statins [60]. However, a report of the 
FIELD (fenofibrate intervention and event lowering in diabetes) study indicated that 
fenofibrate effects on clinical outcome was less than expected [61]. Other fibrates were 
shown to be more cardioprotective, in particular gemfibrozil, in patients with elevated 
plasma TG levels or other components of MetS [60]. NASH is often associated with 
several aspects of MetS; therefore the applicability of fenofibrate and other PPARα 
agonists as a treatment for NASH should be investigated in further detail. 
The findings of this thesis that identify plasma cholesterol as a possible cause of 
hepatic inflammation, indicate that existing cholesterol-lowering strategies may be 
effective to treat at least the inflammatory component of NASH. Indeed, a recent 
prospective, non-randomized and uncontrolled study showed some promising results. 
The HMG-CoA reductase inhibitor atorvastatin was found to be efficient in the 
treatment of dyslipidemia- and hypertension-associated NASH in human subjects, by 
improving both biochemical parameters, steatosis and inflammation [62].  However, 
this study failed to identify an improvement of ongoing fibrosis. Other reports also 
report atorvastatin to be effective and safe in NASH patients with hyperlipidemia [63, 
64]. In addition to its cholesterol-lowering abilities, statins possess direct anti-
inflammatory effects, as was shown in apoe-/- mice, in which cholesterol levels do not 
respond to statin treatment [65]. 
Finally, as described in the introduction of this thesis, weight loss remains currently the 
most effective in the battle against NASH. Bariatric surgery has been shown to be very 
effective as it improves hepatic features in all patients [5]. However, this procedure is 
very invasive, and therefore not pleasant for the patient and not without risk. Currently, 
techniques are being developed that bypass the first part of the small intestine, which 
inhibits food to be digested properly. This duodenal-jejunal bypass sleeve can be 
delivered to the patient in an endoscopic manner, reducing discomfort and risk for the 
patient [66]. 
Despite the current advances in achieving weight loss via surgical procedures, although 
probably less effective [67, 68], weight loss via a modified diet should remain the first 
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option. The current findings can also be of importance for determining the choice of 
diet that is used to achieve weight loss. For example, the Atkins diet, which focuses on 
high-protein and high-fat intakes and extremely low carbohydrate intakes, has been 
shown to induce significant weight loss. However, probably due to ad libitum fat 
intake, people on this diet were shown to have increased plasma cholesterol levels, 
including increased LDL levels [69]. Therefore, this diet may not be suitable in order 
to reduce ones risk to develop hepatic inflammation. Several other diets do reduce 
plasma cholesterol together with body weight [70]. Thus, diets should be specifically 
selected for their ability to lower plasma cholesterol, rather than on their effect on body 
weight alone. 
Future perspectives 
Research almost always gives rise to additional questions and new opportunities. This 
thesis is not different and raised some interesting issues and questions for further 
studies. Both mechanistically and clinically, there are several issues that remain 
elusive. 
First, the mechanism by which cholesterol causes inflammation very early is only 
partially resolved. In chapter 6, we have shown that the scavenger receptors SRA and 
CD36 are probably part of the picture. Since we could not find a complete inhibition of 
hepatic inflammation, suggesting that other mechanisms also contribute to hepatic 
inflammation in the performed experiment. Next to the uptake of cholesterol, 
mechanisms known to be involved in intracellular cholesterol transport and efflux can 
be investigated. Interesting targets are ATP binding cassette (ABC) transporters, more 
specifically ABC-A1 and ABC-G1. These are known to be expressed by macrophages 
and together, they account for the majority of cholesterol efflux [71, 72]. Macrophages 
lacking these receptors are known to accumulate intracellular cholesterol and may 
contribute to hepatic inflammation, in a process similar to atherosclerosis. It was 
shown that macrophages lacking both these transporters displayed increased 
inflammation and aggravated atherosclerosis development [73]. 
Second, as a lot of discussion exists about the precise role of inflammation during 
steatosis and NASH development, it is interesting to determine whether there are 
differences in early, potentially “protective” inflammation and late, chronic 
inflammation. An emerging concept is the existence of different populations of 
macrophages, so called “classically activated” M1 macrophages, and “alternatively 
activated” M2 macrophages. While M1 macrophages propogate inflammatory 
responses and secrete pro-inflammatory cytokines, M2 macrophages promote tissue 
repair and secrete more anti-inflammatory cytokines. As the molecular signature of 
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these subsets can differ dramatically [74], they may have distinct effects on liver 
function. It has been shown that dietary factors are able to alter the hepatic immune 
system in mice with NALFD [75], indicating the potential function of macrophage 
polarization in response to dietary insults. 
Third, it has to kept in mind that the body does not solely consist out of liver. 
Therefore, it will be crucial to link NASH development in our mouse models to events 
in other parts of the organism. A primary candidate is the adipose tissue, as this is the 
most important lipid depot and an important player in MetS. A major question to be 
addressed is whether the fat also reacts similar to the high fat feeding in concert with 
the liver in terms of inflammation or whether it lags behind. Adipose tissue is a 
dynamic structure which is capable of releasing many mediators important for the 
development of steatosis and hepatic inflammation. Next to the release of FFA into the 
plasma, which contributes directly to hepatic lipid accumulation, adipose tissue is an 
endocrine organ. Several of the molecules known to be excreted by adipose tissue have 
been shown to influence different stages of NASH development, such as TNF, IL6 
adiponectin, leptin, and resistin [76]. 
Furthermore, as the mouse models used in our study are known for their atherogenic 
properties, the possible contribution of early hepatic inflammation to atherosclerosis 
development should be investigated. 
Finally, several clinical studies can be envisioned in light of our results. Although there 
were some indications that plasma cholesterol and LDL levels correlate with the degree 
of hepatic inflammation and fibrosis, larger association studies are surely needed to 
determine the importance of our findings in human patients. Because only steatosis, but 
not hepatic inflammation is readily detectable with non-invasive methods, such as 
MRI, measuring plasma LDL cholesterol may prove to become an important diagnostic 
criterium. Such tests may help to determine what people are at risk for the development 
of hepatic inflammation and would consequently benefit of taking a liver biopsy to 
determine their stage of NASH. Moreover, such an association should automatically 
lead to large clinical trials investigating the efficacy of cholesterol-lowering drugs, 
such as statins, against NASH. As the safety of this class of drugs is established and 
several different analogues are already on the market, this may rapidly lead to 
treatments against NASH. The same holds true for PPARα agonists, which have 
already been used in a clinical setting, but may reveal to be beneficial for NASH 
treatment, possibly in combination with statins. 
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Summary 
In chapter 1, NASH was introduced as the hepatic consequence of the metabolic 
syndrome. It consists of the hepatic accumulation of lipids accompanied by an 
inflammatory response. As described in the two-hit hypothesis, NASH is thought to 
develop via a series of hits of which the first consists of the excessive accumulation of 
lipids in hepatocytes. This first hit sensitizes the liver for a second hit, which would 
susequently lead to an inflammatory response in the liver. Once this inflammation is 
established, the disease readily progresses to more advanced stages, including fibrosis, 
cirrhosis, liver failure and possibly liver cancer. Although several processes have been 
identified to occur during the development of liver inflammation, the exact trigger(s) 
that induces liver inflammation and worsen disease outcome remains to be identified.  
In this thesis, we used hyperlipidemic mouse models to investigate the early 
pathogenesis of NASH. The mouse models used are described in detail in chapter 2. 
These models are based on mutations in genes that have been found to be directly 
involved in hyperlipidemia and atherosclerosis risk, i.e. the low density lipoprotein 
receptor (LDLR) and apolipoprotein E (APOE). Chapter 2 compares the different 
models and their use in atherosclerosis research, as this is the field of research where 
they were mostly used up to date. It becomes clear that every model has its particular 
advantages and disadvantages and that the choice of model should depend of the type 
of information that is desired. For example, although the ApoE deficient mouse has 
been primarily used for atherosclerosis studies, the use of these mice is not suitable to 
test certain hypothesis. Because these mice do not respond to several lipid-lowering 
drugs, such as statins and fibrates, other mouse models should be preferably used. 
Next, in chapter 3, we described how one of the described hyperlipidemic mouse 
models, i.e. the APOE2 knock-in mouse, develops NASH very rapidly when fed a diet 
enriched in triglycerides and cholesterol. By combining histological and biochemical 
approaches with large scale gene expression analysis, we revealed that inflammation 
was present much earlier than could be explained by the two-hit model. Macrophage 
infiltration and inflammatory gene expression was already present after only two days 
of high fat feeding, and it progressed at an higher rate than lipid accumulation. This 
suggested that inflammation plays a more important role in the early development of 
NASH than previously assumed. Furthermore, we showed that fenofibrate, a synthetic 
agonist of peroxisome proliferater activated receptor alpha (PPARα), could inhibit 
NASH development when supplemented to the high fat diet. 
To unravel the exact mechanisms how NASH was induced by diet and inhibited by 
fenofibrate supplementation, hepatic gene expression changes during progression and 
inhibition of NASH were studied in further detail in chapter 4. Using specialized 
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software that clusters genes according to their occurrence in literature, we aimed to 
identify pathways that were essential in these processes. We found two major pathways 
to be of particular importance during the progression and inhibition of diet-induced 
NASH: i.e. cholesterol metabolism and inflammation. Changes in cholesterol 
metabolism were probably induced by negative feedback mechanisms induced by 
increased hepatic cholesterol content. Fenofibrate normalized cholesterol metabolism 
decreasing the hepatic content of cholesterol and its precursors. Surprisingly, 
fenofibrate inhibited inflammation probably by interfering with NF-κB, while up-
regulating pathways around AP-1. 
The link between cholesterol and inflammation was firmly established in chapter 5. We 
were able to show that dietary cholesterol directly leads to hepatic inflammation. In 
this chapter, we compared the response high fat, high cholesterol feeding in different 
mouse models. In addition to the previously used APOE2ki mice, we used ldlr 
deficient mice as a hypercholesterolemic model that originates from a different 
mutation. Surprisingly, we found that normolipidemic wild-type mice did not develop 
hepatic inflammation while they did develop steatosis. Contrary, both used female 
hyperlipidemic mouse models, i.e. APOE2ki mice and ldlr knock-out mice, developed 
steatosis accompanied with inflammation. Clearly, steatosis does not necessarily lead 
to hepatic inflammation. Furthermore, we established that in male mice, hepatic 
increases of inflammatory cells could be induced even without the presence steatosis, 
clearly dissociating the development of hepatic lipid accumulation from hepatic 
inflammation. In search of the causal factor of the development of inflammation, we 
found that only diet-induced hypercholesterolemia correlated with the presence of 
inflammation. In addition, we found bloated ‘foamy’ Kupffer cells in these mice, filled 
with lipid droplets and cholesterol crystals. To test whether a causal relationship was 
present between the consumption of cholesterol and inflammation in the liver, we 
compared the response of the used mouse models to the same diet without cholesterol 
added. This resulted in a clear diminishing of plasma VLDL and LDL levels and a 
complete inhibition of hepatic inflammation and in the absence of bloated Kupffer 
cells. These important findings indicate that dietary cholesterol, possibly in the form of 
modified plasma lipoproteins, is an important risk factor to develop hepatic 
inflammation. Our results led to the hypothesis that hyperlipidemic mice display an 
increase of modified plasma lipoproteins upon high cholesterol feeding that leads to an 
increased clearance by Kupffer cells. Kupffer cells may get subsequently activated and 
initiate an inflammatory response. 
Subsequently, in chapter 6, we investigated whether uptake of modified lipoproteins by 
Kupffer cells is indeed the mechanism by which inflammation is initialized in 
hyperlipidemic mice. Two scavenger receptors are known to be important for the 
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majority of the uptake of modified lipoproteins by macrophages, i.e. SR-A and CD36. 
With the technique of bone marrow transplantation were created animals that lack these 
two scavenger receptors in their immune cells. This led to deficiency of both scavenger 
receptors in hepatic immune cells, i.e. Kupffer. When challenged with a high fat diet, 
we found a significant decrease, but no inhibition, in the development of inflammation 
in the animals with SR-1 and CD36 deficient Kupffer cells. Surprisingly, foam cell 
formation remained unaffected, indicating that this is not the mechanism by which 
inflammation was inhibited. These results indicate that these scavenger receptors play 
important roles during hepatic inflammation development, although the exact 
mechanism remains to be determined. 
In chapter 7 we hypothesized that the presence of inflammation this early during 
NASH development may influence the further course of the disease. The mouse 
models previously used were compared with wild-type mice in terms of their response 
to long term high fat feeding. Interestingly, an inverse correlation was found between 
the presence of hepatic inflammation and the degree of liver lipid accumulation. To 
investigate whether increased inflammation was causal for the lower steatosis levels, 
we created animals with high hepatic inflammation. This was done with bone marrow 
transplantation of ldlr-/- mice with bone marrow of hyper-inflammatory TNF receptor 
non-sheddable mice, which display increased TNF signaling. These animals displayed 
a doubling of hepatic inflammation and  a significant decrease in steatosis levels. Even 
without affecting hepatic inflammation directly, we observed an inhibition of steatosis 
in mice that were injected with antibodies neutralizing the anti-inflammatory cytokine 
IL10. 
In the final chapter, the main results of this thesis are discussed and placed in the 
current state of the field. Moreover, future applications are discussed. In conclusion, 
this thesis shows that cholesterol is an important risk factor for the development of 
hepatic inflammation. Moreover, in contrast to the currently believed two-hit 
hypothesis, cholesterol was shown to directly lead to hepatic inflammation, 
disregarding the presence of a first hit, thereby serving as a direct “strikeout” of the 
liver. 
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Samenvatting 
In hoofdstuk 1 werd NASH voorgesteld als het gevolg in de lever van het metabool 
syndroom. Deze aandoening bestaat uit de opstapeling van vetten in levercellen 
gecombineerd met een ontstekingsreactie. Zoals is beschreven in de “twee-hit 
hypothese”, wordt er momenteel gedacht dat NASH ontstaat uit een opeenvolging van 
gebeurtenissen of ‘hits’. De eerste hit bestaat uit een overmatige opeenstapeling van 
vetten in de levercellen. Deze gebeurtenis maakt de lever gevoeliger voor verdere 
schade, oftewel een tweede hit die een ontsteking in de lever veroorzaakt. De 
aanwezigheid hiervan zorgt ervoor dat de aandoening verergert. Mogelijke gevolgen 
hiervan zijn: bindweefselvorming (fibrose), verstijving van de lever (cirrhose), 
leverfalen en zelfs leverkanker. Tot op heden zijn een aantal processen die deel 
uitmaken van de progressie naar ontsteking geïdentificeerd, maar de exacte oorzaken 
zijn tot nog toe onbekend. 
In deze thesis zijn hyperlipidemische muizen gebruikt om de vroege gebeurtenissen te 
onderzoeken tijdens de ontwikkeling van NASH. De gebruikte muismodellen zijn in 
detail beschreven in hoofdstuk 2. Deze muismodellen zijn gebaseerd op mutaties in 
sleutelgenen die bekend staan omwille van hun rol in hyperlipidemie en het risico op 
de vorming van aderverkalking. Deze genen zijn de low density lipoproteïne receptor 
(LDLR) en apolipoproteïne E (APOE). Hoofdstuk 2 vergelijkt de bestaande modellen 
en hun gebruik in het hart- en vatenonderzoek, vermits dit het onderzoeksveld is waarin 
ze tot op heden het meest gebruikt worden. Elk muismodel heeft zo zijn voor- en 
nadelen en de keuze van het te gebruiken muismodel hangt af van het soort informatie 
dat gewenst is. Zo is bijvoorbeeld de ApoE deficiënte muis de het meest gebruikte 
model in het aderverkalkingsonderzoek, maar is het niet het geschikte model voor alle 
soorten hypotheses. Omdat deze muis geen respons vertoont als reactie op bepaalde 
vetverlagende geneesmiddelen, zoals statines en fibraten, worden beter andere 
muismodellen gebruikt om deze stoffen te onderzoeken. 
Vervolgens, in hoofdstuk 3, wordt aangetoond dat een van de beschreven 
hyperlipidemische muismodellen, de APOE2 knock-in muis, zeer snel NASH 
ontwikkelt wanneer het wordt gevoed met een dieet met hoge hoeveelheden 
triglyceriden en cholesterol. Door histologische en biochemische technieken te 
combineren met genexpressie analyse hebben we ontdekt dat de ontstekingsreactie in 
de lever veel vroeger aanwezig is dan kan worden verklaard met het twee-hit model. Al 
na 2 dagen op het vetrijke dieet konden macrofaaginfiltratie en inflammatoire 
genexpressieveranderingen worden waargenomen die sneller optraden dan 
vetophoping. Deze resultaten suggerren dat ontsteking een belangrijkere speelt tijdens 
de ontwikkeling van de ziekte dan eerder gedacht. Daarenboven hebben we aangetoond 
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dat het toedienen fenofibraat, een synthetische agonist van proliferater activated 
receptor alpha (PPARα), de ontwikkeling van NASH kan tegengaan. 
Om vervolgens te onderzoeken via welke mechanismsen NASH wordt geïnduceerd 
door dieet en gïnhibeert door fenofibraat, zijn de genexpressieveranderingen in meer 
detail bestudeerd in hoofdstuk 4. Met gespecialiseerde software die genen groepeert 
volgens hun voorkomen in de literatuur, beoogden we om belangrijke pathways te 
identificiëren. Twee pathways waren van specifiek belang tijdens de ontwikkeling en 
de inhibitie van NASH. Deze waren het cholesterol metabolims en inflammatie of 
ontsteking. De geobserveerde veranderingen in het cholesterol metabolisme werden 
waarschijnlijk veroorzaakt door terugkoppelingsmechanismen als gevolg van een 
verhoogde hoeveelheid cholesterol in de lever. Deze verhoging werd genormaliseerd 
door het toedienen van fenofibraat. Het was verrassend om te vinden dat fenofibraat de 
ontsteking in de lever warschijnlijk inhibeerde door te storen in de NF-κB signalisatie, 
terwijl de expressieniveaus van AP-1 en zijn doelwit genen werden verhoogd. 
Deze opmerkelijke relatie tussen cholesterol en ontsteking werd duidelijk bevestigd in 
hoofdstuk 5. Hier konden we aantonen dat cholesterol uit het dieet rechtstreeks tot een 
ontstekingsreactie in de lever leidt. In dit hoofdstuk werden  de eerder gebruikte 
APOE2ki muizen gebruikt samen met een ander bekend hyperlipidemisch muismodel, 
nl. de ldlr deficiënte (ldlr-/-) muis. Deze muizen vertonen, net als de APOE2ki muizen, 
meer vetten in het bloed veroorzaakt door een andere mutatie. Het was verrassend om 
vast te stellen dat normolipidemische wild-type muizen geen ontsteking vertoonden in 
hun levers terwijl er toch steatose optrad. De gebruikte hyperlipidemische 
muismodellen daarentegen vertoonden een hevige ontstekingsreactie samen met de 
vetophoping. Deze vaststelling laat duidelijk zien dat steatose niet altijd hoeft te leiden 
tot ontsteking in de lever. Daarenboven hebben we aangetoond dat in mannelijke 
muizen er zelfs een ontstekingsreactie in de lever aanwezig kan zijn zonder 
vetopstapeling. Deze bevinding koppelt de twee processen duidelijk los van elkaar. 
Vervolgens gingen we op zoek naar de directe oorzaak van het ontstekingsproces in de 
lever. Het werd duidelijk dat er een relatie bestond tussen de verhoogde 
cholesterolwaardes in het bloed die door het dieet werden veroorzaakt, en de 
aanwezigheid van ontstekingscellen in de lever. Bovendien was het opgevallen dat in 
de lever van deze dieren gezwollen Kupffer cellen aanwezig waren gevuld met 
vetdruppels en cholesterolkristallen. 
Om te zien of er een oorzakelijk verband bestond tussen cholesterol en ontsteking in de 
lever, hebben we de reactie onderzocht in deze muizen op hetzelfde vetrijke dieet maar 
dan zonder de toegevoegde cholesterol. Het weglaten van cholesterol uit het dieet 
resulteerde in een vermindering van “slechte cholesterol” in het bloed (VLDL en LDL) 
en dit inhibeerde volledig deze ontstekingsreactie in de lever. Deze belangrijke 
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bevindingen geven aan dat cholesterol uit het dieet, mogelijk in de vorm van 
gemodificeerde plasma lipoproteïnen, een belangrijke risicofactor is voor het 
ontwikkelen van een ontsteking in de lever. Hieruit volgde de hypothese dat in de 
hyperlipidemische muizen een verhoging optreedt van gemodificeerde plasma 
lipoproteïnen als ze gevoed worden met een cholesterolrijk dieet. Dit zou kunnen 
leiden tot een verhoogde opname door Kupffer cellen, welke hierdoor geactiveerd 
worden en de ontstekingsreactie in gang zetten. 
In het volgende hoofdstuk hebben we onderzocht of de opname van gemodificeerde 
lipoproteïnen door Kupffer cellen het mechanisme is waardoor een ontsteking op gang 
komt in de lever van hyperlipidemische muizen. Twee zogenaamde scavenger 
receptoren staan bekend om verantwoordelijk te zijn voor het grootste deel van de 
opname van gemodificeerde lipoproteïnen door macrofagen: SR-A en CD36. Met 
beenmergtransplantaties hebben we daarom muizen gecreëerd die deze twee scavenger 
receptoren niet hebben in hun immuuncellen, wat ook leidt tot de afwezigheid ervan in 
de immuuncellen van de lever: de Kupffer cellen. Deze dieren vertoonden een 
verlaging, maar geen volledige inhibitie, van de ontsteking in de lever wanneer een 
vetrijk dieet werd gegeven. Verrassend genoeg bleef de hoeveelheid gezwollen Kupffer 
cellen gelijk, wat erop duidt dat deze receptoren belangrijk zijn in de ontwikkeling van 
ontsteking in de lever, maar het exacte mechanisme blijft voorlopig onduidelijk. 
Het feit dat ontsteking in de lever veel vroeger optreedt dan verwacht leidde toe de 
hypothese dat de aanwezigheid ervan een rol kan spleen tijdens de verdure 
ontwikkeling van NASH. Vandaar werden in hoofdstuk 7 de twee eerder gebruikte 
hyperlipidemische muismodellen vergeleken met normolipidemische controle muizen 
wat betreft hun respons op het toedienen van vetrijke voeding gedurende een langere 
periode. We vonden een omgekeerde correlatie tussen de aanwezigheid van ontsteking 
in de lever en de hoeveelheid opgestapeld vet. Om te onderzoeken of een er sprake was 
van een oorzakelijk verband, hebben we dieren gecreëerd met een verhoogde 
ontsteking in de lever. Hiertoe werden beenmergtransplantaties gebruikt. Ldlr-/- 
muizen werden bestraald en getransplanteerd met beenmerg van hyper-inflammatoire 
TNF receptor non-sheddable muizen, welke een verhoogde TNF signalering vertonen. 
Deze dieren hadden een verdubbeling van het aantal ontstekingscellen in de lever, en 
dit leidde tot een verlaging van de vetopstapeling in de lever. Daarenboven hebben we 
gevonden dat de opstapeling van vetten in de lever volledig werd geïnhibeerd na het 
neutraliseren van het anti-inflammatoir cytokine IL10 met antilichamen. Dit gebeurde 
zelfs zonder een verandering van de hoeveelheid ontsteking in de lever. 
In het laatste hoofdstuk worden de belangrijkste resultaten uit deze thesis besproken in 
het licht van de huidige stand van zaken. Daarenboven worden de mogelijke 
toepassingen en gevolgen besproken. We kunnen besluiten dat in deze thesis wordt 
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aangetoond dat cholesterol een belangrijke risicofactor is om ontsteking in de lever te 
ontwikkelen. In tegenstelling tot het huidig geaccepteerde twee-hit model, heeft deze 
thesis aangetoond dat cholesterol mogelijk rechtstreeks leidt tot leverinflammatie, 
ongeacht de aanwezigheid van een eerste “hit”. Cholesterol zorgt daardoor voor een 
onmiddellijke “strike out” van de lever. 
 - 179 - 
 
    
Curriculum Vitae 
 
Curriculum Vitae 
 
- 180 - 
 
Kristiaan Wouters was born on March 8 in Hasselt, Belgium. In 1999 he acquired his 
diploma from secondary school at Humaniora Kindsheid Jesu (Hasselt, Belgium). In 
September of the same year, he started to study Biomedical Sciences at the LUC 
(Limburgs Universitair Centrum) in Diebenbeek, Belgium, where he got his candidate 
diploma cum laude in 2001. He continued his education in Diepenbeek to obtain his 
Master (Licenciate) Magna Cum Laude in Biomedical Sciences at the transnationale 
Universiteit Limburg (tUL), a cooperation between the LUC and Universiteit 
Maastricht (UM) in 2003. For this degree he performed an internship of 7 months at 
the BIOMED research institute in Diepenbeek, Belgium. He participated in a project 
titled “Study of the gene expression pattern of parity-induced differentiation of human 
mammary tissue in relation to the development of breast cancer by using SAGE (Serial 
Analysis of Gene Expression).” 
During his internship, Kristiaan Wouters got intereseted to perform scientific research. 
Therefore, in August 2003 he started to work as a PhD student (Assistant in Opleiding, 
AiO) at the department of Molecular Genetics at the University of Maastricht, The 
Netherlands, headed by Prof. Dr. Marten Hofker. Dr. Hofker participated in the 
supervision together with Dr. Ronit Shiri-Sverdlov and Dr. Marc van Bilsen on a 
project funded by the Netherlands Heart Foundation: “Genomic analysis of the APOE2 
knock-in mouse to identify novel genes involved in Hyperlipidemia”. During this time, 
he assisted at several practical courses for Medicin students (FdG blok 2.1), and he 
mentored several master students during their internships. He also participated to 
several national and international conferences where he was able to present his research 
both orally and by poster presentations. He was awarded the Young Investigator Award 
at the ‘Drugs Affecting Lipid Metabolism’ conference in Venice, Italy in 2004 and the 
travel scholarship to attend the Keystone symposium on Nuclear Receptors and the 
metabolic syndrome in Steamboat, Co, USA in 2007. 
From March 2008 untill present, he works in the laboratory of Bart Staels in Lille, 
France, on a project to investigate the role of macrophage p16INK4A in atherosclerosis 
and metabolic diseases in collaboration with Dr. Menno de Winther from Maastricht 
University. For this project he obtained funding from the European Atherosclerosis 
Society (EAS) and Maastricht University (Kootstra fellowship). 
Curriculum Vitae 
- 181 - 
 
List of publications 
• Wouters K, Van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lütjohann D, Kerksiek 
A, Van Kruchten R, Maeda N, Staels B, Van Bilsen M, Shiri-Sverdlov R, Hofker 
MH. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation 
in hyperlipidemic mouse models of NASH.  
Hepatology. 2008 Aug;48(2):474-86 (IF=10.73) 
• Wouters K, Shiri-Sverdlov R, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, 
Maeda N, van Bilsen M, Hofker MH. Early diet-induced non-alcoholic 
steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. 
 J Hepatol. 2006 Apr;44(4):732-41 (IF=6.64) 
• Wouters K, Shiri-Sverdlov R, van Gorp PJ, van Bilsen M, Hofker MH. 
Understanding hyperlipidemia and atherosclerosis: lessons from genetically 
modified apoe and ldlr mice. 
Clin Chem Lab Med. 2005; 43(5):470-9. Review (IF=1.74) 
• Verlinden I, Gungor N, Wouters K, Janssens J, Raus J, Michiels L. Parity-induced 
changes in global gene expression in the human mammary gland. 
Eur J Cancer Prev. 2005 Apr; 14(2):129-37 (IF=1.63) 
• Vanschoonbeek K, Wouters K, van der Meijden PE, van Gorp PJ, Schurgers LJ, 
Feijge MA, Hofker MH, de Maat MP, and Heemskerk JW.  Anticoagulant effect of 
dietary fish oil in hyperlipidemia: a study of hepatic mRNA expression in APOE2 
knock-in mice.  
Arterioscl Throm Vas Biol. 2008 (IF=7.22) 
• Wouters K, van Bilsen M, Bieghs V, van Gorp PJ, Lütjohann D, Kerksiek A, 
Staels B, Hofker MH, and Shiri-Sverdlov R. A central role for cholesterol 
metabolism and inflammation during the inhibition of non-alcoholic steatohepatitis 
with a synthetic PPARalpha agonist.  
Submitted 
Curriculum Vitae 
 
- 182 - 
 
Poster presentations 
• “Genomic analysis of the APOE knock-in mouse model” NHS-dag, Leiden 15 
april 2004 
• “The APOE2 knock-in mouse as a sensitive model for steatosis and inflammation” 
Drugs Affecting Lipid Metabolism2004, Lorenzini Foundation. Venice 24-27 
October 2004 (Awarded with a Young Investigator Award) 
• “Genomic analysis of the APOE2 knock-in mouse model” CARIM Symposium, 
Maastricht, 17th November 2004 
• “Hyperlipidemic mice are more sensitive to diet-induced hepatic inflammation.” 
Gordon Research Conference on Lipoprotein Metabolism. Boston, USA 2 July 
2006 - 9 July 2006.  
• “Hyperactivation of macrophage TNF signaling inhibits steatosis” Keystone 
Symposia: Nuclear Receptors and the metabolic syndrome. March 26-April 1 2007 
• “Lowering plasma VLDL inhibits the development of liver inflammation in 
hyperlipidemic mice.” European Lipoprotein Club, Tutzing, september 2007 
Oral presentations 
• “The APOE2 knock-in mouse as a model for type III hyperlipidemia and 
steatohepatitis.” ZonMw Genetica retraite, Congrescentrum Rolduc, Kerkrade. 3rd 
March 2005 
•  “PPARalpha induced gene-expression.” EVGN Summer School, 28th June 2005 
• “Diet-induced steatohepatitis in APOE2 knock-in mice and its reversal by fibrates” 
European Lipoprotein Club, Tutzing, 13th September 2005 
• “Early diet-induced steatohepatitis in APOE2 knock-in mice and its reversal by 
fibrates” Nederlandse Vereniging voor Diabetes Onderzoek, 2nd December 2005 
• “The APOE2 knock-in mouse as a model for type III hyperlipidemia and 
steatohepatitis.” ZonMw Genetica retraite, Congrescentrum Rolduc, Kerkrade, 
10th March 2006 
• “Hyperlipidemic mice are more sensitive to diet-induced hepatic inflammation.” 
European Lipoprotein Club, Tutzing, 6th  september 2006  
• “Hyperlipidemic mice are more sensitive to diet-induced hepatic inflammation” 
Nederlandse Vereniging voor Diabetes Onderzoek 2006, 2nd November 2006 
•  “Hyperactivation of macrophage TNF signaling inhibits steatosis” Keystone 
Symposia: Nuclear Receptors and the metabolic syndrome. 29th March 2007 
(travel scholarship awarded) 
 
Dankwoord 
 
 
- 183 - 
 
  
 
Dankwoord 
 
Dankwoord 
 
- 184 - 
 
Zo, hier is het dan eindelijk: mijn dankwoord. Ik heb er al een aantal zien passeren en 
eindelijk is het aan mij om een te schrijven. Ik heb een dikke vier jaar een enorm fijne 
tijd gehad (naast het hard labeur uiteraard) en nu is het hoog tijd om de mensen, die 
mede verantwoordelijk zijn geweest voor de leuke momenten en het harde werk te 
vermelden.  
 
Beste Marten, in de eerste plaats bedankt om mijn promotor te zijn. Van in het begin 
had ik het gevoel gehad dat je in me geloofde en vertrouwen in me had. Dit heb ik 
altijd erg geapprecieerd en heeft me bovenal gestimuleerd. Gaandeweg heb je me meer 
en meer vrijheid gegeven om mezelf op wetenschappelijk gebied te ontplooien, zelfs 
wanneer we het niet helemaal eens waren. Daar pluk ik nu de vruchten van. Altijd 
stond jouw deur open om eventjes met een prangende vraag binnen te springen. 
 
De volgende in lijn is uiteraard Ronit. Hoewel het in het begin even schrikken was toen 
ik voor de eerste keer bij je op gesprek kwam en ik een hoogzwangere vrouw zag in 
plaats van de Meneer Sverdlov waar ik naar vroeg, is het toch nog goed gekomen. Het 
was leuk samenwerken met je. Samen hebben we iets moois gemaakt van het project 
wat er lag. Het was nooit te veel voor je om even naar me te luisteren (omtrent 
werkelijk alles). Jouw opmerkzaamheid en begrip waren enorm! 
 
Marc, jij vervolledigde het promotieteam. Je bracht vaak ideeën aan vanuit een ander 
perspectief en dat was vaak erg verhelderend. Ik wil je ook nog extra bedanken voor de 
tijd die je graag spendeerde om me raad te geven wanneer het nodig was. Jouw 
uitspraak over draagbare computers vertel ik nog steeds aan iedereen die het horen wil! 
 
En dan is er Patrick. Van bij de aanvang was je mijn steun en toeverlaat op Molgen. 
Toen het in het begin niet zo makkelijk voor mij was, heb je me volledig op mijn 
gemak gesteld. De labtechnieken die ik van je heb geleerd zijn ontelbaar, maar vooral 
de manier van werken die je me hebt bijgebracht is onbetaalbaar en is iets waar ik nog 
lang plezier van zal hebben. Daarbovenop hebben we ook nog gewoon veel gelachen 
en plezier gemaakt. Hoewel niet iedereen het daar mee eens was, vond ik de België vs 
Nederland grapjes enorm leuk. Natuurlijk waren er ook nog andere legendarische 
momenten à la “Marseillaise-Marechaussee” en “Dr. Hooters with the black chicks” 
die me altijd bij zullen blijven. Bedankt ook om mijn paranimf te willen zijn. Als ik 
aan jou iets vraag weet ik dat, net zoals op het lab, het wel goed komt. Dit is een luxe 
die ik nu al mis! Ik hoop in ieder geval nog vaak samen met je te kunnen lachen. 
 
Dankwoord 
 
 
- 185 - 
 
Dit brengt me naadloos naar de kamer waar ik begon te werken. Naast Patrick zat ik er 
met Monique en Inge. Ook jullie twee waren geweldige collega’s en altijd bereid me te 
helpen. Jullie technische bagage is dan ook indrukwekkend. Monique, bedankt voor de 
hulp, de erg leuke momenten en de plagerijtjes: het was altijd bibberen als ik je in de 
gang me hoorde roepen: “Meneer Wouters…!” ;-). Inge, ook jij hebt me veel 
bijgebracht en we hebben een leuke tijd gehad, niet alleen op het werk maar ook 
daarbuiten; dat Pukkelpop nog maar enkele jaartjes doorgaat in Hasselt! 
 
Met het vertrek van Sander ben ik dan verhuisd naar de AiO kamer. Bedankt voor die 
goede energie op je oude werkplek Sander! Op die kamer was het erg gezellig en vaak 
heel erg lollig. Soms misschien een beetje “te”, maar er werd ook gewerkt. Roy, jouw 
muziekkeuze was erg goed en je deelde dit graag met de rest. Stijn, jouw creatieve 
geest waarmee prehistorische waterdieren, koosjere kippen en slakken werden 
gekweekt, zal ik me altijd blijven herinneren. Niet enkel deze organische speciën, maar 
ook robotten passeerden de revue samen met experimenten om het temperatuurbereik 
van een speelgoedtelefoon te meten: hilarisch! Mathijs, ik zal voortaan je knuffels 
moeten missen. Gelukkig was jij er om alle computerproblemen op te lossen. Jij hebt 
me ook geïntroduceerd in het leven van de CARIM AiO cursussen, waar we ons altijd 
heel erg goed hebben geamuseerd, en het naaktzwemmen in Tutzing. Ik wens je nog 
goede moed voor het afronden van je proefschrift, je komt er zeker wel! Petra, jij was 
zo een beetje de moederkloek van de kamer en altijd op de hoogte van de laatste 
weetjes. Je was altijd in om mee te lachen en af en toe een leuke, scherpe opmerking te 
geven. Daphna, als het even wat rustiger werd, was er altijd wel wat tijd voor een 
gesprek, ondanks dat we ver uit elkaar verwijderd waren in de kamer. Jij ook veel 
geluk met de laatste loodjes. Jana, ook met jou had ik regelmatig leuke en soms 
noodzakelijke gesprekken. Ik wens je nog veel succes in Groningen! Remco (ook al is 
dat niet een van je voornamen), ik heb enorm genoten van de korte tijd die je bij ons op 
de kamer hebt gespendeerd. Ik ben blij dat je je goed voelt in je nieuwe baan. Veerle 
(C.), ook jij ben maar kort een kamergenoot geweest. Ook jou wens ik veel succes in je 
nieuwe carrière. Ellen (D.), ondanks dat jij er ook nog niet zo heel lang zit, hebben we 
met jou toch ook al veel gelachen ;-)! Veerle, ik ben blij dat jij mijn werk opvolgt. Ik 
denk dat het met jou zeker goedkomt, zeker samen met Patrick en Ronit. Ik wil je graag 
extra bedanken voor de hulp voor het klaarkrijgen van het paper. En last but not least: 
onze Pi! Pieter, met jou klikte het vrijwel meteen, niet alleen op vlak van muziek maar 
ook op vlak van humor en wetenschap. Soms begrepen we elkaar zelfs zonder woorden 
en was een blik al voldoende om in lachen uit te barsten. Ik hoop met jou nog vaak 
concertjes te doen. Misschien kom je wel eens bij mijn ouders eten? Laat het duidelijk 
Dankwoord 
 
- 186 - 
 
zijn dat ik me heel erg thuis voelde bij jullie allemaal en dat het echt een onvergetelijke 
tijd was! Lauran, ik denk dat jij je daar ook wel goed gaat voelen.  
 
Naast de genoemde kamergenoten waren er natuurlijk nog andere leuke collega-AiO’s 
waarmee we geweldige koffiepauzes en andere momenten mee hebben gespendeerd, 
zoals pokeravonden. Hanneke, veel geluk op pathologie en met je naderende promotie. 
Frank, laat me nog maar iets weten wanneer er gevoetbald wordt en nog veel succes 
met het vergaren van de laatste data. Wino, ondanks alle doodsbedreigingen die ik van 
je heb gekregen heb je mijn eeuwig respect voor het wereldrecord “langste appelschil”. 
Let in het vervolg wel op als je weer iemand gaat tackelen! Céline, j’espère que tout va 
bien avec toi et avec tes enfants. Peggy, met jou is er altijd wel plezier (soms misschien 
wel wat overenthousiasme als het over mijn oor gaat?). Laura, veel succes met je 
onderzoek. En dan waren er ook nog Debby en Susan, ik herinner me nog goed dat 
jullie twee, samen met Daphna, alle prijzen wegkaapten van de voetbalpronostiek! 
 
Guillaume, met jou was het ook altijd lachen. Maar je was ook altijd klaar voor een 
serieus gesprek dat af en toe wel eens nodig was. Samen met jou en Claudia het 
labuitje organiseren was erg leuk. Menno, jij was wetenschappelijk altijd wel een 
voorbeeld en ik ben blij dat we nog even blijven samenwerken. Bedankt voor de hulp 
bij de voorbije beursaanvragen. Jan, ook jij hebt me goed geholpen om verder te 
kunnen na mij AiO schap. Marion, hoewel ik in het begin een beetje aan je moest 
wennnen, is jouw bijdrage achter de microscoop (oftewel scoren!) essentieel geweest 
voor het project en dit proefschrift. Het waren in ieder geval erg gezellige uurtjes. 
Wilma, jij bent zeker een vermelding waard. De energie waarmee je mij en iedereen 
wilde helpen was ongelooflijk. Ik hoop dat je geniet van je verdiend pensioen! 
 
En er waren nog een pak meer mensen op Molgen die mee de goede sfeer bepaald 
hebben op en naast de werkvloer: Anne, Arjen, Daniëlle (bedankt voor het faute 
feestje!), Franky, Iris, Joost, Le, Maurice, Mohammed, Raymond, Robert, Sofia, en 
Willem. Will, met jou discusiëren over politiek, sossen en xenofobe Belgen was zalig. 
 
Een deel van de resultaten uit deze thesis, en een deel dat er jammer genoeg net niet in 
geraakt is, is bij elkaar gepipeteerd door enkele studenten. Ook met jullie was het fijn 
samenwerken. Bedankt Silvie, Caroline en Roger.  
 
Buiten Molgen waren er nog een hoop mensen die hebben bijgedragen aan de toffe 
sfeer, verdeeld over de verschillende afdelingen van de UM en het CPV: Kees, Wim, 
Wout, Leo, Sonia, Tine, Kees, Hans, Pascal, Linda, Paola, Johan, Kristof, Remels, 
Dankwoord 
 
 
- 187 - 
 
Karen, Nejla, Andries, Ronald, Mieke, Marie-Hélène, Francien, Ruben, Ann, Bianca, 
Torik, Rosy, Erica, Richard, Paulien, Allard, Rik, Nadien, Marlies en ongetwijfeld nog 
vele anderen die mij jammer genoeg niet te binnen schieten (met mijn welgemeende 
excuses). 
 
Er waren ook nog een deel mensen van buiten de UM die hebben bijgedragen aan deze 
thesis. Dieter, many thanks for your availability and for the time you worked on our 
livers. Prof. Holvoet, jammer dat dat de resultaten niet onmiddellijk bruikbaar waren. 
Ik heb uw medewerking zeker op prijs gesteld. Bart, jij hebt vaak je ideën gegeven 
over onze data en dat heeft zeker bijgedragen tot de kwaliteit van deze thesis. Ik ook 
erg blij met de kans die je me hebt gegeven om bij jou in Rijsel/Lille te komen werken. 
 
Naast het lab waren ook nog andere mensen belangrijk voor het welslagen van deze 
thesis, al was het maar om af en toe voor wat afleiding te zorgen of een luisterend oor. 
Ik heb jullie de laatste tijd veel te weinig gezien, laten we hopen dat het nu weer wat 
beter gaat gaan! Bleu, je bent samen met Annelies en je twee schatten van kinderen zo 
goed als familie geworden. Ik ben heel erg vereerd en dankbaar dat ik de peter mag zijn 
van Mitu. Ik zal ook nooit vergeten op welke manier jullie me steeds met open armen 
hebben opgevangen wanneer het nodig was. Ik had me dan ook niemand anders als 
paranimf kunnen voorstellen. Tim, je bent begonnen als student op Molgen en zo via 
carpoolmaat uitgegroeid tot echte vriend. Samen met Bleu hebben we een geweldige 
tijd gehad samen in de auto waar het af en toe ook nog eens serieus aan toe ging. Een 
dikke proficiat voor jou en Evy met jullie kindje. Roeland, ik hoop dat we nu dat we 
allebei onze thesis af hebben, er weer wat meer tijd komt voor plezier. Veel succes in 
Parijs en met de kleine (ook aan Daisy). Cédric, ook jij hebt al een belangrijke rol 
gespeeld in mijn leven: al meer dan 14 jaar vriendschap die alles heeft kunnen 
doorstaan. Met gemak doen we er nog een heel deel jaren bij! In dit rijtje mag zeker 
ook Vis niet ontbreken en de harde kern van ZVK Echternach: Michel, Brecht, (nog 
eens) Tim (nog een keer) Johannes, Eric, Doully, Roger en Peter. 
 
Naast deze vrienden heb ik het geluk om een geweldige familie te hebben waar ik 
ongeacht wanneer en waarom bij terecht kan. Mama en Papa, jullie hebben me alle 
kansen gegeven die maar mogelijk waren. Belangrijker nog, jullie hebben me altijd 
gestimuleerd om deze kansen te grijpen en te gaan voor wat ik waard was. Het was 
thuis altijd een liefdevolle, gezellige en erg aangename plaats om te vertoeven. Dankzij 
jullie ben ik geworden wie ik ben en sta ik waar ik sta. Het resultaat dat jullie nu in 
jullie handen hebben, is ook voor een deel jullie verdienste! 
Dankwoord 
 
- 188 - 
 
Brecht, mijn broer, ik ben blij dat we de laatste tijd zo naar elkaar zijn gegroeid. Ook 
aan jou heb ik een echte vriend waarop ik weet dat ik altijd zal kunnen bouwen. 
Véronique, ook al zien we elkaar niet meer zo vaak, heb ik het altijd leuk gevonden om 
je in huis te hebben. Mareine en Moeke, ook jullie hebben altijd in me geloofd en zijn 
altijd trots op me geweest. Dat is een fijn gevoel. 
En dan zijn er ook nog Jos en Angèle (en Koen, we hebben nog niet echt de kans gehad 
elkaar beter te leren kennen maar ik hoop dat dat snel verandert). Jullie hebben me 
vanaf de eerste dag in jullie armen gesloten en me onmiddellijk doen thuis voelen. Ook 
van jullie krijg ik heel veel steun. Bedankt voor de warmte! 
  
Ellen, wie had gedacht (buiten heel Molgen dan) dat jij nu naast mij zou staan? De 
steun die ik van je heb gekregen tijdens het schrijven van deze thesis is ongelooflijk. Je 
hebt me laten werken terwijl je de rest van het huishoudelijke werk op je nam, zelfs 
toen we nog niet samenwoonden. Ik heb van je onvoorwaardelijke steun en begrip 
gehad op de momenten dat het wat minder ging. Jij hebt echt enorm bijgedragen aan 
deze thesis en daar ben ik enorm dankbaar voor. Ik hoop dat ik voor jou hetzelfde zal 
mogen doen binnen enkele jaren, je bent in ieder geval al erg goed op weg… 
 
Mijn lief Elleke, sinds jij in mijn leven gekomen bent is alles beter geworden, inclusief 
ik. Je geeft me de vrijheid om te zijn wie ik ben en om me verder te kunnen ontplooien. 
Niets is je te veel als je weet dat het me blij maakt. Het is echt een wonderlijk gevoel 
om te weten dat er iemand zo achter je staat en van je houdt zoals jij dat doet. Vanaf nu 
gaan we wat meer tijd hebben voor elkaar en ik ben er zeker van dat het een 
aaneenschakeling van mooie momenten gaat zijn. Ik hoop dat deze momenten de rest 
van ons leven blijven duren met jou aan mijn zijde als mijn vrouw, als je wil. 
 
 
 
 - 189 - 
 
 
List of abbreviations 
List of abbreviations 
 
- 190 - 
 
A Abc   Adenosine Triphosphate binding cassette 
ABCC3   ATP Binding Casette 3 
ACC   Acyl-CoA Carboxylase 
acLDL   acetylated Low Density Lipoproteins 
Acox-1   Acyl CoA oxidase 1 
AP-1   Activating Protein-1 
Apo   Apolipoproteins 
APOE3L  APOE3 Leiden 
APOE2TG  APOE2 Transgene 
ASH   Alcoholic Steatohepatitis 
ATF6   Activating Transcription Factor 6 
B BMT   Bone Marrow Transplantation 
C ChREBP  Carbohydrate Response Element Binding Protein 
CETP    Cholesteryl Ester Transfer Protein 
Clcsf13   C-type Lectin, SuperFamily 13   
CM   Chylomicrons 
CMR   Chylomicron remnants 
Cpt1   Carnitine acyl-carnitine translocase 1 
CRP1   C Reactive Protein 1 
CVD   CardioVascular Disease 
CYP2E1  Cytochrome P450 2E1 
D Dko   Double knock-out 
E eQTL   expression Quantitative Trait Loci 
ER   Endoplasmatic Reticulum  
EVGN   European Vascular Genomics Network 
F FA   Fatty acids 
FABP2   Fatty Acid Binding Protein 2 
FAS   Fatty Acid Synthase 
FD   Familial Dysbetalipoproteinemia 
Fdft1   Farnesyl Disphosphate Farnesyl Transferase 1 
FF   Fenofibrate 
FFA   Free Fatty Acid 
FH   Familial Hypercholesterolemia 
G GO   Gene ontology 
GC-FID  Gas Chromatography-Flame Ionization Detection 
 GC-MS   Gas Chromatography-Mass Spectrometry 
H HDL   High Density Lipoprotein 
HE   Heamatoxilin/Eosin 
HFC   High Fat, High Cholesterol diet 
HFC+FF  High Fat, High Cholesterol diet with FF 
HFD   High Fat Diet 
HFnC   High Fat Diet without Cholesterol 
HLP   HyperLipoProteinemia 
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HMG-CoA  3-Hydroxy-3-MethylGlutaryl-Coenzyme A  
Hmgc1   HMG-CoA lyase 
HMGCS  HMG-CoA Synthase  
Hmgcs   HMG-CoA Synthetase  
HNE   trans-4-Hydroxy-2-Noneal 
HNF4A   Hepatic Nuclear Factor 4A 
HSL   Hormone Sensitive Lipase 
I Icam1   Intracellular Adhesion Molecule 1 
IDF   International Diabetes Federation 
Ifit1 Interferon-Induced protein with tetratricopeptide 
repeats 1 
IKKβ   IκB Kinase beta 
IL   Interleukin 
Insig2   Insulin Induced Gene 2 
IR   Insulin Resistance 
IRE-1   Inositol-Requiring Enzyme 1 
IPA   Ingenuity Pathway Analysis 
J JNK   C-Jun N-terminal Kinase 
K KC   Kupffer cells 
Ki   Knock-in 
Ko   Knock-out 
L LDL   Low Density Lipoproteins 
Ldlr -/-   Low Density Lipoproteins Deficient 
LDLR   LDL Receptor 
Lip1   Lipase 1 
LipC   Lipin C 
LpL   Liprotein Lipase 
LPS   Lipopolysacharide 
Lrp   Low Density Lipoproteins Receptor Related Protein 
LXR   Liver X Receptor 
Lyzs   Lysozyme 
M MCD   Methionine and Choline Deficient 
Mcp-1   Monocyte Chemoattractant Protein 1 
MDA   Malondialdehyde 
MetS   Metabolic Syndrome 
Mgll   Monoglyceride Lipase 
MRI   Magnetic Resonance Imaging 
MTP   Mitochondrial TG Transfer Protein 
N NAFLD  Non-Alcoholic Fatty Liver Disease 
NASH   Non-Alcoholic Steatohepatitis 
NCEP   National Cholesterol Education Program 
NF-κB   Nuclear Factor Kappa B 
NHS   Netherlands Heart Foundation 
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NWO   Netherlands Organization for Scientific Research 
O ORO   Oil Red O 
oxLDL   Oxidized Low Density Lipoproteins 
P PAS   Periodic Acid Schiff 
PC   Phosphatidylcholine 
PE   Phosphatidylethanolamine 
PERK   PKR like Endoplasmatic Reticulum Kinase 
PUFA   Poly-Unsaturated Fatty Acid 
PPAR   Peroxisome Proliferating Activated Receptor 
Ppia   Cyclophillin A 
PPRE   Peroxisome Proliferator Response Elements 
PXR   Pregnane X Receptor 
Q QPCR   Real-Time Quantitative PCR 
QTL   Quantitative Trait Loci 
R ROS   Reactive Oxygen Species 
S SRA-1   Scavenger Receptor A1 
SAA   Serum Amyloid A 
SAP   Serum Amyloid P 
SC   Scavenger Receptor 
SCD1   Stearoyl CoA Desaturase 1 
SF   Scaling Factor 
SOCS   Suppressor of Cytokine Signaling 
SRBI   Scavenger Receptor B type I 
SREBP-1c  Sterol Regulatory Element-Binding Protein 1c 
T T2D   Type 2 Diabetes 
TC   Total Cholesterol 
TG   Triglycerides 
TGF-β   Transforming Growth Factor beta 
Tgtp   T-cell specific GTPase 
TLDA   Taqman-Low Density Array 
Tlr   Toll like receptor 
TNF   Tumor Necrosis Factor 
TNFR   Tumor Necrosis Factor Receptor 
TNFRns Tumor Necrosis Factor Receptor non-sheddable 
TZD   Thiazolidinediones 
U UPR   Unfolded Protein Response 
V VLDL   Very Low Density Lipoproteins 
VLDLR  Very Low Density Lipoproteins Remnants 
W WBC   White Blood Cells 
WT   Wild-Type 
